WO2023054396A1 - 下垂体組織を含む細胞集団の製造方法及びその細胞集団 - Google Patents
下垂体組織を含む細胞集団の製造方法及びその細胞集団 Download PDFInfo
- Publication number
- WO2023054396A1 WO2023054396A1 PCT/JP2022/036019 JP2022036019W WO2023054396A1 WO 2023054396 A1 WO2023054396 A1 WO 2023054396A1 JP 2022036019 W JP2022036019 W JP 2022036019W WO 2023054396 A1 WO2023054396 A1 WO 2023054396A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- signaling pathway
- pituitary
- culture
- Prior art date
Links
- 230000001817 pituitary effect Effects 0.000 title claims abstract description 237
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 132
- 210000004027 cell Anatomy 0.000 claims abstract description 886
- 239000003112 inhibitor Substances 0.000 claims abstract description 215
- 230000019491 signal transduction Effects 0.000 claims abstract description 171
- 210000001778 pluripotent stem cell Anatomy 0.000 claims abstract description 120
- 239000000556 agonist Substances 0.000 claims abstract description 53
- 238000012258 culturing Methods 0.000 claims abstract description 48
- 230000008410 smoothened signaling pathway Effects 0.000 claims abstract description 47
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract description 42
- 230000004156 Wnt signaling pathway Effects 0.000 claims abstract description 29
- 239000000126 substance Substances 0.000 claims description 148
- 238000004114 suspension culture Methods 0.000 claims description 84
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 239000012825 JNK inhibitor Substances 0.000 claims description 36
- 238000012423 maintenance Methods 0.000 claims description 34
- 229940118135 JNK inhibitor Drugs 0.000 claims description 30
- 230000037361 pathway Effects 0.000 claims description 30
- 239000013543 active substance Substances 0.000 claims description 25
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 claims description 24
- 102000013814 Wnt Human genes 0.000 claims description 24
- 108050003627 Wnt Proteins 0.000 claims description 24
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 102000043168 TGF-beta family Human genes 0.000 claims description 14
- 108091085018 TGF-beta family Proteins 0.000 claims description 14
- 230000036542 oxidative stress Effects 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 6
- 230000003938 response to stress Effects 0.000 claims description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 3
- 108091008743 testicular receptors 4 Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 109
- 210000001519 tissue Anatomy 0.000 description 221
- 239000002609 medium Substances 0.000 description 187
- 230000004069 differentiation Effects 0.000 description 115
- 230000006698 induction Effects 0.000 description 76
- 108090000623 proteins and genes Proteins 0.000 description 75
- 210000000130 stem cell Anatomy 0.000 description 67
- 229960000258 corticotropin Drugs 0.000 description 66
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 61
- 101800000414 Corticotropin Proteins 0.000 description 61
- 102400000739 Corticotropin Human genes 0.000 description 61
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 61
- 238000007792 addition Methods 0.000 description 56
- 230000000694 effects Effects 0.000 description 51
- 210000000981 epithelium Anatomy 0.000 description 47
- 239000012679 serum free medium Substances 0.000 description 44
- VFSUUTYAEQOIMW-YHBQERECSA-N 3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide Chemical compound C1C[C@@H](NC)CC[C@@H]1N(C(=O)C1=C(C2=CC=CC=C2S1)Cl)CC1=CC=CC(C=2C=CN=CC=2)=C1 VFSUUTYAEQOIMW-YHBQERECSA-N 0.000 description 41
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 39
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 39
- 238000010586 diagram Methods 0.000 description 38
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 37
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 37
- -1 KRpep-2d Chemical compound 0.000 description 36
- 210000002220 organoid Anatomy 0.000 description 35
- 206010062767 Hypophysitis Diseases 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 32
- 210000003635 pituitary gland Anatomy 0.000 description 32
- FHYUGAJXYORMHI-UHFFFAOYSA-N SB 431542 Chemical group C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCOC3=CC=2)=C(C=2N=CC=CC=2)N1 FHYUGAJXYORMHI-UHFFFAOYSA-N 0.000 description 31
- 239000010410 layer Substances 0.000 description 31
- 230000001537 neural effect Effects 0.000 description 31
- 229940088597 hormone Drugs 0.000 description 30
- 239000005556 hormone Substances 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical group S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 29
- 210000002469 basement membrane Anatomy 0.000 description 29
- 238000011282 treatment Methods 0.000 description 29
- 230000000977 initiatory effect Effects 0.000 description 28
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 27
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 27
- 210000002569 neuron Anatomy 0.000 description 24
- 230000008569 process Effects 0.000 description 24
- 102000000905 Cadherin Human genes 0.000 description 23
- 108050007957 Cadherin Proteins 0.000 description 23
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 23
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 23
- 108010085895 Laminin Proteins 0.000 description 23
- 102000007547 Laminin Human genes 0.000 description 23
- 108010029223 MAP kinase kinase kinase 7 Proteins 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 22
- 229940126864 fibroblast growth factor Drugs 0.000 description 22
- 239000000960 hypophysis hormone Substances 0.000 description 22
- 230000028327 secretion Effects 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 19
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 18
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 description 18
- 210000003981 ectoderm Anatomy 0.000 description 18
- 239000000122 growth hormone Substances 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- GJFCSAPFHAXMSF-UXBLZVDNSA-N 3-[[(e)-4-(dimethylamino)but-2-enoyl]amino]-n-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide Chemical compound CN(C)C\C=C\C(=O)NC1=CC=CC(C(=O)NC=2C=C(C)C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)=CC=2)=C1 GJFCSAPFHAXMSF-UXBLZVDNSA-N 0.000 description 17
- 108010051696 Growth Hormone Proteins 0.000 description 17
- 102100038803 Somatotropin Human genes 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 210000000653 nervous system Anatomy 0.000 description 16
- 108010088225 Nestin Proteins 0.000 description 15
- 102000008730 Nestin Human genes 0.000 description 15
- 102000003946 Prolactin Human genes 0.000 description 15
- 108010057464 Prolactin Proteins 0.000 description 15
- 230000004956 cell adhesive effect Effects 0.000 description 15
- 210000005055 nestin Anatomy 0.000 description 15
- 229940097325 prolactin Drugs 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 101000583156 Homo sapiens Pituitary homeobox 1 Proteins 0.000 description 14
- 102100030345 Pituitary homeobox 1 Human genes 0.000 description 14
- 230000001780 adrenocortical effect Effects 0.000 description 14
- 230000021164 cell adhesion Effects 0.000 description 14
- 239000002771 cell marker Substances 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 14
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 13
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 13
- 101001020452 Homo sapiens LIM/homeobox protein Lhx3 Proteins 0.000 description 13
- 101710154084 Interferon-inducible double-stranded RNA-dependent protein kinase activator A Proteins 0.000 description 13
- 102100036106 LIM/homeobox protein Lhx3 Human genes 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 102100029757 Retinal homeobox protein Rx Human genes 0.000 description 13
- 239000000853 adhesive Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 230000001070 adhesive effect Effects 0.000 description 12
- 239000006185 dispersion Substances 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 108010061174 Thyrotropin Proteins 0.000 description 11
- 102000011923 Thyrotropin Human genes 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 210000001671 embryonic stem cell Anatomy 0.000 description 11
- 210000002919 epithelial cell Anatomy 0.000 description 11
- 210000003016 hypothalamus Anatomy 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 241001481760 Erethizon dorsatum Species 0.000 description 10
- 108010070047 Notch Receptors Proteins 0.000 description 10
- 102000005650 Notch Receptors Human genes 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 210000002744 extracellular matrix Anatomy 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 238000012744 immunostaining Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 108010038862 laminin 10 Proteins 0.000 description 10
- 229940040129 luteinizing hormone Drugs 0.000 description 10
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 9
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 9
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 9
- 102000009151 Luteinizing Hormone Human genes 0.000 description 9
- 108010073521 Luteinizing Hormone Proteins 0.000 description 9
- 230000005913 Notch signaling pathway Effects 0.000 description 9
- 208000014993 Pituitary disease Diseases 0.000 description 9
- 210000003855 cell nucleus Anatomy 0.000 description 9
- 230000002490 cerebral effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 229940028334 follicle stimulating hormone Drugs 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 239000003223 protective agent Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 9
- CJLMANFTWLNAKC-UHFFFAOYSA-N 3-[6-amino-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenol Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=NC=C(C=2)C=2C=C(O)C=CC=2)N)=C1 CJLMANFTWLNAKC-UHFFFAOYSA-N 0.000 description 8
- 229920002971 Heparan sulfate Polymers 0.000 description 8
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 8
- 238000004115 adherent culture Methods 0.000 description 8
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000001120 cytoprotective effect Effects 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 229930002330 retinoic acid Natural products 0.000 description 8
- FJCDSQATIJKQKA-UHFFFAOYSA-N 2-fluoro-n-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]methyl]aniline Chemical compound CC1=CC=CC(C2=C(N=C(CNC=3C(=CC=CC=3)F)N2)C2=CN3N=CN=C3C=C2)=N1 FJCDSQATIJKQKA-UHFFFAOYSA-N 0.000 description 7
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 7
- NEQZWEXWOFPKOT-BYRRXHGESA-N 5Z-7-oxozeaenol Chemical compound O([C@@H](C)C\C=C/C(=O)[C@@H](O)[C@@H](O)C/C=C/1)C(=O)C=2C\1=CC(OC)=CC=2O NEQZWEXWOFPKOT-BYRRXHGESA-N 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 7
- CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 description 7
- 210000001130 astrocyte Anatomy 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 238000011109 contamination Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 210000001900 endoderm Anatomy 0.000 description 7
- 238000010362 genome editing Methods 0.000 description 7
- 210000001654 germ layer Anatomy 0.000 description 7
- 238000005286 illumination Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 210000003716 mesoderm Anatomy 0.000 description 7
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 7
- 210000001178 neural stem cell Anatomy 0.000 description 7
- 210000004498 neuroglial cell Anatomy 0.000 description 7
- 238000010899 nucleation Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 210000001578 tight junction Anatomy 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- KHZOJCQBHJUJFY-UHFFFAOYSA-N 2-[4-(2-methylpyridin-4-yl)phenyl]-n-(4-pyridin-3-ylphenyl)acetamide Chemical compound C1=NC(C)=CC(C=2C=CC(CC(=O)NC=3C=CC(=CC=3)C=3C=NC=CC=3)=CC=2)=C1 KHZOJCQBHJUJFY-UHFFFAOYSA-N 0.000 description 6
- FVRYPYDPKSZGNS-UHFFFAOYSA-N 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline Chemical compound C1=CC(OC)=CC=C1C1=CN2N=CC(C=3C4=CC=CN=C4C=CC=3)=C2N=C1 FVRYPYDPKSZGNS-UHFFFAOYSA-N 0.000 description 6
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 6
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 6
- IVRXNBXKWIJUQB-UHFFFAOYSA-N LY-2157299 Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 IVRXNBXKWIJUQB-UHFFFAOYSA-N 0.000 description 6
- 101710173438 Late L2 mu core protein Proteins 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 101710188315 Protein X Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 229940112869 bone morphogenetic protein Drugs 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000012137 double-staining Methods 0.000 description 6
- NEQZWEXWOFPKOT-UHFFFAOYSA-N f152A1 Natural products C1=CCC(O)C(O)C(=O)C=CCC(C)OC(=O)C=2C1=CC(OC)=CC=2O NEQZWEXWOFPKOT-UHFFFAOYSA-N 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000007667 floating Methods 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 108010082117 matrigel Proteins 0.000 description 6
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 6
- 210000000944 nerve tissue Anatomy 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- 229960001727 tretinoin Drugs 0.000 description 6
- HIJMSZGHKQPPJS-UHFFFAOYSA-N 3-(6-methylpyridin-2-yl)-n-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide Chemical compound CC1=CC=CC(C=2C(=CN(N=2)C(=S)NC=2C=CC=CC=2)C=2C3=CC=CC=C3N=CC=2)=N1 HIJMSZGHKQPPJS-UHFFFAOYSA-N 0.000 description 5
- DXLXRNZCYAYUED-UHFFFAOYSA-N 4-[2-[4-(3-quinolin-4-ylpyrazolo[1,5-a]pyrimidin-6-yl)phenoxy]ethyl]morpholine Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=CC=1OCCN1CCOCC1 DXLXRNZCYAYUED-UHFFFAOYSA-N 0.000 description 5
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 5
- BBDGBGOVJPEFBT-UHFFFAOYSA-N 5-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CN=C3C=CC=2)C=C1 BBDGBGOVJPEFBT-UHFFFAOYSA-N 0.000 description 5
- 108010059616 Activins Proteins 0.000 description 5
- RYVZYACBVYKUHD-UHFFFAOYSA-N Alk5 Natural products CC#CC#CCCCCC=CC(=O)NCC(C)C RYVZYACBVYKUHD-UHFFFAOYSA-N 0.000 description 5
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 description 5
- 101000632178 Homo sapiens Homeobox protein Nkx-2.1 Proteins 0.000 description 5
- 101000845269 Homo sapiens Transcription termination factor 1 Proteins 0.000 description 5
- 206010021067 Hypopituitarism Diseases 0.000 description 5
- 102100026818 Inhibin beta E chain Human genes 0.000 description 5
- 108091005461 Nucleic proteins Proteins 0.000 description 5
- 239000012826 P38 inhibitor Substances 0.000 description 5
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 5
- 101150081664 PAX6 gene Proteins 0.000 description 5
- 108091005735 TGF-beta receptors Proteins 0.000 description 5
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 5
- 239000000488 activin Substances 0.000 description 5
- ACPOUJIDANTYHO-UHFFFAOYSA-N anthra[1,9-cd]pyrazol-6(2H)-one Chemical group C1=CC(C(=O)C=2C3=CC=CC=2)=C2C3=NNC2=C1 ACPOUJIDANTYHO-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- IBGLGMOPHJQDJB-IHRRRGAJSA-N chembl1950289 Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=NC=C(N=C(NC=2C(=CC(F)=CC=2F)F)N2[C@@H]3COCC3)C2=N1 IBGLGMOPHJQDJB-IHRRRGAJSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 210000002451 diencephalon Anatomy 0.000 description 5
- 210000003890 endocrine cell Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229950000456 galunisertib Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 108010008217 nidogen Proteins 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 101150103310 pitx1 gene Proteins 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 description 4
- JUHTXZGCTPDXRU-UHFFFAOYSA-N 1-[4-(1,3-benzodioxol-5-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]bicyclo[2.2.2]octane-4-carboxamide Chemical compound CC1=CC=CC(C2=C(N=C(N2)C23CCC(CC2)(CC3)C(N)=O)C=2C=C3OCOC3=CC=2)=N1 JUHTXZGCTPDXRU-UHFFFAOYSA-N 0.000 description 4
- BHUXVRVMMYAXKN-UHFFFAOYSA-N 1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=NC=C(C=2)C=2C=CC(=CC=2)N2CCNCC2)C)=C1 BHUXVRVMMYAXKN-UHFFFAOYSA-N 0.000 description 4
- QTRXIFVSTWXRJJ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)-n-(6-phenylpyridazin-3-yl)acetamide Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC(=O)NC(N=N1)=CC=C1C1=CC=CC=C1 QTRXIFVSTWXRJJ-UHFFFAOYSA-N 0.000 description 4
- RBFDSBJDWZOTGR-UHFFFAOYSA-N 2-[(3,6-dimethyl-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C(C)C=C2SC(NC(=O)CSC3=NC=4CC(SC=4C(=O)N3C)C)=NC2=C1 RBFDSBJDWZOTGR-UHFFFAOYSA-N 0.000 description 4
- QESQGTFWEQMCMH-UHFFFAOYSA-N 2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-n-(5-phenylpyridin-2-yl)acetamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=NC=1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 QESQGTFWEQMCMH-UHFFFAOYSA-N 0.000 description 4
- HZTYDQRUAWIZRE-UHFFFAOYSA-N 2-[[2-[[1-[2-(dimethylamino)-1-oxoethyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide Chemical compound CNC(=O)C1=C(F)C=CC=C1NC1=C2C=CN=C2NC(NC=2C(=CC=3CCN(C=3C=2)C(=O)CN(C)C)OC)=N1 HZTYDQRUAWIZRE-UHFFFAOYSA-N 0.000 description 4
- XVMHQSDMKWQNBK-UHFFFAOYSA-N 2-[[3-(4-fluorophenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=C(F)C=C1 XVMHQSDMKWQNBK-UHFFFAOYSA-N 0.000 description 4
- XDJCLCLBSGGNKS-UHFFFAOYSA-N 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole Chemical compound C=1C=CC(C=2C3=CC(=CC=C3NN=2)C=2NN=CN=2)=CC=1OCCN1CCCCC1 XDJCLCLBSGGNKS-UHFFFAOYSA-N 0.000 description 4
- KJTYZDORHCDZPS-UHFFFAOYSA-N 4-[5-(6-methylpyridin-2-yl)-1h-pyrazol-4-yl]quinoline Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2C3=CC=CC=C3N=CC=2)=N1 KJTYZDORHCDZPS-UHFFFAOYSA-N 0.000 description 4
- DKPQHFZUICCZHF-UHFFFAOYSA-N 6-[2-tert-butyl-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline Chemical compound CC1=CC=CC(C2=C(N=C(N2)C(C)(C)C)C=2C=C3N=CC=NC3=CC=2)=N1 DKPQHFZUICCZHF-UHFFFAOYSA-N 0.000 description 4
- MGGBYMDAPCCKCT-UHFFFAOYSA-N ASP-3026 Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=NC=1NC1=CC=CC=C1S(=O)(=O)C(C)C MGGBYMDAPCCKCT-UHFFFAOYSA-N 0.000 description 4
- GCYIGMXOIWJGBU-UHFFFAOYSA-N AZD3463 Chemical compound C=1C=C(NC=2N=C(C(Cl)=CN=2)C=2C3=CC=CC=C3NC=2)C(OC)=CC=1N1CCC(N)CC1 GCYIGMXOIWJGBU-UHFFFAOYSA-N 0.000 description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 4
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 4
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 4
- JMIFGARJSWXZSH-UHFFFAOYSA-N DMH1 Chemical compound C1=CC(OC(C)C)=CC=C1C1=CN2N=CC(C=3C4=CC=CC=C4N=CC=3)=C2N=C1 JMIFGARJSWXZSH-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 4
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 4
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 4
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 4
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 description 4
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 4
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 4
- 150000000996 L-ascorbic acids Chemical class 0.000 description 4
- XXYGTCZJJLTAGH-UHFFFAOYSA-N LGK974 Chemical compound C1=NC(C)=CC(C=2C(=CC(CC(=O)NC=3N=CC(=CC=3)C=3N=CC=NC=3)=CN=2)C)=C1 XXYGTCZJJLTAGH-UHFFFAOYSA-N 0.000 description 4
- IBCXZJCWDGCXQT-UHFFFAOYSA-N LY 364947 Chemical compound C=1C=NC2=CC=CC=C2C=1C1=CNN=C1C1=CC=CC=N1 IBCXZJCWDGCXQT-UHFFFAOYSA-N 0.000 description 4
- 108700042694 Lhx3 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- HEKAIDKUDLCBRU-UHFFFAOYSA-N N-[4-[2-ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]benzamide Chemical compound S1C(CC)=NC(C=2C=C(C)C=CC=2)=C1C(C=1)=CC=NC=1NC(=O)C1=CC=CC=C1 HEKAIDKUDLCBRU-UHFFFAOYSA-N 0.000 description 4
- 102100037369 Nidogen-1 Human genes 0.000 description 4
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 4
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 4
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- WGZOTBUYUFBEPZ-UHFFFAOYSA-N SB 505124 Chemical compound CC1=CC=CC(C2=C(N=C(N2)C(C)(C)C)C=2C=C3OCOC3=CC=2)=N1 WGZOTBUYUFBEPZ-UHFFFAOYSA-N 0.000 description 4
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- LLFCXRYULHMNCG-UHFFFAOYSA-N chembl2207988 Chemical compound CC1=CSC(C2=C(NC=N2)C=2C=C3SC=NC3=CC=2)=N1 LLFCXRYULHMNCG-UHFFFAOYSA-N 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 4
- 238000011977 dual antiplatelet therapy Methods 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000010363 gene targeting Methods 0.000 description 4
- 230000000762 glandular Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- ZAVGJDAFCZAWSZ-UHFFFAOYSA-N hydroxyfasudil Chemical compound C1=CC=C2C(O)=NC=CC2=C1S(=O)(=O)N1CCCNCC1 ZAVGJDAFCZAWSZ-UHFFFAOYSA-N 0.000 description 4
- 230000002267 hypothalamic effect Effects 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- LXFKEVQQSKQXPR-UHFFFAOYSA-N n-(6-chloro-1,3-benzothiazol-2-yl)-3-(3,4-dimethoxyphenyl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1CCC(=O)NC1=NC2=CC=C(Cl)C=C2S1 LXFKEVQQSKQXPR-UHFFFAOYSA-N 0.000 description 4
- SAGZIBJAQGBRQA-UHFFFAOYSA-N n-(oxan-4-yl)-4-[4-(5-pyridin-2-yl-1h-pyrazol-4-yl)pyridin-2-yl]benzamide Chemical compound C=1C=C(C=2N=CC=C(C=2)C2=C(NN=C2)C=2N=CC=CC=2)C=CC=1C(=O)NC1CCOCC1 SAGZIBJAQGBRQA-UHFFFAOYSA-N 0.000 description 4
- AXXNRMISICMFNS-UHFFFAOYSA-N n-[5-(4-acetylpiperazin-1-yl)pyridin-2-yl]-2-[6-(2-fluoropyridin-4-yl)-5-methylpyridin-3-yl]acetamide Chemical compound C1CN(C(=O)C)CCN1C(C=N1)=CC=C1NC(=O)CC1=CN=C(C=2C=C(F)N=CC=2)C(C)=C1 AXXNRMISICMFNS-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- FYBHCRQFSFYWPY-UHFFFAOYSA-N purmorphamine Chemical compound C1CCCCC1N1C2=NC(OC=3C4=CC=CC=C4C=CC=3)=NC(NC=3C=CC(=CC=3)N3CCOCC3)=C2N=C1 FYBHCRQFSFYWPY-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 3
- MWUFVYLAWAXDHQ-HMNLTAHHSA-N (2e,5s,6s,8z,10r,11s)-17-(ethylamino)-5,6,15-trihydroxy-10,11-dimethyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,8,14,16-pentaene-7,13-dione Chemical compound O([C@@H](C)[C@H](C)\C=C/C(=O)[C@@H](O)[C@@H](O)C/C=C/1)C(=O)C=2C\1=CC(NCC)=CC=2O MWUFVYLAWAXDHQ-HMNLTAHHSA-N 0.000 description 3
- ROFMCPHQNWGXGE-SFHVURJKSA-N (3s)-n-[2-[2-(dimethylamino)ethoxy]-4-(1h-pyrazol-4-yl)phenyl]-6-methoxy-3,4-dihydro-2h-chromene-3-carboxamide Chemical compound O=C([C@@H]1COC2=CC=C(C=C2C1)OC)NC(C(=C1)OCCN(C)C)=CC=C1C=1C=NNC=1 ROFMCPHQNWGXGE-SFHVURJKSA-N 0.000 description 3
- IPFOCHMOYUMURK-UHFFFAOYSA-N 1-[3-[4-[2-[4-chloro-2-hydroxy-5-(1-methylcyclopropyl)anilino]acetyl]piperazin-1-yl]azetidin-1-yl]prop-2-en-1-one Chemical compound C=1C(NCC(=O)N2CCN(CC2)C2CN(C2)C(=O)C=C)=C(O)C=C(Cl)C=1C1(C)CC1 IPFOCHMOYUMURK-UHFFFAOYSA-N 0.000 description 3
- TXDIRJCYNAWBOS-UHFFFAOYSA-N 1-[4-[4-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-chloropyrimidin-4-yl]amino]-3-methoxyphenyl]piperazin-1-yl]ethanone Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(Cl)C=1NC(C(=C1)OC)=CC=C1N1CCN(C(C)=O)CC1 TXDIRJCYNAWBOS-UHFFFAOYSA-N 0.000 description 3
- RCYPVQCPYKNSTG-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-2-[2-[2-(3-pyridinyl)ethylamino]-4-pyrimidinyl]acetonitrile Chemical compound N=1C2=CC=CC=C2SC=1C(C#N)C(N=1)=CC=NC=1NCCC1=CC=CN=C1 RCYPVQCPYKNSTG-UHFFFAOYSA-N 0.000 description 3
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 3
- XKZDWYDHEBCGCG-UHFFFAOYSA-N 2-(4-bromo-2-chlorophenoxy)-n-[[4-[(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenyl]carbamothioyl]acetamide Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(NC(=S)NC(=O)COC=3C(=CC(Br)=CC=3)Cl)=CC=2)=N1 XKZDWYDHEBCGCG-UHFFFAOYSA-N 0.000 description 3
- LSECOAJFCKFQJG-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)-5-[5-[7-(trifluoromethyl)quinolin-4-yl]sulfanylpentoxy]pyran-4-one;dihydrochloride Chemical compound Cl.Cl.C=1C=NC2=CC(C(F)(F)F)=CC=C2C=1SCCCCCOC(C(C=1)=O)=COC=1CN1CCOCC1 LSECOAJFCKFQJG-UHFFFAOYSA-N 0.000 description 3
- QHPKKGUGRGRSGA-UHFFFAOYSA-N 2-({2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl}amino)benzamide Chemical compound NC(=O)C1=CC=CC=C1NC1=CC=NC(NC=2C=C(O)C=CC=2)=N1 QHPKKGUGRGRSGA-UHFFFAOYSA-N 0.000 description 3
- UHBFMJAKLZGVDS-UHFFFAOYSA-N 2-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1,3-benzothiazole Chemical compound S1C([N+](=O)[O-])=CN=C1SC1=NC2=CC=CC=C2S1 UHBFMJAKLZGVDS-UHFFFAOYSA-N 0.000 description 3
- GKHIVNAUVKXIIY-UHFFFAOYSA-N 2-[3-[4-(1h-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-ylacetamide Chemical compound CC(C)NC(=O)COC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=C4C=NNC4=CC=3)N=2)=C1 GKHIVNAUVKXIIY-UHFFFAOYSA-N 0.000 description 3
- JQGOCCALXFSRHZ-UHFFFAOYSA-N 2-[4-[2-fluoro-5-[5-(6-methylpyridin-2-yl)-1h-pyrazol-4-yl]phenyl]pyrazol-1-yl]ethanol Chemical compound CC1=CC=CC(C=2C(=CNN=2)C=2C=C(C(F)=CC=2)C2=CN(CCO)N=C2)=N1 JQGOCCALXFSRHZ-UHFFFAOYSA-N 0.000 description 3
- PNPFMWIDAKQFPY-UHFFFAOYSA-N 2-[4-[[4-[1-cyclopropyl-3-(oxan-4-yl)pyrazol-4-yl]oxypyridin-2-yl]amino]pyridin-2-yl]propan-2-ol Chemical compound C1(CC1)N1N=C(C(=C1)OC1=CC(=NC=C1)NC1=CC(=NC=C1)C(C)(C)O)C1CCOCC1 PNPFMWIDAKQFPY-UHFFFAOYSA-N 0.000 description 3
- RHUJMHOIQBDFQR-UHFFFAOYSA-N 2-[[3-(2-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound COC1=CC=CC=C1N1C(=O)C(SCC2)=C2N=C1SCC(=O)NC1=NC2=CC=C(C)C=C2S1 RHUJMHOIQBDFQR-UHFFFAOYSA-N 0.000 description 3
- RYKSGWSKILPDDY-UHFFFAOYSA-N 3-[[5-(6-methylpyridin-2-yl)-4-quinoxalin-6-yl-1h-imidazol-2-yl]methyl]benzamide Chemical compound CC1=CC=CC(C2=C(N=C(CC=3C=C(C=CC=3)C(N)=O)N2)C=2C=C3N=CC=NC3=CC=2)=N1 RYKSGWSKILPDDY-UHFFFAOYSA-N 0.000 description 3
- QFRLDZGQEZCCJZ-UHFFFAOYSA-N 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(5-nitro-2-thiazolyl)thio]-1H-1,2,4-triazol-5-one Chemical compound S1C([N+](=O)[O-])=CN=C1SC1=NNC(=O)N1C1=CC=C(OCCO2)C2=C1 QFRLDZGQEZCCJZ-UHFFFAOYSA-N 0.000 description 3
- IHLVSLOZUHKNMQ-UHFFFAOYSA-N 4-[2-[4-(2-pyridin-2-yl-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl]oxyethyl]morpholine Chemical compound C=1C=C2C(C=3C(=NN4CCCC4=3)C=3N=CC=CC=3)=CC=NC2=CC=1OCCN1CCOCC1 IHLVSLOZUHKNMQ-UHFFFAOYSA-N 0.000 description 3
- QBNZBMVRFYREHK-UHFFFAOYSA-N 4-[3-(4-methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1C1N(C=2C=CC(=CC=2)S(N)(=O)=O)N=C(C=2C=CC=CC=2)C1 QBNZBMVRFYREHK-UHFFFAOYSA-N 0.000 description 3
- UEOZXMAOIHDDQE-UHFFFAOYSA-N 4-[[4-(2,6-dimethylpyridin-3-yl)oxypyridin-2-yl]amino]benzenesulfonamide Chemical compound CC1=NC(C)=CC=C1OC1=CC=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=C1 UEOZXMAOIHDDQE-UHFFFAOYSA-N 0.000 description 3
- AFTZZRFCMOAFCR-UHFFFAOYSA-N 4-n-(9-ethylcarbazol-3-yl)-2-n-(3-morpholin-4-ylpropyl)pyrimidine-2,4-diamine Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NC(N=1)=CC=NC=1NCCCN1CCOCC1 AFTZZRFCMOAFCR-UHFFFAOYSA-N 0.000 description 3
- QQWUGDVOUVUTOY-UHFFFAOYSA-N 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)C(C)C QQWUGDVOUVUTOY-UHFFFAOYSA-N 0.000 description 3
- LJCANTASZGYJLG-UHFFFAOYSA-N 9-ethyl-3-(5-phenyltriazol-1-yl)carbazole Chemical compound C(C)N1C2=CC=CC=C2C=2C=C(C=CC1=2)N1N=NC=C1C1=CC=CC=C1 LJCANTASZGYJLG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 229920001342 Bakelite® Polymers 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 108091016585 CD44 antigen Proteins 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 3
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 description 3
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 3
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 description 3
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 3
- 101001096159 Homo sapiens Pituitary-specific positive transcription factor 1 Proteins 0.000 description 3
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000025282 Hypothalamo-pituitary disease Diseases 0.000 description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- 108050000637 N-cadherin Proteins 0.000 description 3
- 101150111110 NKX2-1 gene Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 3
- 108010067372 Pancreatic elastase Proteins 0.000 description 3
- 102000016387 Pancreatic elastase Human genes 0.000 description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 3
- 201000005746 Pituitary adenoma Diseases 0.000 description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 description 3
- 102100037914 Pituitary-specific positive transcription factor 1 Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- KCSAJXDPYPCGAE-UHFFFAOYSA-N S1C=NC2=C1C=C(C=C2)C1=CC(=NN1C1=NC(=CC=C1)C)C(=O)NC1=CC=C(C=C1)O Chemical compound S1C=NC2=C1C=C(C=C2)C1=CC(=NN1C1=NC(=CC=C1)C)C(=O)NC1=CC=C(C=C1)O KCSAJXDPYPCGAE-UHFFFAOYSA-N 0.000 description 3
- QHKYPYXTTXKZST-UHFFFAOYSA-N SB-202190 Chemical compound C1=CC(O)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 QHKYPYXTTXKZST-UHFFFAOYSA-N 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 108090000054 Syndecan-2 Proteins 0.000 description 3
- 108010031318 Vitronectin Proteins 0.000 description 3
- 102100035140 Vitronectin Human genes 0.000 description 3
- 238000011276 addition treatment Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003470 adrenal cortex hormone Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004198 anterior pituitary gland Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000004720 cerebrum Anatomy 0.000 description 3
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000002518 glial effect Effects 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000031146 intracellular signal transduction Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- JIUFLMSAFMXEEC-UHFFFAOYSA-N n-(6-methoxy-1,3-benzothiazol-2-yl)-2-[(4-propyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide Chemical compound CCCN1C(SCC(=O)NC=2SC3=CC(OC)=CC=C3N=2)=NN=C1C1=CC=NC=C1 JIUFLMSAFMXEEC-UHFFFAOYSA-N 0.000 description 3
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 3
- 210000003061 neural cell Anatomy 0.000 description 3
- 210000000933 neural crest Anatomy 0.000 description 3
- 210000005155 neural progenitor cell Anatomy 0.000 description 3
- 210000004248 oligodendroglia Anatomy 0.000 description 3
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 208000021310 pituitary gland adenoma Diseases 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- MDLUYYGRCGDKGL-UHFFFAOYSA-N propyl 4-[(1-hexyl-4-hydroxy-2-oxoquinoline-3-carbonyl)amino]benzoate Chemical compound O=C1N(CCCCCC)C2=CC=CC=C2C(O)=C1C(=O)NC1=CC=C(C(=O)OCCC)C=C1 MDLUYYGRCGDKGL-UHFFFAOYSA-N 0.000 description 3
- WUILNKCFCLNXOK-CFBAGHHKSA-N salirasib Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O WUILNKCFCLNXOK-CFBAGHHKSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 3
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000000603 stem cell niche Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QSHGISMANBKLQL-OWJWWREXSA-N (2s)-2-[[2-(3,5-difluorophenyl)acetyl]amino]-n-[(7s)-5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl]propanamide Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C2=CC=CC=C21)=O)C(=O)CC1=CC(F)=CC(F)=C1 QSHGISMANBKLQL-OWJWWREXSA-N 0.000 description 2
- NRHASZRDWOUMFD-SFHVURJKSA-N (2s)-3-phenyl-1-n-(2-pyridin-4-yl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)propane-1,2-diamine Chemical compound C([C@@H](N)CC=1C=CC=CC=1)NC(C=1C=2CCCCC=2SC=1N=1)=NC=1C1=CC=NC=C1 NRHASZRDWOUMFD-SFHVURJKSA-N 0.000 description 2
- AWDORCFLUJZUQS-ZDUSSCGKSA-N (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(C)=C12 AWDORCFLUJZUQS-ZDUSSCGKSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- INGCLXPSKXSYND-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-(1-methylpiperidin-4-yl)-1h-indol-5-ol Chemical compound OC(=O)\C=C/C(O)=O.C1CN(C)CCC1C1=CNC2=CC=C(O)C=C12 INGCLXPSKXSYND-BTJKTKAUSA-N 0.000 description 2
- DVIJFJSZZNOTLP-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-2-[2-(trifluoromethyl)phenyl]guanidine Chemical compound CC1=CC(C)=CC(NC(=N)NC=2C(=CC=CC=2)C(F)(F)F)=C1 DVIJFJSZZNOTLP-UHFFFAOYSA-N 0.000 description 2
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 2
- GDVRVPIXWXOKQO-UHFFFAOYSA-N 1-[(3-hydroxyphenyl)methyl]-3-(4-pyridin-4-yl-1,3-thiazol-2-yl)urea Chemical compound OC1=CC=CC(CNC(=O)NC=2SC=C(N=2)C=2C=CN=CC=2)=C1 GDVRVPIXWXOKQO-UHFFFAOYSA-N 0.000 description 2
- LNMRSSIMGCDUTP-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[[5-fluoro-2-[1-(2-hydroxyethyl)indazol-5-yl]oxyphenyl]methyl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NCC=2C(=CC=C(F)C=2)OC=2C=C3C=NN(CCO)C3=CC=2)=CC(C(C)(C)C)=N1 LNMRSSIMGCDUTP-UHFFFAOYSA-N 0.000 description 2
- ZQFBVJBAWLZLOM-UHFFFAOYSA-N 1-cyano-2-[2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]guanidine Chemical compound CC1=CC(F)=CC=C1C1=NC(NCCNC(=N)NC#N)=NC2=C1C=CC(=O)N2C1=C(F)C=CC=C1F ZQFBVJBAWLZLOM-UHFFFAOYSA-N 0.000 description 2
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 2
- YSZJLXPXVFGTNK-UHFFFAOYSA-N 2-(4-ethylphenoxy)-n-(4-fluoro-3-nitrophenyl)acetamide Chemical compound C1=CC(CC)=CC=C1OCC(=O)NC1=CC=C(F)C([N+]([O-])=O)=C1 YSZJLXPXVFGTNK-UHFFFAOYSA-N 0.000 description 2
- VDYRZXYYQMMFJW-UHFFFAOYSA-N 2-(dimethylamino)-n-(1-oxo-2h-isoquinolin-6-yl)-2-thiophen-3-ylacetamide Chemical compound C=1C=C2C(O)=NC=CC2=CC=1NC(=O)C(N(C)C)C=1C=CSC=1 VDYRZXYYQMMFJW-UHFFFAOYSA-N 0.000 description 2
- QMLOYDPILBUVBV-UHFFFAOYSA-N 2-[5-methyl-4-[2-(trifluoromethyl)pyridin-4-yl]imidazol-1-yl]-N-(5-pyrazin-2-ylpyridin-2-yl)acetamide Chemical compound CC1=C(N=CN1CC(=O)NC1=NC=C(C=C1)C1=NC=CN=C1)C1=CC(=NC=C1)C(F)(F)F QMLOYDPILBUVBV-UHFFFAOYSA-N 0.000 description 2
- ANEBQUSWQAQFQB-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]-1,3-thiazole-5-carboxamide Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC(C(=CC=1)C)=CC=1NC(=O)C1=CC=CC(C(F)(F)F)=C1 ANEBQUSWQAQFQB-UHFFFAOYSA-N 0.000 description 2
- MCKLJFJEQRYRQT-APGJSSKUSA-N 20-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@](C)(O)CCCC(C)C)[C@@]1(C)CC2 MCKLJFJEQRYRQT-APGJSSKUSA-N 0.000 description 2
- AKUKHICVNCCQHN-UHFFFAOYSA-N 3,4,6-trichloro-2-(2,3,5-trichloro-6-hydroxyphenyl)sulfonylphenol Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1S(=O)(=O)C1=C(O)C(Cl)=CC(Cl)=C1Cl AKUKHICVNCCQHN-UHFFFAOYSA-N 0.000 description 2
- HXMGCTFLLWPVFM-GOSISDBHSA-N 3-(2,4-difluoroanilino)-9-[(2r)-2,3-dihydroxypropoxy]-5,6-dihydrodibenzo[3,1-[7]annulen-11-one Chemical compound C=1C=C2C(=O)C3=CC(OC[C@H](O)CO)=CC=C3CCC2=CC=1NC1=CC=C(F)C=C1F HXMGCTFLLWPVFM-GOSISDBHSA-N 0.000 description 2
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 2
- OCUQMWSIGPQEMX-UHFFFAOYSA-N 3-[3-[N-[4-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indol-6-yl]-N-ethylprop-2-ynamide Chemical compound CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4 OCUQMWSIGPQEMX-UHFFFAOYSA-N 0.000 description 2
- MTFAYLZZDJGFGV-UHFFFAOYSA-N 3-[4-[(3-methylphenyl)carbamoylamino]pyrazol-1-yl]-n-(3,4,5-trimethoxyphenyl)benzamide Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)C=2C=C(C=CC=2)N2N=CC(NC(=O)NC=3C=C(C)C=CC=3)=C2)=C1 MTFAYLZZDJGFGV-UHFFFAOYSA-N 0.000 description 2
- WGPXKFOFEXJMBD-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N)O WGPXKFOFEXJMBD-UHFFFAOYSA-N 0.000 description 2
- UNTPTSFVGRSTDC-UHFFFAOYSA-N 3-amino-5-[4-(morpholin-4-ylmethyl)phenyl]thiophene-2-carboxamide Chemical compound NC1=C(C(=O)N)SC(C=2C=CC(CN3CCOCC3)=CC=2)=C1 UNTPTSFVGRSTDC-UHFFFAOYSA-N 0.000 description 2
- UOZVVPXKJGOFIG-UHFFFAOYSA-N 3-n-(1-propylbenzimidazol-2-yl)benzene-1,3-dicarboxamide Chemical compound N=1C2=CC=CC=C2N(CCC)C=1NC(=O)C1=CC=CC(C(N)=O)=C1 UOZVVPXKJGOFIG-UHFFFAOYSA-N 0.000 description 2
- HXBKPYIEQLLNBK-UHFFFAOYSA-N 4-(4-octylphenyl)benzoic acid Chemical compound C1=CC(CCCCCCCC)=CC=C1C1=CC=C(C(O)=O)C=C1 HXBKPYIEQLLNBK-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- KFBPBWUZXBYJDG-UHFFFAOYSA-N 4-[(1,1,3,3-tetramethyl-2-oxoindene-5-carbonyl)amino]benzoic acid Chemical compound C=1C=C2C(C)(C)C(=O)C(C)(C)C2=CC=1C(=O)NC1=CC=C(C(O)=O)C=C1 KFBPBWUZXBYJDG-UHFFFAOYSA-N 0.000 description 2
- JTVBXQAYBIJXRP-SNVBAGLBSA-N 4-[(1R)-1-aminoethyl]-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical compound C1=CC([C@H](N)C)=CC=C1C(=O)NC1=CC=NC2=C1C=CN2 JTVBXQAYBIJXRP-SNVBAGLBSA-N 0.000 description 2
- QIFJOFNVIVQRNJ-UHFFFAOYSA-N 4-[2-(2-fluorophenyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl]pyridine Chemical compound C1=CC(F)=CC=C1C1=C(C=2C=CN=CC=2)NC(C=2C(=CC=CC=2)F)=N1 QIFJOFNVIVQRNJ-UHFFFAOYSA-N 0.000 description 2
- HSAOETBFVAWNRP-UHFFFAOYSA-N 4-[4-(2-butoxyethoxy)-5-methyl-1,3-thiazol-2-yl]-2-fluorobenzoic acid Chemical compound S1C(C)=C(OCCOCCCC)N=C1C1=CC=C(C(O)=O)C(F)=C1 HSAOETBFVAWNRP-UHFFFAOYSA-N 0.000 description 2
- BGIYKDUASORTBB-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-imidazol-5-yl]pyridine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 BGIYKDUASORTBB-UHFFFAOYSA-N 0.000 description 2
- VXPWQNBKEIVYIS-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-2-methylsulfanyl-1h-imidazol-4-yl]-n-(1-phenylethyl)pyridin-2-amine Chemical compound N1C(SC)=NC(C=2C=C(NC(C)C=3C=CC=CC=3)N=CC=2)=C1C1=CC=C(F)C=C1 VXPWQNBKEIVYIS-UHFFFAOYSA-N 0.000 description 2
- VCQGNUWOMLYNNG-UHFFFAOYSA-N 4-[7-(1-adamantyl)-6-hydroxynaphthalen-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=C(O)C(=C2)C34CC5CC(CC(C5)C3)C4)C2=C1 VCQGNUWOMLYNNG-UHFFFAOYSA-N 0.000 description 2
- KTSDBMVHAKWDRK-UHFFFAOYSA-N 4-chloro-7,10-dioxa-13,17,18,21-tetrazatetracyclo[12.5.2.12,6.017,20]docosa-1(20),2(22),3,5,14(21),15,18-heptaene Chemical compound Clc1cc2OCCOCCNc3ccn4ncc(-c(c1)c2)c4n3 KTSDBMVHAKWDRK-UHFFFAOYSA-N 0.000 description 2
- URUSABQSUCBGGJ-UHFFFAOYSA-N 5-(5,5,8,8-tetramethyl-6,7-dihydroanthracen-2-yl)thiophene-3-carboxylic acid Chemical compound C=1C=C2C=C3C(C)(C)CCC(C)(C)C3=CC2=CC=1C1=CC(C(O)=O)=CS1 URUSABQSUCBGGJ-UHFFFAOYSA-N 0.000 description 2
- NARMJPIBAXVUIE-UHFFFAOYSA-N 5-[2-tert-butyl-4-(4-fluorophenyl)-1h-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.N1=C2N(CC(C)(C)C)C(N)=NC2=CC=C1C=1N=C(C(C)(C)C)NC=1C1=CC=C(F)C=C1 NARMJPIBAXVUIE-UHFFFAOYSA-N 0.000 description 2
- MQUYTXDAVCOCMX-UHFFFAOYSA-N 6-phenyl-2-imidazo[2,1-b][1,3,4]thiadiazolesulfonamide Chemical compound N1=C2SC(S(=O)(=O)N)=NN2C=C1C1=CC=CC=C1 MQUYTXDAVCOCMX-UHFFFAOYSA-N 0.000 description 2
- IAUZTOZLTFSMIE-UHFFFAOYSA-N 9-hydroxy-4-phenyl-6h-pyrrolo[3,4-c]carbazole-1,3-dione Chemical compound C=12C(=O)NC(=O)C2=C2C3=CC(O)=CC=C3NC2=CC=1C1=CC=CC=C1 IAUZTOZLTFSMIE-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- 101100256985 Arabidopsis thaliana SIS3 gene Proteins 0.000 description 2
- 239000000592 Artificial Cell Substances 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 2
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 2
- 108010040163 CREB-Binding Protein Proteins 0.000 description 2
- 102100021975 CREB-binding protein Human genes 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 102100024155 Cadherin-11 Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000009798 Craniopharyngioma Diseases 0.000 description 2
- 101100239628 Danio rerio myca gene Proteins 0.000 description 2
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100023721 Ephrin-B2 Human genes 0.000 description 2
- 108010044090 Ephrin-B2 Proteins 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 2
- RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 description 2
- 239000012571 GlutaMAX medium Substances 0.000 description 2
- 102000003693 Hedgehog Proteins Human genes 0.000 description 2
- 108090000031 Hedgehog Proteins Proteins 0.000 description 2
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 2
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 2
- 101000958332 Homo sapiens Lymphocyte antigen 6 complex locus protein G6d Proteins 0.000 description 2
- 101001069727 Homo sapiens Paired mesoderm homeobox protein 1 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 241000283953 Lagomorpha Species 0.000 description 2
- 241000288903 Lemuridae Species 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 241000288986 Lorisidae Species 0.000 description 2
- 102100038210 Lymphocyte antigen 6 complex locus protein G6d Human genes 0.000 description 2
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 2
- 101150039798 MYC gene Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 2
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- 101100445103 Mus musculus Emx2 gene Proteins 0.000 description 2
- 101000716728 Mus musculus Kit ligand Proteins 0.000 description 2
- 101100074807 Mus musculus Lhx3 gene Proteins 0.000 description 2
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 description 2
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000005640 Myosin Type II Human genes 0.000 description 2
- 108010045128 Myosin Type II Proteins 0.000 description 2
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 2
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 210000005156 Müller Glia Anatomy 0.000 description 2
- WQGDQGAFSDMBLA-UHFFFAOYSA-N N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide Chemical compound C1=CC=C2C(C(NC3=C(C=4CCCCC=4S3)C#N)=O)=CC=CC2=C1 WQGDQGAFSDMBLA-UHFFFAOYSA-N 0.000 description 2
- OLIIUAHHAZEXEX-UHFFFAOYSA-N N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyridine-5-carboxamide Chemical compound C1C(=O)NC(C)=C(C(=O)NC=2C(=CC=3NN=CC=3C=2)F)C1C1=CC=C(C(F)(F)F)C=C1 OLIIUAHHAZEXEX-UHFFFAOYSA-N 0.000 description 2
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 2
- JGQSLTZPBLZNBX-UHFFFAOYSA-N N-ethyl-2-hydroxy-N-methyl-3-[C-phenyl-N-[4-(piperidin-1-ylmethyl)phenyl]carbonimidoyl]-1H-indole-6-carboxamide Chemical compound CCN(C)C(=O)C1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN4CCCCC4)C5=CC=CC=C5 JGQSLTZPBLZNBX-UHFFFAOYSA-N 0.000 description 2
- DEFBCZWQLILOJF-UHFFFAOYSA-N NSC 23766 Chemical compound CCN(CC)CCCC(C)NC1=NC(C)=CC(NC=2C=C3C(N)=CC(C)=NC3=CC=2)=N1 DEFBCZWQLILOJF-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- KCAJXIDMCNPGHZ-UHFFFAOYSA-N PH 797804 Chemical compound CNC(=O)C1=CC=C(C)C(N2C(C(Br)=C(OCC=3C(=CC(F)=CC=3)F)C=C2C)=O)=C1 KCAJXIDMCNPGHZ-UHFFFAOYSA-N 0.000 description 2
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 2
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
- 102100033786 Paired mesoderm homeobox protein 1 Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000006877 Pituitary Hormones Human genes 0.000 description 2
- 108010047386 Pituitary Hormones Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108700017836 Prophet of Pit-1 Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 102000011425 S100 Calcium Binding Protein beta Subunit Human genes 0.000 description 2
- 108010023918 S100 Calcium Binding Protein beta Subunit Proteins 0.000 description 2
- CATQHDWESBRRQA-UHFFFAOYSA-N SD-06 Chemical compound C1CN(C(=O)CO)CCC1C1=NNC(C=2C=CC(Cl)=CC=2)=C1C1=CC=NC=N1 CATQHDWESBRRQA-UHFFFAOYSA-N 0.000 description 2
- CDKIEBFIMCSCBB-CALJPSDSSA-N SIS3 Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)\C=C\C(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-CALJPSDSSA-N 0.000 description 2
- 101150086694 SLC22A3 gene Proteins 0.000 description 2
- 101150106167 SOX9 gene Proteins 0.000 description 2
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 2
- 102100034201 Sclerostin Human genes 0.000 description 2
- 102100034447 Serine/threonine-protein kinase NLK Human genes 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000004535 Tankyrases Human genes 0.000 description 2
- 108010017601 Tankyrases Proteins 0.000 description 2
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108010063130 Type II Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
- 102000010571 Type II Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 description 2
- VEPKQEUBKLEPRA-UHFFFAOYSA-N VX-745 Chemical compound FC1=CC(F)=CC=C1SC1=NN2C=NC(=O)C(C=3C(=CC=CC=3Cl)Cl)=C2C=C1 VEPKQEUBKLEPRA-UHFFFAOYSA-N 0.000 description 2
- 241000545067 Venus Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 102100035071 Vimentin Human genes 0.000 description 2
- 102000006757 Wnt Receptors Human genes 0.000 description 2
- 108010047118 Wnt Receptors Proteins 0.000 description 2
- 102100038258 Wnt inhibitory factor 1 Human genes 0.000 description 2
- 101710194167 Wnt inhibitory factor 1 Proteins 0.000 description 2
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 2
- NGBKFLTYGSREKK-PMACEKPBSA-N Z-Val-Phe-H Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C(=O)OCC1=CC=CC=C1 NGBKFLTYGSREKK-PMACEKPBSA-N 0.000 description 2
- WBSWWONMTZEOGS-PTGBLXJZSA-N [(e)-indeno[1,2-b]quinoxalin-11-ylideneamino] furan-2-carboxylate Chemical compound C\12=CC=CC=C2C2=NC3=CC=CC=C3N=C2C/1=N/OC(=O)C1=CC=CO1 WBSWWONMTZEOGS-PTGBLXJZSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- WTZMCUOBQPTERK-UHFFFAOYSA-N [2-methoxy-3-(4,5,10-triazatetracyclo[7.7.0.02,6.012,16]hexadeca-1(9),2(6),3,7,10,12(16)-hexaen-11-yl)phenyl]boronic acid Chemical compound COc1c(cccc1-c1nc2ccc3[nH]ncc3c2c2CCCc12)B(O)O WTZMCUOBQPTERK-UHFFFAOYSA-N 0.000 description 2
- PWPNYABQEOGNNC-UHFFFAOYSA-N [3-[[4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carbonyl]amino]phenyl] n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=CC=CC(NC(=O)C2(CN)CCN(CC2)C=2C=3C(C)=CNC=3N=CN=2)=C1 PWPNYABQEOGNNC-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
- 239000002318 adhesion promoter Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229950010482 alpelisib Drugs 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940126313 avutometinib Drugs 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- LZAXPYOBKSJSEX-UHFFFAOYSA-N blebbistatin Chemical compound C1CC2(O)C(=O)C3=CC(C)=CC=C3N=C2N1C1=CC=CC=C1 LZAXPYOBKSJSEX-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000017455 cell-cell adhesion Effects 0.000 description 2
- 230000025611 cell-substrate adhesion Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960001602 ceritinib Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- 235000015246 common arrowhead Nutrition 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- SWWVFYHSSOWZMF-UHFFFAOYSA-N cyclohexyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,6,8-tetrahydroquinoline-3-carboxylate Chemical compound C1C(C)(C)CC(=O)C2=C1NC(C)=C(C(=O)OC1CCCCC1)C2C1=CC=C([N+]([O-])=O)C=C1 SWWVFYHSSOWZMF-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- ULFUJLFTRWWLPO-UHFFFAOYSA-N ethyl 2,7,7-trimethyl-5-oxo-4-(4-phenylphenyl)-1,4,6,8-tetrahydroquinoline-3-carboxylate Chemical compound CCOC(=O)C1=C(C)NC(CC(C)(C)CC2=O)=C2C1C(C=C1)=CC=C1C1=CC=CC=C1 ULFUJLFTRWWLPO-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000000842 folliculostellate cell Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000004368 gonadotroph Anatomy 0.000 description 2
- SCMLRESZJCKCTC-KMYQRJGFSA-N gtpl8173 Chemical compound C12=CC=C(CSCC)C=C2C2=C(CNC3=O)C3=C3C4=CC(CSCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@](O)(C(=O)OC)C[C@H]4O1 SCMLRESZJCKCTC-KMYQRJGFSA-N 0.000 description 2
- NQQBNZBOOHHVQP-UHFFFAOYSA-N halicin Chemical compound S1C(N)=NN=C1SC1=NC=C([N+]([O-])=O)S1 NQQBNZBOOHHVQP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000007728 intracellular signaling mechanism Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- HBQGFROGWOHBAG-UHFFFAOYSA-K manganese(3+);2-[2-[(2-oxidophenyl)methylideneamino]ethyliminomethyl]phenolate;chloride Chemical compound [Cl-].[Mn+3].[O-]C1=CC=CC=C1C=NCCN=CC1=CC=CC=C1[O-] HBQGFROGWOHBAG-UHFFFAOYSA-K 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- DQNMDJGZWFZNHS-UHFFFAOYSA-N n-(4,5-dihydrobenzo[e][1,3]benzothiazol-2-yl)-2-(3,4-dimethoxyphenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)NC(S1)=NC2=C1CCC1=CC=CC=C21 DQNMDJGZWFZNHS-UHFFFAOYSA-N 0.000 description 2
- JRVSFZKYQCETAH-OAHLLOKOSA-N n-[(1r)-1-(3-methoxyphenyl)ethyl]-4-pyridin-4-ylbenzamide Chemical compound COC1=CC=CC([C@@H](C)NC(=O)C=2C=CC(=CC=2)C=2C=CN=CC=2)=C1 JRVSFZKYQCETAH-OAHLLOKOSA-N 0.000 description 2
- DPZSYTMLVCLGRU-UHFFFAOYSA-N n-[1-[(4-methylsulfanylphenyl)methyl]piperidin-3-yl]-1h-indazol-5-amine Chemical compound C1=CC(SC)=CC=C1CN1CC(NC=2C=C3C=NNC3=CC=2)CCC1 DPZSYTMLVCLGRU-UHFFFAOYSA-N 0.000 description 2
- YOVNFNXUCOWYSG-UHFFFAOYSA-N n-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide Chemical compound C1=C2N(CC)C(C=3C(=NON=3)N)=NC2=CN=C1OC(C=1)=CC=CC=1NC(=O)C(C=C1)=CC=C1OCCN1CCOCC1 YOVNFNXUCOWYSG-UHFFFAOYSA-N 0.000 description 2
- SMPGEBOIKULBCT-UHFFFAOYSA-N n-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1h-pyrrolo[2,3-b]pyridin-4-yloxy)benzamide Chemical compound C1CN(CC)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(OC=2C=3C=CNC=3N=CC=2)=C1 SMPGEBOIKULBCT-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000001020 neural plate Anatomy 0.000 description 2
- 210000000276 neural tube Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 108010000953 osteoblast cadherin Proteins 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 2
- 229940069510 parthenolide Drugs 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 208000017402 pituitary gland disease Diseases 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 101150027852 pou3f2 gene Proteins 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- QSKQVZWVLOIIEV-NSHDSACASA-N ripasudil Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(F)=C12 QSKQVZWVLOIIEV-NSHDSACASA-N 0.000 description 2
- 229950008669 salirasib Drugs 0.000 description 2
- 229950009919 saracatinib Drugs 0.000 description 2
- 210000004739 secretory vesicle Anatomy 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- ZMELOYOKMZBMRB-DLBZAZTESA-N talmapimod Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)C=2C(=CC=3N(C)C=C(C=3C=2)C(=O)C(=O)N(C)C)Cl)N1CC1=CC=C(F)C=C1 ZMELOYOKMZBMRB-DLBZAZTESA-N 0.000 description 2
- 229950002902 tanzisertib Drugs 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000002444 unipotent stem cell Anatomy 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 1
- IIRWNGPLJQXWFJ-KRWDZBQOSA-N (1s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)phenyl]ethanol Chemical compound C1([C@](O)(CN)C=2C=CC(=CC=2)C2=CNN=C2)=CC=C(Cl)C=C1 IIRWNGPLJQXWFJ-KRWDZBQOSA-N 0.000 description 1
- RRJOMESUBQAYOA-BZSNNMDCSA-N (2S)-2-[[(2S)-2-[[2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]acetyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-6-aminohexanamide Chemical compound NCCCC[C@H](NC(=O)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CN=CN1 RRJOMESUBQAYOA-BZSNNMDCSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BZNPYIWZPTYCQH-KFTPUPIBSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3-(2,3-dihydroxypropoxy)-4-octoxy-2h-furan-5-one Chemical compound CCCCCCCCOC1=C(OCC(O)CO)[C@@H]([C@@H](O)CO)OC1=O BZNPYIWZPTYCQH-KFTPUPIBSA-N 0.000 description 1
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MJQMRGWYPNIERM-HNNXBMFYSA-N (4s)-4-(2,4-difluoro-5-pyrimidin-5-ylphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine Chemical compound C=1C(C=2C=NC=NC=2)=C(F)C=C(F)C=1[C@]1(C)CCSC(N)=N1 MJQMRGWYPNIERM-HNNXBMFYSA-N 0.000 description 1
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- GGXCUZHEJUJACD-UHFFFAOYSA-N 1-(1,2,3-benzothiadiazol-6-yl)-3-[2-(cyclohexen-1-yl)ethyl]urea Chemical compound C=1C=C2N=NSC2=CC=1NC(=O)NCCC1=CCCCC1 GGXCUZHEJUJACD-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- XCPPIJCBCWUBNT-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-2-[2-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]pyrimidin-4-yl]acetonitrile Chemical compound N=1C2=CC=CC=C2SC=1C(C#N)C(N=1)=CC=NC=1OCC(C=C1)=CC=C1CN1CCOCC1 XCPPIJCBCWUBNT-UHFFFAOYSA-N 0.000 description 1
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 1
- AAGYAFASCRVPTC-UHFFFAOYSA-N 2-(triazol-1-yl)acetamide Chemical compound NC(=O)CN1C=CN=N1 AAGYAFASCRVPTC-UHFFFAOYSA-N 0.000 description 1
- JDVOIBFEFVKUPL-UHFFFAOYSA-N 2-[(4-bromophenyl)methylsulfanyl]-1,3-benzoxazole Chemical compound C1=CC(Br)=CC=C1CSC1=NC2=CC=CC=C2O1 JDVOIBFEFVKUPL-UHFFFAOYSA-N 0.000 description 1
- CMJVDHCUKXXBFF-UHFFFAOYSA-N 2-[2-(5-chloro-2-fluorophenyl)pteridin-4-yl]pyridin-4-amine Chemical compound NC1=CC=NC(C=2C3=NC=CN=C3N=C(N=2)C=2C(=CC=C(Cl)C=2)F)=C1 CMJVDHCUKXXBFF-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical compound CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 description 1
- ZGXOBLVQIVXKEB-UHFFFAOYSA-N 3-[N-[3-[(dimethylamino)methyl]phenyl]-C-phenylcarbonimidoyl]-2-hydroxy-N,N-dimethyl-1H-indole-6-carboxamide Chemical compound CN(C)CC1=CC(=CC=C1)N=C(C2=CC=CC=C2)C3=C(NC4=C3C=CC(=C4)C(=O)N(C)C)O ZGXOBLVQIVXKEB-UHFFFAOYSA-N 0.000 description 1
- RXZDWPYJFCAZCW-UHFFFAOYSA-N 3-chloro-4,7-difluoro-n-[4-(methylamino)cyclohexyl]-n-[(3-pyridin-4-ylphenyl)methyl]-1-benzothiophene-2-carboxamide Chemical compound C1CC(NC)CCC1N(C(=O)C1=C(C2=C(F)C=CC(F)=C2S1)Cl)CC1=CC=CC(C=2C=CN=CC=2)=C1 RXZDWPYJFCAZCW-UHFFFAOYSA-N 0.000 description 1
- AANFHDFOMFRLLR-UHFFFAOYSA-N 3-fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(O)C(=O)NC1=CC=C(C(O)=O)C=C1F AANFHDFOMFRLLR-UHFFFAOYSA-N 0.000 description 1
- 229940120145 3-o-ethylascorbic acid Drugs 0.000 description 1
- KZYAHEIPPAPADQ-UHFFFAOYSA-N 4-(4-chloro-2-fluorophenyl)-2-(2-chloropyridin-4-yl)-n-(6-fluoro-1h-indazol-5-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide Chemical compound N1C(C)=C(C(=O)NC=2C(=CC=3NN=CC=3C=2)F)C(C=2C(=CC(Cl)=CC=2)F)N=C1C1=CC=NC(Cl)=C1 KZYAHEIPPAPADQ-UHFFFAOYSA-N 0.000 description 1
- HEAIGWIZTYAQTC-UHFFFAOYSA-N 4-(4-fluorophenyl)-n-(1h-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxamide Chemical compound N1C(=O)NC(C)=C(C(=O)NC=2C=C3C=NNC3=CC=2)C1C1=CC=C(F)C=C1 HEAIGWIZTYAQTC-UHFFFAOYSA-N 0.000 description 1
- IYOZTVGMEWJPKR-VOMCLLRMSA-N 4-[(1R)-1-aminoethyl]-N-pyridin-4-yl-1-cyclohexanecarboxamide Chemical compound C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-VOMCLLRMSA-N 0.000 description 1
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 1
- FOUVTBKPJRMLPE-FMIVXFBMSA-N 4-[(e)-3-(3,5-ditert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=CC(C(=O)\C=C\C=2C=CC(=CC=2)C(O)=O)=C1 FOUVTBKPJRMLPE-FMIVXFBMSA-N 0.000 description 1
- KXHLIEBAIGSNDD-UHFFFAOYSA-N 4-[2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethyl]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1CCC1=CC=C(C(O)=O)C=C1 KXHLIEBAIGSNDD-UHFFFAOYSA-N 0.000 description 1
- MFBCDACCJCDGBA-UHFFFAOYSA-N 4-[3-(3-tert-butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid Chemical compound CC(C)(C)C1=CC(C=2C(=CC=C(C=2)C=2C=CC(=CC=2)C(O)=O)OCCO)=CC=C1N1CCCC1 MFBCDACCJCDGBA-UHFFFAOYSA-N 0.000 description 1
- ZQUSFAUAYSEREK-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1-imidazolyl]-1-cyclohexanol Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)C2CCC(O)CC2)=N1 ZQUSFAUAYSEREK-UHFFFAOYSA-N 0.000 description 1
- GDTQLZHHDRRBEB-UHFFFAOYSA-N 4-[5-(cyclopropylcarbamoyl)-2-methylanilino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide Chemical compound C12=C(C)C(C(=O)NCCC)=CN2N=CN=C1NC(C(=CC=1)C)=CC=1C(=O)NC1CC1 GDTQLZHHDRRBEB-UHFFFAOYSA-N 0.000 description 1
- CMQXLLAILGGLRV-UHFFFAOYSA-N 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride Chemical compound Cl.Cl.C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12 CMQXLLAILGGLRV-UHFFFAOYSA-N 0.000 description 1
- IBGLGMOPHJQDJB-MOKVOYLWSA-N 4-[[9-[(3s)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol Chemical compound C1CC(O)CCC1NC1=NC=C(N=C(NC=2C(=CC(F)=CC=2F)F)N2[C@@H]3COCC3)C2=N1 IBGLGMOPHJQDJB-MOKVOYLWSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- IYWFOPPYQUEKHN-VOTSOKGWSA-N 5-[(e)-2-phenylethenyl]benzene-1,2,3-triol Chemical compound OC1=C(O)C(O)=CC(\C=C\C=2C=CC=CC=2)=C1 IYWFOPPYQUEKHN-VOTSOKGWSA-N 0.000 description 1
- GXZDVPICTGFDMP-UHFFFAOYSA-N 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]-1H-quinolin-2-one Chemical compound C1=CC(OC)=CC=C1C1=CN2N=CC(C=3C=4C=CC(=O)NC=4C=CC=3)=C2N=C1 GXZDVPICTGFDMP-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- YYWSVTSMIZAJNY-UHFFFAOYSA-N 6-(4-tert-butylphenyl)pyridin-3-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(N)C=N1 YYWSVTSMIZAJNY-UHFFFAOYSA-N 0.000 description 1
- IPEXHQGMTHOKQV-UHFFFAOYSA-N 6-piperidin-4-yloxy-2h-isoquinolin-1-one Chemical compound C=1C=C2C(=O)NC=CC2=CC=1OC1CCNCC1 IPEXHQGMTHOKQV-UHFFFAOYSA-N 0.000 description 1
- KMNVOGVCCZNVNU-UHFFFAOYSA-N 6-piperidin-4-yloxy-2h-isoquinolin-1-one;hydrochloride Chemical compound Cl.C=1C=C2C(=O)NC=CC2=CC=1OC1CCNCC1 KMNVOGVCCZNVNU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- CJFSBECQAATXRD-UHFFFAOYSA-N 7-(4-propan-2-yloxyphenyl)-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyridine Chemical compound C1=CC(OC(C)C)=CC=C1C1=CC2=NC=C(C3=CNN=C3)N2C=C1 CJFSBECQAATXRD-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 229940121819 ATPase inhibitor Drugs 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 102100034111 Activin receptor type-1 Human genes 0.000 description 1
- 102100034134 Activin receptor type-1B Human genes 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- 101100455868 Arabidopsis thaliana MKK2 gene Proteins 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 229940123644 Bcl9 inhibitor Drugs 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 1
- 101710120271 Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100022291 C-Jun-amino-terminal kinase-interacting protein 1 Human genes 0.000 description 1
- 101710105206 C-Jun-amino-terminal kinase-interacting protein 1 Proteins 0.000 description 1
- WYUCHGXEHSPFOC-UHFFFAOYSA-N CC(C=C1)=CC2=C1N=C(NC(CSC(N(C1=C(C)C=CC=C1)C1=O)=NC3=C1SCC3)=O)S2 Chemical compound CC(C=C1)=CC2=C1N=C(NC(CSC(N(C1=C(C)C=CC=C1)C1=O)=NC3=C1SCC3)=O)S2 WYUCHGXEHSPFOC-UHFFFAOYSA-N 0.000 description 1
- 102100024210 CD166 antigen Human genes 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 238000010446 CRISPR interference Methods 0.000 description 1
- 102100035350 CUB domain-containing protein 1 Human genes 0.000 description 1
- CGLCZHMKCYFTNQ-UHFFFAOYSA-O C[N+](C)(C)CC(O)=P(CCOC)=O Chemical compound C[N+](C)(C)CC(O)=P(CCOC)=O CGLCZHMKCYFTNQ-UHFFFAOYSA-O 0.000 description 1
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- 101710116137 Calcium/calmodulin-dependent protein kinase II Proteins 0.000 description 1
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000008122 Casein Kinase I Human genes 0.000 description 1
- 108010049812 Casein Kinase I Proteins 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 description 1
- 241000202252 Cerberus Species 0.000 description 1
- PMTPYUTZAJWGPE-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC(=O)C1CN(CC(C1)(F)F)C(C1=CC(=CC=C1)C=1OC=CC=1)=O Chemical compound ClC1=CC=C(C=C1)NC(=O)C1CN(CC(C1)(F)F)C(C1=CC(=CC=C1)C=1OC=CC=1)=O PMTPYUTZAJWGPE-UHFFFAOYSA-N 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101150059254 Cux1 gene Proteins 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102100025287 Cytochrome b Human genes 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108091065053 DAN family Proteins 0.000 description 1
- 102000038900 DAN family Human genes 0.000 description 1
- 101150051240 DLX2 gene Proteins 0.000 description 1
- 101100462378 Danio rerio otpb gene Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000004648 Distal-less homeobox proteins Human genes 0.000 description 1
- 101150070666 Dlx1 gene Proteins 0.000 description 1
- 101150118728 Dlx5 gene Proteins 0.000 description 1
- 101100295848 Drosophila melanogaster Optix gene Proteins 0.000 description 1
- 101100477839 Drosophila melanogaster Smurf gene Proteins 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101150099612 Esrrb gene Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010000722 Excitatory Amino Acid Transporter 1 Proteins 0.000 description 1
- 102100031563 Excitatory amino acid transporter 1 Human genes 0.000 description 1
- 241000027355 Ferocactus setispinus Species 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 101710087964 Forkhead box protein G1 Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 229940125633 GPCR agonist Drugs 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102100038367 Gremlin-1 Human genes 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 1
- 102100021185 Guanine nucleotide-binding protein-like 3 Human genes 0.000 description 1
- 101710147092 Guanine nucleotide-binding protein-like 3 Proteins 0.000 description 1
- 102000009094 Hepatocyte Nuclear Factor 3-beta Human genes 0.000 description 1
- 108010087745 Hepatocyte Nuclear Factor 3-beta Proteins 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 description 1
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 1
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 description 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 101100287682 Homo sapiens CAMK2G gene Proteins 0.000 description 1
- 101100126883 Homo sapiens CAMK4 gene Proteins 0.000 description 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000737742 Homo sapiens CUB domain-containing protein 1 Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000858267 Homo sapiens Cytochrome b Proteins 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- 101100281008 Homo sapiens FGF2 gene Proteins 0.000 description 1
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 description 1
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 1
- 101000867099 Homo sapiens Humanin Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000604411 Homo sapiens NADH-ubiquinone oxidoreductase chain 1 Proteins 0.000 description 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000595669 Homo sapiens Pituitary homeobox 2 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001070479 Homo sapiens Probable G-protein coupled receptor 101 Proteins 0.000 description 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 1
- 101000684673 Homo sapiens Protein APCDD1 Proteins 0.000 description 1
- 101000684679 Homo sapiens Protein APCDD1-like Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- 101001078886 Homo sapiens Retinaldehyde-binding protein 1 Proteins 0.000 description 1
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 description 1
- 101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 description 1
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 1
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000687911 Homo sapiens Transcription factor SOX-3 Proteins 0.000 description 1
- 101000841466 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 8 Proteins 0.000 description 1
- 101000944219 Homo sapiens cAMP-dependent protein kinase catalytic subunit beta Proteins 0.000 description 1
- 101001026573 Homo sapiens cAMP-dependent protein kinase type I-alpha regulatory subunit Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102100031450 Humanin Human genes 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 208000006001 Hypothalamic Neoplasms Diseases 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 108010022222 Integrin beta1 Proteins 0.000 description 1
- 102000012355 Integrin beta1 Human genes 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 description 1
- 108010070507 Keratin-7 Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 229940122140 Lim kinase inhibitor Drugs 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- GYYDQHBKIHQHEB-UHFFFAOYSA-N N-(5-phenylpyridin-2-yl)-2-(5-phenyl-4-pyridin-4-yltriazol-1-yl)acetamide Chemical compound O=C(Cn1nnc(c1-c1ccccc1)-c1ccncc1)Nc1ccc(cn1)-c1ccccc1 GYYDQHBKIHQHEB-UHFFFAOYSA-N 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- QOIOJVPRHIAONM-UHFFFAOYSA-N N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)benzamide trihydrochloride Chemical compound Cl.Cl.Cl.CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(Oc4ccnc5[nH]ccc45)c3)cc2C(F)(F)F)CC1 QOIOJVPRHIAONM-UHFFFAOYSA-N 0.000 description 1
- GOMFFTZBKYVUOE-UHFFFAOYSA-N N-[[5-fluoro-6-(2-methylpyridin-4-yl)pyridin-3-yl]methyl]-9H-carbazole-2-carboxamide Chemical compound Cc1cc(ccn1)-c1ncc(CNC(=O)c2ccc3c(c2)[nH]c2ccccc32)cc1F GOMFFTZBKYVUOE-UHFFFAOYSA-N 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 102100038625 NADH-ubiquinone oxidoreductase chain 1 Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- CPUHORIUXPQCHW-UHFFFAOYSA-N NSC 23766 trihydrochloride Chemical compound Cl.Cl.Cl.CCN(CC)CCCC(C)NC1=NC(C)=CC(NC=2C=C3C(N)=CC(C)=NC3=CC=2)=N1 CPUHORIUXPQCHW-UHFFFAOYSA-N 0.000 description 1
- 102000007530 Neurofibromin 1 Human genes 0.000 description 1
- 108010085793 Neurofibromin 1 Proteins 0.000 description 1
- 101150114527 Nkx2-5 gene Proteins 0.000 description 1
- 101150025249 Notum gene Proteins 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 102000017954 Nuclear factor of activated T cells (NFAT) Human genes 0.000 description 1
- 108050007058 Nuclear factor of activated T cells (NFAT) Proteins 0.000 description 1
- 101150022539 OTP gene Proteins 0.000 description 1
- 101150092239 OTX2 gene Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 1
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 1
- 101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 102100036090 Pituitary homeobox 2 Human genes 0.000 description 1
- 206010051944 Pituitary hypoplasia Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 102100034137 Probable G-protein coupled receptor 101 Human genes 0.000 description 1
- 206010036832 Prolactinoma Diseases 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100023735 Protein APCDD1 Human genes 0.000 description 1
- 102100023736 Protein APCDD1-like Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010067520 RADA16-I Proteins 0.000 description 1
- 108091008730 RAR-related orphan receptors β Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 1
- 102100024694 Reelin Human genes 0.000 description 1
- 108700038365 Reelin Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 102100030053 Secreted frizzled-related protein 3 Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 101710116197 Serine/threonine kinase NLK Proteins 0.000 description 1
- 101710175706 Serine/threonine-protein kinase NLK Proteins 0.000 description 1
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 1
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 1
- 108700010572 Sine oculis homeobox homolog 3 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100023155 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Human genes 0.000 description 1
- 102100031715 Succinate dehydrogenase assembly factor 2, mitochondrial Human genes 0.000 description 1
- 108050007461 Succinate dehydrogenase assembly factor 2, mitochondrial Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940125920 TGFβR inhibitor Drugs 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 1
- 102100021382 Transcription factor GATA-6 Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102100024276 Transcription factor SOX-3 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100029088 Ubiquitin carboxyl-terminal hydrolase 8 Human genes 0.000 description 1
- 101150096238 VAX1 gene Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 1
- 101001062354 Xenopus tropicalis Forkhead box protein A2 Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- PHWHNHYZZNJPLB-MRVPVSSYSA-N [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-7-yl]-[(3r)-3-aminopyrrolidin-1-yl]methanone Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=CN=CC=1C(=O)N1CC[C@@H](N)C1 PHWHNHYZZNJPLB-MRVPVSSYSA-N 0.000 description 1
- HSROPTGRSYJPJY-JZGIKJSDSA-N [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-7-yl]-[(3s)-3-aminopyrrolidin-1-yl]methanone;dihydrochloride Chemical compound Cl.Cl.C=12N(CC)C(C=3C(=NON=3)N)=NC2=CN=CC=1C(=O)N1CC[C@H](N)C1 HSROPTGRSYJPJY-JZGIKJSDSA-N 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- QFYLTUDRXBNZFQ-UHFFFAOYSA-N [4-[4-chloro-3-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-[4-(5-methylpyrazol-1-yl)phenyl]methanone Chemical compound CC1=CC=NN1C1=CC=C(C(=O)N2CCN(CC2)S(=O)(=O)C=2C=C(C(Cl)=CC=2)C(F)(F)F)C=C1 QFYLTUDRXBNZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 229910052767 actinium Inorganic materials 0.000 description 1
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003329 adenohypophysis hormone Substances 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 210000002867 adherens junction Anatomy 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 230000001263 anti-prolactin effect Effects 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 229930188866 apocynin Natural products 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000019276 ascorbyl stearate Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- HYGWNUKOUCZBND-UHFFFAOYSA-N azanide Chemical compound [NH2-] HYGWNUKOUCZBND-UHFFFAOYSA-N 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940074162 belumosudil Drugs 0.000 description 1
- 229950006785 bentamapimod Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- BXZFTTVQAOLWHY-INIZCTEOSA-N beta-Ala-Lys-N(epsilon)-AMCA Chemical compound C1=C(N)C=CC2=C1OC(=O)C(CC(=O)NCCCC[C@H](NC(=O)CCN)C(O)=O)=C2C BXZFTTVQAOLWHY-INIZCTEOSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229950003054 binimetinib Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- OVPPMIXGVMXSNS-CLIBVNCNSA-N c-jun peptide Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1[C@H](C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 OVPPMIXGVMXSNS-CLIBVNCNSA-N 0.000 description 1
- 102100033065 cAMP-dependent protein kinase catalytic subunit beta Human genes 0.000 description 1
- 102100037490 cAMP-dependent protein kinase type I-alpha regulatory subunit Human genes 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N caffeic acid Chemical compound OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 108010007877 calpain inhibitor III Proteins 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 101150113535 chek1 gene Proteins 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 102000006533 chordin Human genes 0.000 description 1
- 108010008846 chordin Proteins 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229950005521 doramapimod Drugs 0.000 description 1
- 108091066386 draxin family Proteins 0.000 description 1
- 102000039185 draxin family Human genes 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000000647 epithalamus Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000003054 facial bone Anatomy 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- GUGBQOJXKJAMTE-UHFFFAOYSA-N indeno[1,2-b]quinoxalin-11-one Chemical compound C1=CC=C2N=C3C(=O)C4=CC=CC=C4C3=NC2=C1 GUGBQOJXKJAMTE-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000001955 intestinal smooth muscle cell Anatomy 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 101150002688 kremen1 gene Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150108076 lin28a gene Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- OAWZTKNCHQQRKF-UHFFFAOYSA-L manganese(3+);4-[10,15,20-tris(4-carboxyphenyl)porphyrin-22,24-diid-5-yl]benzoic acid Chemical compound [Mn+3].C1=CC(C(=O)O)=CC=C1C(C1=CC=C([N-]1)C(C=1C=CC(=CC=1)C(O)=O)=C1C=CC(=N1)C(C=1C=CC(=CC=1)C(O)=O)=C1C=CC([N-]1)=C1C=2C=CC(=CC=2)C(O)=O)=C2N=C1C=C2 OAWZTKNCHQQRKF-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229940071539 mirdametinib Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- PKMBRIPHIVDBSP-UHFFFAOYSA-N mn(iii)tbap Chemical compound C1=CC(C(=O)O)=CC=C1C1=C2N3C(N45)(N67)N8C1CCC8=C(C=1C=CC(=CC=1)C(O)=O)C7=CC=C6C(C=1C=CC(=CC=1)C(O)=O)=C5CCC4C(C=1C=CC(=CC=1)C(O)=O)=C3C=C2 PKMBRIPHIVDBSP-UHFFFAOYSA-N 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000011675 multiple endocrine neoplasia type 4 Diseases 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- KQMPRSZTUSSXND-UHFFFAOYSA-N n-(4-amino-5-cyano-6-ethoxypyridin-2-yl)-2-(2,5-dimethoxyphenyl)acetamide Chemical compound NC1=C(C#N)C(OCC)=NC(NC(=O)CC=2C(=CC=C(OC)C=2)OC)=C1 KQMPRSZTUSSXND-UHFFFAOYSA-N 0.000 description 1
- KVRDVBWKZWPKFE-UHFFFAOYSA-N n-(4-amino-5-cyano-6-ethoxypyridin-2-yl)-2-(2,5-dimethylphenyl)acetamide Chemical compound NC1=C(C#N)C(OCC)=NC(NC(=O)CC=2C(=CC=C(C)C=2)C)=C1 KVRDVBWKZWPKFE-UHFFFAOYSA-N 0.000 description 1
- QRJTZIJWDLJKQO-UHFFFAOYSA-N n-(cyclopropylmethyl)-4-[[4-(6-hydroxy-3,4-dihydro-2h-quinolin-1-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1CCC2=CC(O)=CC=C2N1C(N=1)=CC=NC=1NC(C=C1)=CC=C1S(=O)(=O)NCC1CC1 QRJTZIJWDLJKQO-UHFFFAOYSA-N 0.000 description 1
- ANQWETXPBPZVOF-UHFFFAOYSA-N n-cyclopropyl-4-[4-(4-fluorophenyl)-2-piperidin-4-yl-1,3-thiazol-5-yl]pyrimidin-2-amine;dihydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C1=C(C=2N=C(NC3CC3)N=CC=2)SC(C2CCNCC2)=N1 ANQWETXPBPZVOF-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229940069817 neflamapimod Drugs 0.000 description 1
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- JYYLVUFNAHSSFE-UHFFFAOYSA-N pamapimod Chemical compound O=C1N(C)C2=NC(NC(CCO)CCO)=NC=C2C=C1OC1=CC=C(F)C=C1F JYYLVUFNAHSSFE-UHFFFAOYSA-N 0.000 description 1
- 229950001749 pamapimod Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000009958 panhypopituitarism Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229950006299 pelitinib Drugs 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 229950002913 pexmetinib Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229950002592 pimasertib Drugs 0.000 description 1
- 208000003068 pituitary dwarfism Diseases 0.000 description 1
- 230000006584 pituitary dysfunction Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- AANFHDFOMFRLLR-LJQANCHMSA-N r-3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid Chemical compound O=C([C@H](O)C=1C=C2C(C)(C)CCC(C2=CC=1)(C)C)NC1=CC=C(C(O)=O)C=C1F AANFHDFOMFRLLR-LJQANCHMSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229950008933 refametinib Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 210000001164 retinal progenitor cell Anatomy 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229950007455 ripasudil Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- HVAKSLUOHARFLM-UHFFFAOYSA-N selenium;sodium Chemical compound [Se][Na] HVAKSLUOHARFLM-UHFFFAOYSA-N 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 description 1
- 210000001587 telencephalon Anatomy 0.000 description 1
- MURCDOXDAHPNRQ-UHFFFAOYSA-N tert-butyl n-[6-[[1-[(1-amino-1-oxo-3-phenylpropan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-5-benzyl-3-hydroxy-6-oxo-1-phenylhexan-2-yl]carbamate Chemical compound C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC=1C=CC=CC=1)CC(O)C(NC(=O)OC(C)(C)C)CC1=CC=CC=C1 MURCDOXDAHPNRQ-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000211 third ventricle Anatomy 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229950008964 trifarotene Drugs 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229950006594 verosudil Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940121396 wnt pathway inhibitor Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Definitions
- the present invention relates to a method for producing a cell population containing pituitary tissue and the cell population. Furthermore, the present invention relates to a cell population containing nervous system cells or neural tissue, pituitary tissue, and mesenchymal cells in the cell population.
- the pituitary gland is an endocrine organ located in the head, and produces various pituitary hormones such as adrenocorticotropic hormone (ACTH) and growth hormone, which are important for the maintenance and growth of the body.
- ACTH adrenocorticotropic hormone
- Hypopituitarism, pituitary hypoplasia, pituitary adenoma, and other diseases that cause pituitary dysfunction can cause serious symptoms similar to failure to thrive, genital-related abnormalities, and adrenal and thyroid abnormalities. . In general, it is rare for damaged pituitary tissue to spontaneously regenerate and restore function.
- Patent Document 1 and Non-Patent Documents 1 and 2 describe human pluripotent stem cells as inhibitors or agents of BMP signaling pathway, Sonic Hedgehog (herein, sometimes referred to as Shh) signaling pathway. It has been reported that head placode-derived cells containing pituitary cells were produced by inducing differentiation in the presence of an action factor and a TGF- ⁇ signaling pathway inhibitor. However, the produced cells are two-dimensionally cultured, and have not yet reproduced the complex pituitary tissue structure of the living body, which is important for its function. The present inventors produced three-dimensional pituitary tissue from pluripotent stem cells in Patent Documents 2 to 4 and Non-Patent Documents 3 and 4, and reported that the tissue has the ability to produce pituitary hormones. .
- the object of the present invention is to provide a method for more efficiently producing a cell population containing pituitary tissue from pluripotent stem cells.
- the object is to provide a method for efficiently producing a cell population containing high-quality pituitary tissue suitable for human transplantation and regenerative medicine.
- it is to identify and produce a cell population corresponding to an intermediate product suitable for the production and purification of the final product.
- feeder-free cultured pluripotent stem cells can be used as a starting material, and by reducing the amount of expensive recombinant proteins used and producing them at a lower cost, we provide a method for efficiently producing them. That is.
- the present inventors conducted repeated studies to solve the above problems, and found that pluripotent stem cells were cultured in the presence of a c-jun N-terminal kinase (JNK) signaling pathway inhibitor, and a BMP signaling pathway agonist and Sonic-Hedgehog signal transduction pathway active substance, it was found that a cell population containing pituitary tissue can be efficiently produced. Furthermore, the present inventors have found that a cell population containing pituitary tissue can be more efficiently produced by simultaneously adding the JNK signaling pathway inhibitor and the Wnt signaling pathway inhibitor. That is, the present invention relates to the following.
- JNK c-jun N-terminal kinase
- a method for producing a cell population containing pituitary tissue comprising the following steps (1) and (2); (1) a first step of culturing pluripotent stem cells in the presence of a c-jun N-terminal kinase (JNK) signaling pathway inhibitor and a Wnt signaling pathway inhibitor to obtain a cell population; (2) A second step of culturing the cell population obtained in the first step in the presence of a BMP signaling pathway agonist and a Sonic hedgehog signaling pathway agonist to obtain a cell population containing pituitary tissue.
- JNK c-jun N-terminal kinase
- pluripotent stem cells are subjected to the following step (a) before the first step; (a) Pluripotent stem cells are cultured in a medium containing 1) a TGF ⁇ family signaling pathway inhibitor and/or Sonic hedgehog signaling pathway agonist, and 2) an undifferentiated maintenance factor in the absence of feeder cells Step a.
- the TGF ⁇ family signaling pathway inhibitor added in the step (a) is an Alk5/TGF ⁇ R1 inhibitor, and the Alk5/TGF ⁇ R1 inhibitor is SB431542, SB505124, SB525334, LY2157299, GW788388, LY364947, SD -208, EW-7197, A83-01, A77-01, RepSox, BIBF-0775, TP0427736, TGFBR1-IN-1, SM-16, TEW-7197, LY3200882, LY2109761, KRCA 0008, GSK 1838705, Crizoertinib, Coritinib , ASP 3026, TAE684, AZD3463 and derivatives thereof.
- the culturing in the first step is further in the presence of a Sonic hedgehog signaling pathway agonist, and the culturing period in the presence of the Sonic hedgehog signaling pathway agonist in the first step and the second step is , 30 days.
- step (b) The production method according to [4], characterized in that the cell population obtained in the second step is subjected to the following step (b) before the third step; (b) step b of culturing the cell population obtained in the second step in the presence of a BMP signaling pathway inhibitor; [5-1] The production method according to [5], wherein the BMP signaling pathway inhibitor added in step (b) comprises a type I BMP receptor inhibitor.
- the type I BMP receptor inhibitor includes K02288, Dorsomorphin, LDN-193189, LDN-212854, LDN-214117, ML347, DMH1, DMH2, Compound 1, VU5350, OD52, E6201, Saracatinib, BYL719 and The production method according to [5-1], which contains at least one selected from the group consisting of these derivatives. [6] The production according to any one of [1] to [5], [2-1], [5-1] and [5-2], wherein the JNK signaling pathway inhibitor comprises a JNK inhibitor Method.
- the JNK inhibitor is SP600125, JNK-IN-8, DB07268, IQ-1S, Tanzisertib, Bentamapimod, BI-78D3, BI-87G3, CC-401, TCS JNK 5a, AS601245, CV-65 , D-JNK1, ER-358063, ER-409903, ER-417258, CC-359, CC-930, SB203580 and at least one selected from the group consisting of derivatives thereof, the production method according to [6]. .
- the JNK inhibitor contains JNK-IN-8 or SP600125, and the step (1) is initiated in a medium containing 1 nM to 50 ⁇ M JNK-IN-8 or 1 nM to 25 ⁇ M SP600125. , [6] or [6-1].
- the Rac inhibitor is at least one selected from the group consisting of NSC23766, EHop-016, ZCL278, MBQ-167, KRpep-2d, ARS-853, Salirasib, ML141, EHT1864 and derivatives thereof
- the manufacturing method according to [7] comprising: [8] [1] to [7], [2-1], [5-1], [5-2], wherein the Wnt signaling pathway inhibitor includes a substance having inhibitory activity against the non-canonical Wnt pathway ], [6-1], [6-2], and [7-1].
- the substance having inhibitory activity against the non-classical Wnt pathway is a PORCN inhibitor
- the PORCN inhibitor is IWP-2, IWP-3, IWP-4, IWP-L6, IWP-12, IWP- O1, LGK-974, Wnt-C59, ETC-131, ETC-159, GNF-1331, GNF-6231, Porcn-IN-1, RXC004, CGX1321 and at least one selected from the group consisting of derivatives thereof , the manufacturing method according to [8].
- a TGF signaling pathway inhibitor is further present, [1] to [8], [2 -1], [5-1], [5-2], [6-1], [6-2], [7-1] and [8-1].
- the Sonic hedgehog signaling pathway active substance added in any one or more of the above step a, first step, second step and b step consists of SAG, Purmorphamine and GSA-10 including at least one selected from the group [1] to [9], [2-1], [5-1], [5-2], [6-1], [6-2], [7- 1] and [8-1].
- a TAK1 inhibitor is further present, [1] to [9], [2-1] , [5-1], [5-2], [6-1], [6-2], [7-1], [8-1], and [9-1].
- the TAK1 inhibitor comprises at least one selected from the group consisting of (5Z)-7-Oxozeaenol, N-Des(aminocarbonyl)AZ-TAK1 inhibitor, Takinib, NG25, Sarsasapogenin and derivatives thereof , the manufacturing method according to [10].
- An FGF signaling pathway agonist is further present in any one or more of the second step, b step, and third step, [1] to [10], [2-1], [ 5-1], [5-2], [6-1], [6-2], [7-1], [8-1], [9-1], or [10-1] Method of manufacture as described. [11-1] The production method according to [11], wherein the FGF signaling pathway agent contains at least one selected from the group consisting of FGF2, FGF3, FGF8, FGF10 and variants thereof.
- any one or more of the second step, b step, and third step there is further a substance that has an action to reduce oxidative stress, [1] to [11], [2-1] ], [5-1], [5-2], [6-1], [6-2], [7-1], [8-1], [9-1], [10-1], The production method according to any one of [11-1].
- [12-1] to [12] wherein the substance having an effect of reducing oxidative stress includes at least one selected from the group consisting of ascorbic acid, N-acetyl-L-cysteine, nicotinamide, and derivatives thereof; Method of manufacture as described.
- an inhibitor against the stress response signaling pathway is further present, [1] to [12], [2-1] ], [5-1], [5-2], [6-1], [6-2], [7-1], [8-1], [9-1], [10-1], [11-1], and the production method according to any one of [12-1].
- [14] In any one or more of the second step, b step, and third step, culturing the cells while shaking, [1] to [13], [2-1], [5] -1], [5-2], [6-1], [6-2], [7-1], [8-1], [9-1], [10-1], [11-1 ], and the production method according to any one of [12-1].
- any one or more of the first step, second step, b step, and third step is carried out in a cultureware in which at least one well is formed, and the well is a plurality of are divided into microwells, and suspension culture is performed so that one cell cluster is formed for each of the microwells, [1] to [15], [2-1], [5- 1], [5-2], [6-1], [6-2], [7-1], [8-1], [9-1], [10-1], [11-1] , and the production method according to any one of [12-1].
- the effect of a JNK signaling pathway inhibitor increases the efficiency of induction of differentiation into ectoderm, and efficient production of a cell population containing pituitary tissue with higher hormone-producing ability from pluripotent stem cells. becomes possible.
- FIG. 1 is a diagram schematically showing the method for producing a cell population containing pituitary tissue of the present invention (embodiment performed in steps (a), (1) and (2): Example 1) ( Upper diagram) and a diagram (lower diagram) showing the morphology of the resulting cell population (cell mass).
- FIG. 2A is a diagram schematically showing the method for producing a cell population containing pituitary tissue of the present invention (embodiment performed in steps (a), (1) and (2): Example 2). be.
- FIG. 2B is a diagram showing the morphology of the cell population (cell mass) produced by the process shown in FIG. 2A.
- FIG. 1 is a diagram schematically showing the method for producing a cell population containing pituitary tissue of the present invention (embodiment performed in steps (a), (1) and (2): Example 1) ( Upper diagram) and a diagram (lower diagram) showing the morphology of the resulting cell population (cell mass).
- FIG. 2A is a diagram schematically showing the method
- FIG. 3A is a diagram schematically showing the method for producing a cell population containing pituitary tissue of the present invention (embodiment performed in steps (a), (1) and (2): Example 3).
- FIG. 3B is a diagram showing the expression of Lhx3, Pitx1 and E-cadherin in the cell population (cell mass) produced by the process shown in FIG. 3A.
- FIG. 4A schematically shows the method for producing a cell population containing pituitary tissue of the present invention (embodiment performed in steps (a), (1), (2) and (3): Example 4). is a diagram shown in FIG.
- FIG. 4B shows differentiation induction of pituitary tissue from the cell population (cell mass) produced by the process shown in FIG.
- FIG. 4A is a graph showing the results of examination of ACTH) secretion ability.
- FIG. 5 schematically shows the method for producing a cell population containing pituitary tissue of the present invention (embodiment performed in steps (a), (1), (2) and (3): Example 5). 2 (upper diagram) and a diagram (lower diagram) showing the morphology of the resulting cell population (cell mass). Step (3) was performed with shaking culture.
- FIG. 6 schematically shows the method for producing a cell population containing pituitary tissue of the present invention (embodiment performed in steps (a), (1), (2) and (3): Example 6).
- FIG. 7A is a diagram schematically showing the steps of Reference Example 1 of the method for producing a cell population containing pituitary tissue from human ES cells (conditions in which no JNK inhibitor is added in step (1)).
- FIG. 7B is a diagram showing the expression status of RAX, PITX1 and E-cadherin on day 32 of cell aggregates produced by the process shown in FIG. 7A.
- FIG. 8A schematically shows the steps of Reference Example 2 of the method for producing a cell population containing pituitary tissue from human iPS cells (examination of the addition period of IWP2, SB431542 and BMP4 in steps (1) and (2)).
- FIG. 8B-1 shows the expression status of RAX, PITX1, LHX3 and E-cadherin on day 29 of cell aggregates produced by the steps shown in FIG. 8A (IWP2, SB431542 addition period: d0-6). It is a diagram.
- the upper stage shows the case where the BMP4 addition period is d2-6, and the lower stage shows the case where the BMP4 addition period is d2-18.
- FIG. 8B-2 shows the expression status of RAX, PITX1, LHX3 and E-cadherin on day 29 of cell aggregates produced by the process shown in FIG. 8A (IWP2, SB431542 addition period: d0-12). It is a diagram. The upper stage shows the case where the BMP4 addition period is d2-6, and the lower stage shows the case where the BMP4 addition period is d2-18.
- FIG. 8B-3 shows the expression status of RAX, PITX1, LHX3 and E-cadherin on day 29 of cell aggregates produced by the process shown in FIG. 8A (IWP2, SB431542 addition period: d0-29). It is a diagram.
- the upper stage shows the case where the BMP4 addition period is d2-6, and the lower stage shows the case where the BMP4 addition period is d2-18.
- the upper figure (A) shows the steps of Reference Example 3 of the method for producing a cell population containing pituitary tissue from human ES cells (addition of IWP2, BMP4 and SAG in steps (1), (2) and (3)).
- FIG. 10 is a diagram schematically showing a study of concentration).
- the figure below (B) shows the results of examining the ability of the cell aggregates produced by the process shown in A to secrete ACTH 61 days, 103 days, 152 days, 201 days, and 250 days after the initiation of differentiation induction.
- the upper diagram (A) shows the method for producing a cell population containing pituitary tissue of the present invention (embodiment performed in step (a), step (1), step (2) and step (3): Example 7). It is a diagram schematically showing the. (B) below shows the expression of ACTH and E-cadherin 103 days after initiation of induction of differentiation of cell aggregates produced by the process shown in A.
- FIG. The upper row shows the results when the JNK inhibitor was not added, and the lower row shows the results when the JNK inhibitor was added.
- FIG. 11 shows the method for producing a cell population containing pituitary tissue of the present invention (embodiment performed in steps (a), (1), (2) and (3): Example 8).
- FIG. 2 shows the expression of ACTH and SOX2 on day 59 after initiation of induction of differentiation of cell aggregates.
- the upper diagram (A) shows the method for producing a cell population containing pituitary tissue of the present invention (embodiment performed in step (a), step (1), step (2) and step (3): Example 9). It is a diagram schematically showing the.
- B as shown in A, cell aggregates were produced separately in the case of SAG treatment up to 30 days after the start of differentiation induction and in the case of continuous SAG treatment thereafter, and each ACTH secretion FIG.
- FIG. 13A schematically shows the method for producing a cell population containing pituitary tissue of the present invention (embodiment performed in steps (a), (1), (2) and (3): Example 10). is a diagram shown in FIG.
- FIG. 13B shows the results of quantifying the expression levels of various cell markers on days 3, 6, 19, 30, 60, 100, and 201 after initiation of differentiation induction of cell aggregates produced by the process shown in FIG. 13A. It is a diagram. Results for PITX1, LHX3, and POMC are shown in the upper row.
- Figure 14 shows PRL and POU1F1 in cell aggregates produced by the steps (step (a), step (1), step (2) and step (3); Example 11) shown in Figure 13A. , TSH, LH, FSH and GH.
- A Triple staining of PRL, POU1F1 and DAPI 103 days after the start of suspension culture (left figure) and double staining of PRL and DAPI 103 days after the start of suspension culture (right figure)
- B TSH and DAPI 103 days after the start of suspension culture
- C double staining of LH and DAPI 103 days after the start of suspension culture
- D double staining of FSH and DAPI 103 days after the start of suspension culture
- E GH, POU1F1 and DAPI 152 days after the start of suspension culture (left) and double staining of GH and DAPI (right) 152 days after the start of suspension culture.
- FIG. 15 shows the steps shown in FIG.
- FIG. 13A (embodiments performed in steps (a), (1), (2) and (3); Example 12) 201 days after initiation of differentiation induction is a view of the cell aggregates observed with an electron microscope.
- FIG. 16 shows the steps shown in FIG. 13A (embodiments performed in step (a), step (1), step (2) and step (3); Example 13). It is a figure confirming the expression of ACTH and CXADR on post-103 days.
- A is the embodiment performed in the steps (step (a), step (1), step (2) and step (3) shown in FIG. 13A; Example 14) after initiation of differentiation induction
- FIG. 3 shows the ACTH secretion ability on the 29th, 61st, 103rd, 152nd, 201st and 250th days.
- FIG. 13A shows the results of an ACTH stimulation test with CRH (B) or dexamethasone (C) on day 103 of initiation. **: p ⁇ 0.01, paired t-test.
- Figure 18A shows the steps shown in Figure 13A (embodiments carried out in steps (a), (1), (2) and (3); Example 15). , 100-day cell aggregates, and undifferentiated cells confirming the expression of each cell marker.
- FIG. 18B shows differentiation induction of cell aggregates produced by the steps (step (a), step (1), step (2) and step (3); Example 15) shown in Figure 13A.
- FIG. 2 shows the expression of NESTIN and SOX11 in eyes. a: NESTIN, SOX11 and DAPI triple staining, b: NESTIN and DAPI double staining, c: SOX11 and DAPI double staining, d: NESTIN, SOX11 and DAPI triple staining.
- FIG. 19A shows a method for producing pituitary organoids from human iPS cells using cultureware having divided microwells (step (a), step (1) and step (2) embodiment: Example 16) is a schematic diagram.
- FIG. 19B is a diagram showing the results of oblique illumination observation of the shape of the cell aggregates produced by the process shown in FIG. 19A 29 days after initiation of induction of differentiation.
- Pituitary organoids with placode-like pituitary tissue were formed.
- FIG. 20A schematically shows the method for producing a cell population containing pituitary tissue from human iPS cells of the present invention (embodiment performed in steps (a), (1) and (2): Example 17).
- FIG. 20B is a diagram showing the results of oblique illumination observation of the shape of the cell aggregate produced by the process shown in FIG. 20A 28 days after initiation of induction of differentiation.
- Pituitary organoids having a placode-like pituitary tissue were formed under both BMP4 addition conditions 1 day and 2 days after initiation of differentiation induction.
- a “stem cell” means an undifferentiated cell having differentiation potential and proliferation potential (especially self-renewal potential).
- Stem cells include pluripotent stem cells, multipotent stem cells, unipotent stem cells, etc., depending on their ability to differentiate.
- a “pluripotent stem cell” refers to a stem cell that can be cultured in vitro and has the ability (pluripotency) to differentiate into all the cells that make up the living body. All cells are derived from three germ layers: ectoderm, mesoderm and endoderm.
- multipotent stem cell is meant a stem cell that has the ability to differentiate into multiple, but not all, types of tissues and cells.
- a “unipotent stem cell” means a stem cell that has the ability to differentiate into a specific tissue or cell.
- Pluripotent stem cells can be derived from fertilized eggs, cloned embryos, germ stem cells, tissue stem cells, somatic cells, etc.
- pluripotent stem cells include embryonic stem cells (ES cells: Embryonic stem cells), EG cells (Embryonic germ cells), induced pluripotent stem cells (iPS cells: induced pluripotent stem cells), and the like.
- Pluripotent stem cells also include Muse cells (Multi-lineage differentiating Stress Enduring cells) obtained from mesenchymal stem cells (MSCs) and GS cells produced from germ cells (eg, testis). Human embryonic stem cells are those established from human embryos within 14 days of fertilization.
- Embryonic stem cells were first established in 1981 and have been applied to the production of knockout mice since 1989. Human embryonic stem cells were established in 1998 and are being used in regenerative medicine. ES cells can be produced by culturing the inner cell population on feeder cells or in a medium containing a leukemia inhibitory factor (LIF). Methods for producing ES cells are described in, for example, WO96/22362, WO02/101057, US Pat. No. 5,843,780, US Pat. No. 6,200,806, US Pat. It is Embryonic stem cells can be obtained from designated institutions and can also be purchased commercially. For example, human embryonic stem cells KhES-1, KhES-2 and KhES-3 are available from the Institute for Frontier Medical Sciences, Kyoto University.
- LIF leukemia inhibitory factor
- ntES cell nuclear-transplanted ES cell
- EG cells can be produced by culturing primordial germ cells in a medium containing mouse stem cell factor (mSCF), LIF and basic fibroblast growth factor (bFGF) (Cell, 70:841-847, 1992).
- mSCF mouse stem cell factor
- bFGF basic fibroblast growth factor
- “Induced pluripotent stem cells” are cells in which pluripotency is induced by reprogramming somatic cells by known methods.
- induced pluripotent stem cells specifically, somatic cells differentiated into fibroblasts, peripheral blood mononuclear cells, etc. are Oct3/4, Sox2, Klf4, Myc (c-Myc, N-Myc, L-Myc). , Glis1, Nanog, Sall4, lin28, Esrrb, etc., and reprogrammed by the expression of multiple genes to induce pluripotency.
- Yamanaka et al. established mouse induced pluripotent stem cells (Cell, 2006, 126(4) pp.663-676).
- Induced pluripotent stem cells were also established in human fibroblasts in 2007, and have pluripotency and self-renewal ability like embryonic stem cells (Cell, 2007, 131(5) pp.861-872; Science, 2007, 318(5858) pp. 1917-1920; Nat. Biotechnol., 2008, 26(1) pp. 101-106).
- induced pluripotent stem cells can be induced from somatic cells by addition of compounds, etc., in addition to the method of producing induced pluripotent stem cells by direct reprogramming by gene expression (Science, 2013, 341, pp. 651- 654).
- Somatic cells used for producing induced pluripotent stem cells are not particularly limited, but tissue-derived fibroblasts, blood cells (e.g., peripheral blood mononuclear cells, T cells, etc.), hepatocytes, pancreas cells, intestinal epithelial cells, smooth muscle cells, and the like.
- Means for expressing genes include, for example, infection methods using viral vectors (e.g., retroviral vectors, lentiviral vectors, Sendai viral vectors, adenoviral vectors, adeno-associated viral vectors), plasmid vectors (e.g., plasmid vectors, episomal vectors). vector) using gene transfer method (e.g. calcium phosphate method, lipofection method, retronectin method, electroporation method), gene transfer method using RNA vector (e.g. calcium phosphate method, lipofection method, electroporation method), protein A direct injection method and the like can be mentioned.
- viral vectors e.g., retroviral vectors, lentiviral vectors, Sendai viral vectors, adenoviral vectors, adeno-associated viral vectors
- plasmid vectors e.g., plasmid vectors, episomal vectors.
- gene transfer method e.g. calcium phosphate method, lipofection
- induced pluripotent stem cell lines for example, 201B7 cells, 201B7-Ff cells, 253G1 cells, 253G4 cells, 1201C1 cells, 1205D1 cells, and 1210B2 cells established at Kyoto University.
- 1231A3 cells are available from Kyoto University and iPS Academia Japan.
- established induced pluripotent stem cell lines for example, Ff-I01 cells, Ff-I14 cells and QHJI01s04 cells established at Kyoto University are available from Kyoto University.
- Pluripotent stem cells may be genetically modified.
- Genetically modified pluripotent stem cells can be produced, for example, by using homologous recombination techniques.
- Genes on the chromosome to be modified include, for example, cell marker genes, histocompatibility antigen genes, and disease-associated genes based on nervous system cell disorders. ⁇ Manipulating the Mouse Embryo,A Laboratory Manual,Second Edition,Cold Spring Harbor Laboratory Press(1994) ⁇ Gene Targeting,A Practical Approach,IRL Press at Oxford University Press(1993) ⁇ 8. Gene targeting, generation of mutant mice using ES cells, methods described in Yodosha (1995), etc. can be used.
- the genomic gene of the target gene to be modified (e.g., cell marker gene, histocompatibility antigen gene, disease-related gene, etc.) is isolated, and the target gene is homologously recombined using the isolated genomic gene.
- Create a target vector for By introducing the produced target vector into stem cells and selecting cells in which homologous recombination has occurred between the target gene and the target vector, stem cells in which genes on chromosomes have been modified can be produced.
- Methods for isolating the genomic gene of the target gene include those described in Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989) and Current Protocols in Molecular Biology, Johns Wiley 7-19 (19), etc. A well-known method is mentioned.
- a genomic DNA library screening system manufactured by Genome Systems
- Universal GenomeWalker Kits manufactured by Clontech
- Target vectors for homologous recombination of target genes Preparation of target vectors for homologous recombination of target genes and efficient selection of homologous recombinants are described in Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), Biomanual Series 8, Gene Targeting , Production of Mutant Mouse Using ES Cells, Yodosha (1995), and the like. Either a replacement type or an insertion type target vector can be used.
- methods such as positive selection, promoter selection, negative selection, poly A selection, and the like can be used.
- Methods for selecting the desired homologous recombinant from the screened cell lines include Southern hybridization method and PCR method for genomic DNA.
- Genome-edited pluripotent stem cells can also be used as pluripotent stem cells.
- Gene editing is a technique for intentionally modifying a target gene or genomic region by the principle of site-specific cleavage of genomic DNA strands using a nuclease, chemical conversion of bases, or the like.
- Site-specific nucleases include zinc finger nucleases (ZFNs), TALENs, CRISPR/Cas9, and the like.
- Disease-specific pluripotent stem cells may be used as pluripotent stem cells.
- a “disease-specific pluripotent stem cell” refers to a pluripotent stem cell with a genetic background or mutation of a gene involved in disease development.
- Disease-specific pluripotent stem cells are obtained by establishing induced pluripotent stem cells from patients with the target disease or their relatives by the method described above, or by obtaining the genome of already established pluripotent stem cells. It can be produced by a modification method using genome editing techniques such as zinc finger nuclease (ZFN), TALEN, and CRISPR.
- ZFN zinc finger nuclease
- TALEN TALEN
- “Mammals” include rodents, ungulates, cats, lagomorphs, primates, and the like. Rodents include mice, rats, hamsters, guinea pigs, and the like. Hoofed animals include pigs, cows, goats, horses, sheep, and the like. The Felida includes dogs, cats, and the like. Lagomorpha includes rabbits and the like.
- the term “primate” refers to mammals belonging to the order Primates, and includes lemurs, lorises, and primates of the order Prosapiforma, such as lemurs, lorises, and tsubai, and primates, such as monkeys, anthropoids, and humans.
- the pluripotent stem cells used in the present invention are mammalian pluripotent stem cells, preferably rodent (e.g., mouse, rat) or primate (e.g., human, monkey) pluripotent stem cells, most preferably. are human pluripotent stem cells.
- Cell adhesion includes cell-to-cell adhesion (cell-cell adhesion) and cell-to-extracellular matrix (substrate) adhesion (cell-substrate adhesion). Adhesion of cells to culture equipment and the like that occurs in an in vitro artificial culture environment is also included in cell adhesion.
- the junctions formed in cell-cell adhesion are cell-cell junctions, and the junctions formed in cell-substrate adhesion are cell-substrate junctions.
- Types of cell adhesion include, for example, anchoring junctions, communicating junctions, and occluding junctions.
- Tight junctions are relatively strong cell-cell junctions and can occur in epithelial cells. The presence or absence of tight junctions between cells can be detected, for example, by techniques such as immunohistochemistry using antibodies against tight junction constituents (anti-claudin antibody, anti-ZO-1 antibody, etc.).
- suspension culture refers to culturing cells while maintaining the state in which they are floating in the culture solution.
- suspension culture is carried out under conditions that do not allow cells to adhere to the cultureware and feeder cells on the cultureware (hereinafter referred to as “cultureware, etc.”). culture). More specifically, suspension culture refers to culture under conditions that do not form strong cell-substrate bonds between cells and cultureware. A person skilled in the art can easily determine whether the cultured cells are in a state of suspension culture or adherence culture, for example, by swinging culture equipment during microscopic observation.
- Adhesive culture refers to culturing while maintaining the state in which cells adhere to cultureware and the like.
- the adherence of cells to a cultureware or the like means that a strong cell-substrate bond, which is a type of cell adhesion, can be formed between the cells and the cultureware or the like.
- cell aggregates in suspension culture cells adhere to each other.
- strong cell-substrate bonds are not formed between cells and cultureware, and cell-substrate bonds are hardly formed, or even if they are formed, they do not contribute. small.
- Plant attachment between cells means that the cells adhere to each other on the plane. More specifically, "cells are surface-to-cell adhered” means that the ratio of the surface area of a certain cell that is adhered to the surface of another cell is, for example, 1% or more, preferably 3% or more, more preferably means 5% or more.
- the cell surface can be observed by staining with a membrane-staining reagent (eg, DiI), immunostaining with cell adhesion factors (eg, E-cadherin, N-cadherin, etc.), and the like.
- a membrane-staining reagent eg, DiI
- cell adhesion factors eg
- the cultureware used for adherent culture is not particularly limited as long as it allows adherent culture, and can be appropriately determined by those skilled in the art.
- Examples of such culture equipment include flasks, tissue culture flasks, dishes, tissue culture dishes, multidishes, microplates, microwell plates, micropores, multiplates, multiwell plates, chamber slides, Petri dishes, tubes, Biofunctional chips such as trays, culture bags, and organ-on-chips are included.
- the cell-adhesive cultureware those whose surfaces are artificially treated for the purpose of improving adhesion to cells can be used.
- the artificial treatment includes, for example, coating treatment with extracellular matrix, polymer, etc., and surface treatment such as gas plasma treatment and positive charge treatment.
- extracellular matrices to which cells adhere include basement membrane samples, laminin, entactin, collagen, gelatin and the like.
- Polymers include polylysine, polyornithine, and the like.
- the culture surface of the cultureware may be flat or uneven.
- laminin is a heterotrimeric molecule consisting of ⁇ , ⁇ , and ⁇ chains, and is an extracellular matrix protein that has isoforms with different subunit chain compositions. Specifically, laminin has about 15 isoforms, which are heterotrimeric combinations of 5 ⁇ -chains, 4 ⁇ -chains and 3 ⁇ -chains.
- the name of laminin is determined by combining the respective numbers of the ⁇ chain ( ⁇ 1 to ⁇ 5), ⁇ chain ( ⁇ 1 to ⁇ 4) and ⁇ chain ( ⁇ 1 to ⁇ 3). For example, laminin composed of a combination of ⁇ 5 chain, ⁇ 1 chain and ⁇ 1 chain is called laminin-511.
- the cultureware used for suspension culture is not particularly limited as long as it is capable of suspension culture, and can be appropriately determined by those skilled in the art.
- Examples of such culture equipment include flasks, tissue culture flasks, dishes, petri dishes, tissue culture dishes, multidishes, microplates, microwell plates, micropores, multiplates, multiwell plates, chamber slides, petri dishes. , tubes, trays, culture bags, spinner flasks and roller bottles.
- These cultureware are preferably cell non-adhesive in order to enable suspension culture.
- the non-cell-adherent cultureware the surface of the cultureware is not subjected to the artificial treatment described above for the purpose of improving the adhesion to cells.
- non-cell-adhesive cultureware cultureware whose surface has been artificially treated for the purpose of reducing adhesion to cells can also be used.
- the culture surface of the cultureware may be flat, U-bottomed or V-bottomed, and may be uneven.
- treatments that reduce adhesion to cells include 2-methyloxyethyl phosphorylcholine (MPC) polymer, Poly (2-hydroxyethyl methacrylate) (Poly-HEMA), and superhydrophilic treatment by coating with polyethylene glycol (PEG). Low adsorption treatment and the like can be mentioned.
- “Shake culture” is a culture method that agitates the culture medium by shaking the cultureware to promote the supply of oxygen to the culture medium and the exchange of substances with the surroundings of the cells. Stirring culture, channel culture, and the like can also be performed.
- cell aggregates For the purpose of protecting cell aggregates from physical stress such as shear force generated during suspension culture, increasing the local concentration of growth factors and cytokines secreted by cells, and promoting tissue development, cell aggregates can be embedded in a gel or encapsulated in a substance-permeable capsule and then subjected to suspension culture (Nature, 2013, 501.7467:373).
- the encapsulated cell aggregates may be cultured with shaking.
- Gels or capsules used for embedding may be made of either biological or synthetic polymers.
- gels or capsules used for such purposes examples include Matrigel (manufactured by Corning), PuraMatrix (manufactured by 3D Matrix), VitroGel 3D (manufactured by The Well Bioscience), collagen gel (manufactured by Nitta Gelatin), alginate gel ( PG Research), Cell-in-a-Box (manufactured by Austrianova), and the like.
- the medium used for culturing cells can be prepared using the medium normally used for culturing animal cells as a basal medium.
- a medium for culturing pluripotent stem cells based on the above basal medium, preferably a known medium for embryonic stem cells or induced pluripotent stem cells, pluripotent stem cells under feeder-free conditions.
- a medium for culturing (feeder-free medium) or the like can be used.
- Many synthetic media have been developed and are commercially available as feeder-free media, such as Essential 8 medium.
- Essential 8 medium is DMEM / F12 medium, as additives, L-ascorbic acid-2-phosphate magnesium (64 mg / l), sodium selenium (14 ⁇ g / 1), insulin (19.4 mg / l), NaHCO 3 ( 543 mg/l), transferrin (10.7 mg/l), bFGF (100 ng/ml), and TGF ⁇ family signaling pathway agonists (TGF ⁇ 1 (2 ng/ml) or Nodal (100 ng/ml)) (Nature Methods, 8, 424-429 (2011)).
- feeder-free media examples include Essential 8 (manufactured by Thermo Fisher Scientific), S-medium (manufactured by DS Pharma Biomedical), StemPro (manufactured by Thermo Fisher Scientific), hESF9, mTeSR1 (manufactured by STEMCELL Technologies), mTeSR2 (manufactured by STEMCELL Technologies), TeSR-E8 (manufactured by STEMCELL Technologies), mTeSR Plus (manufactured by STEMCELL Technologies), StemFit (manufactured by Ajinomoto Co.), ReproMed iPSC Medium (manufactured by Reprocell), NutriBustrialStem ), NutriStem V9 (manufactured by Biological Industries), Cellartis DEF-CS Xeno-Free Culture Medium (manufactured by Takara Bio), Stem-Partner SF (manufactured by Kyokuto Pharmaceutical), PluriSTEM Human ES/
- the serum-free medium may contain serum replacement.
- serum substitutes include those appropriately containing albumin, transferrin, fatty acids, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thiolglycerol, or equivalents thereof.
- serum substitutes can be prepared, for example, by the method described in WO98/30679. A commercially available product may be used as a serum substitute.
- serum substitutes include, for example, Knockout Serum Replacement (manufactured by Thermo Fisher Scientific) (hereinafter sometimes referred to as "KSR"), Chemically-defined Lipid concentrated (manufactured by Thermo Fisher Scientific), Glutath Scientific), B27 Supplement (Thermo Fisher Scientific), N2 Supplement (Thermo Fisher Scientific), and the like.
- KSR Knockout Serum Replacement
- Chemically-defined Lipid concentrated manufactured by Thermo Fisher Scientific
- Glutath Scientific Glutath Scientific
- B27 Supplement Thermo Fisher Scientific
- N2 Supplement Thermo Fisher Scientific
- Serum-free media used in suspension culture and adhesion culture suitably contain fatty acids or lipids, amino acids (e.g., non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, pyruvic acid, buffers, and inorganic salts. etc. may be included.
- an appropriate amount for example, about 0.5% to about 30%, preferably about 1% to about 20%
- a serum-free medium for example, a 1:1 mixture of F-12 medium and IMDM medium supplemented with 1 ⁇ chemically-defined Lipid concentrated, 5% KSR and 450 ⁇ M 1-monothioglycerol
- the medium disclosed in Japanese Patent Publication No. 2001-508302 can be mentioned as a KSR equivalent.
- “Serum medium” means a medium containing unadjusted or unpurified serum.
- the medium contains fatty acids or lipids, amino acids (eg, non-essential amino acids), vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, 1-monothioglycerol, pyruvic acid, buffers, inorganic salts, and the like.
- Cultivation in the present invention is preferably performed under xeno-free conditions.
- Xeno-free means conditions under which components derived from a biological species different from the biological species of cells to be cultured are eliminated.
- the medium used in the present invention is preferably a chemically defined medium (CDM) containing components.
- Basis membrane structure means a thin membranous structure composed of an extracellular matrix.
- basement membranes are formed on the basal side of epithelial cells.
- Basement membrane components include type IV collagen, laminin, heparan sulfate proteoglycan (perlecan), entactin/nidogen, cytokines, growth factors, and the like. Whether the basement membrane is present in the tissue derived from the living body and in the cell population prepared by the production method of the present invention can be determined by tissue staining such as PAM staining, and an antibody against a component of the basement membrane (anti-laminin antibody , anti-type IV collagen antibody, etc.).
- Base membrane preparation refers to the ability to control epithelial cell-like cell morphology, differentiation, proliferation, motility, functional expression, etc., when desired cells with basement membrane-forming ability are seeded on it and cultured. It refers to those containing basement membrane constituents having In the present invention, when cells are adherently cultured, they can be cultured in the presence of a basement membrane sample.
- basement membrane component refers to a thin membrane-like extracellular matrix molecule present between the epithelial cell layer and the stromal cell layer in animal tissues.
- a basement membrane preparation is obtained by removing, for example, cells having the ability to form a basement membrane adhered to a support via the basement membrane from the support using a solution having lipid-dissolving ability of the cells, an alkaline solution, or the like. It can be made by Basement membrane preparations include commercially available basement membrane preparations such as Matrigel (manufactured by Corning), Geltrex (manufactured by Thermo Fisher Scientific), extracellular matrix molecules known as basement membrane components (e.g., laminin, IV type collagen, heparan sulfate proteoglycan, entactin, etc.).
- basement membrane preparations include commercially available basement membrane preparations such as Matrigel (manufactured by Corning), Geltrex (manufactured by Thermo Fisher Scientific), extracellular matrix molecules known as basement membrane components (e.g., laminin, IV type collagen, heparan sulfate proteoglycan, entactin, etc.).
- a basement membrane preparation such as Matrigel (manufactured by Corning) extracted and solubilized from tissues or cells such as Engelbreth-Holm-Swarm (EHS) mouse sarcoma can be used.
- EHS Engelbreth-Holm-Swarm
- basement membrane components used in cell culture human solubilized amniotic membrane (manufactured by Bioresources Applied Research Laboratories), human recombinant laminin produced in HEK293 cells (manufactured by BioLamina), human recombinant laminin fragment (manufactured by Nippi), Human recombinant vitronectin (manufactured by Thermo Fisher Scientific) and the like can also be used.
- the basement membrane preparation preferably uses a recombinant protein whose components are clear.
- the terms "medium containing substance X" and “in the presence of substance X” refer to a medium supplemented with exogenous substance X, a medium containing exogenous substance X, and a medium containing exogenous substance X, respectively. means the presence of the substance X of An exogenous substance X is distinguished from an endogenous substance X, for example, which is endogenously expressed, secreted or produced by cells or tissues present in the culture medium. Substance X in the medium may undergo a slight change in concentration due to decomposition of substance X or evaporation of the medium.
- the term “at the start of culture in a medium having a concentration of substance X of Y” preferably refers to the time at which the concentration of substance X in the medium becomes uniform at Y, but the culture vessel is sufficiently small. (For example, a 96-well plate or culture with a culture solution of 200 ⁇ L or less), culture at a concentration Y at the time when the medium addition operation, half medium exchange operation, or whole medium exchange operation described later is performed so that the concentration becomes Y. Interpret as the start time.
- the concentration of substance X in the medium is Y
- the period containing substance X at the concentration of Y is 50% or more of the culture period.
- the period during which the substance X is contained at the concentration Y is equal to or longer than the shortest culture period assumed in each step.
- exogenous substance X in the absence of substance X means a medium to which exogenous substance X is not added, a medium free of exogenous substance X, or a medium in which exogenous substance X is not present. means state.
- human protein X means that protein X has the amino acid sequence of protein X that is naturally expressed in the human body.
- isolated protein X does not include endogenous protein X produced from the cells or tissues to be cultured and contained in the cells, tissues, or medium.
- the purity of "isolated protein X" is usually 70% or higher, preferably 80% or higher, more preferably 90% or higher, further preferably 99% or higher, Most preferably 100%.
- a “derivative” refers to a group of compounds produced by substituting a part of the molecule of a specific compound with another functional group or another atom.
- a “variant” of a protein refers to a protein in which amino acid residues have been mutated, such as deletion, addition, or substitution, to the extent that the properties of the original protein can be maintained.
- the number of amino acids to be mutated is not particularly limited, but may be 1-4, 1-3, 1-2, or 1.
- a “variant" of a protein is at least 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, It may be a protein having an amino acid sequence showing 99% or more, or 99.5% or more identity. Amino acids mutated in variants may be non-natural.
- after A time (A day) includes A time (A day) and refers to after A time (A day).
- Within B hours (B days) includes B hours (B days) and refers to before B hours (B days).
- feeder cells refer to cells other than the stem cells that coexist when the stem cells are cultured.
- Examples of feeder cells used for undifferentiated maintenance culture of pluripotent stem cells include mouse fibroblasts (MEF), human fibroblasts, SNL cells and the like.
- the feeder cells are preferably growth-inhibitory treated.
- the growth inhibitory treatment includes growth inhibitor (eg, mitomycin C) treatment, UV irradiation, and the like.
- Feeder cells used for undifferentiated maintenance culture of pluripotent stem cells secrete humoral factors (preferably undifferentiated maintenance factors) and prepare scaffolds (extracellular matrix) for cell adhesion, thereby preserving pluripotent stem cells. Contributes to maintenance of differentiation.
- feeder-free means culturing in the absence of feeder cells.
- the absence of feeder cells includes, for example, conditions in which feeder cells are not added or conditions in which feeder cells are not substantially contained (for example, the ratio of feeder cells to the total number of cells is 3% or less).
- a "cell aggregate” is a clump formed by aggregation of cells, and refers to a clump in which the cells are adhered to each other.
- Cell aggregates, embryoid bodies, spheres, spheroids and organoids are also included in cell aggregates.
- the cells are preferably surface-adhered to each other.
- some or all of the cell aggregates have cell-to-cell adhesion, eg, formation of adherence junctions.
- two or more cell aggregates can also be artificially adhered or aggregated together.
- Cell aggregates also include clumps and assemblebloids in which cell populations are further adhered or aggregated.
- the morphology of cell aggregates is not limited to a spherical shape, and may be, for example, a bispherical shape, a beaded shape, an aggregate shape of spheres, a cord-like/branched shape (Scientific reports, 11: 21421 (2021), the shape described in Japanese Patent Application No. 2021-078154). ) or the like.
- Uniform cell aggregate means that the size of each cell aggregate is constant when culturing multiple cell aggregates, and the size of the cell aggregate is evaluated by the length of the maximum diameter.
- uniform cell aggregates means that the lengths of the largest diameters have a small variance. More specifically, in cell aggregates of 75% or more of the plurality of cell aggregates, the maximum diameter is within ⁇ 100% of the average maximum diameter of the plurality of cell aggregates, preferably ⁇ of the average maximum diameter It means within 50%, more preferably within ⁇ 20% of the average maximum diameter.
- Cell population refers to a cell group composed of two or more cells.
- a cell population may be composed of one type of cells, or may be composed of multiple types of cells.
- the cells that make up the cell population may be floating in the medium, or may be adhered to cultureware or the like.
- the cells constituting the cell population may be single cells, or at least a part of the cell population may be cell-adhered to each other to form a cell population.
- the term “single cell” refers to, for example, cells in which cell-to-cell adhesion (eg surface adhesion) is almost lost.
- dispersed in single cells includes a state in which cell-to-cell junctions (eg, adherens junctions) are almost absent.
- a cell population may comprise cell aggregates.
- tissue refers to the structure of a cell population that has a structure in which multiple types of cells with different morphologies and properties are three-dimensionally arranged in a certain pattern.
- Ectoderm refers to the outermost germ layer of the three germ layers formed after egg fertilization in the process of early development of an organism.
- the ectoderm is divided into neuroectoderm and superficial ectoderm according to the progress of development, and the neuroectoderm is further divided into neural tube and neural crest.
- Various organs of the body are formed from these ectoderm, and organs formed from ectoderm are said to be derived from ectoderm.
- central nervous system organs or tissues such as the brain and spinal cord are formed from the neural tube.
- central nervous system cells for example, some central nervous system cells, facial bones and cartilage, sensory nerve cells, autonomic nerve cells, pigment cells, mesenchymal cells, and the like are formed from the neural crest.
- the superficial ectoderm forms the epidermis, inner ear, anterior pituitary gland, upper respiratory tract tissues including the olfactory epithelium, and the like. Placode and placode-derived tissues are derived from the superficial ectoderm.
- Pluripotent stem cells express genes known as ectoderm markers, such as Pax3, Otx2, and Sox1, in the process of differentiation into ectoderm.
- Endoderm represents the innermost germ layer among the three germ layers formed after egg fertilization in the process of early development of an organism.
- the endoderm forms, for example, the digestive tract, urinary tract, pharynx, trachea, bronchi, and lungs.
- Pluripotent stem cells express genes known as endoderm markers, such as SOX17, HNF-3 ⁇ /FoxA2, Klf5, GATA4, GATA6, PDX-1, during differentiation into endoderm.
- Mesoderm represents the germ layer formed between the ectoderm and the endoderm. Organs or tissues such as circulatory organs, skeletons, and muscles are formed from the mesoderm. Pluripotent stem cells express genes known as mesoderm markers, such as T/Brachury, SMA, ABCA4, Nkx2.5, PDGFR ⁇ , during differentiation into mesoderm.
- Neuro tissue means a tissue composed of nervous system cells such as the developing or adult cerebrum, midbrain, cerebellum, spinal cord, retina, sensory nerves, and peripheral nerves.
- nerve tissue refers to an epithelial structure in which nerve tissue has a layered structure, and neuroepithelial tissue in nerve tissue is determined by bright field observation using an optical microscope. can be evaluated.
- Central nervous system refers to the area where nerve tissue is concentrated and forms the center of information processing. In vertebrates, the brain and spinal cord are included in the central nervous system. The central nervous system derives from the ectoderm.
- Neuron progenitor cells refers to cells other than epidermal cells among ectodermal-derived tissues.
- nervous system cells include cells such as nervous system progenitor cells, neurons (nerve cells), glial cells, neural stem cells, neuron progenitor cells, and glial progenitor cells.
- the nervous system cells also include cells (retinal cells) that constitute the retinal tissue described below, retinal progenitor cells, retinal layer-specific nerve cells, neural retinal cells, and retinal pigment epithelial cells.
- Neural cells can be identified using markers such as Nestin, ⁇ III tubulin (Tuj1), PSA-NCAM, and N-cadherin.
- Neurons are functional cells that form neural circuits and contribute to information transmission. can be identified by indicators.
- Glial cells include astrocytes, oligodendrocytes, Müller glia, and the like.
- astrocyte markers include GFAP, oligodendrocyte markers such as O4, and Müller glia markers such as CRALBP.
- Neural stem cells are cells that have the ability to differentiate into neurons and glial cells (pluripotency) and the ability to proliferate while maintaining pluripotency (sometimes referred to as self-renewal ability).
- Neural stem cell markers include Nestin, Sox2, Musashi, Hes family, CD133, etc., but these markers are general progenitor cell markers and are not considered neural stem cell-specific markers. The number of neural stem cells can be evaluated by neurosphere assay, clonal assay and the like.
- Neuronal progenitor cells are cells that have the ability to proliferate, produce nerve cells, and do not produce glial cells. Markers of neuronal progenitor cells include Tbr2, T ⁇ 1 and the like. Cells positive for immature neuronal markers (TuJ1, Dcx, HuC/D) and proliferation markers (Ki67, pH3, MCM) can also be identified as neuronal progenitor cells. Glial progenitor cells are proliferative cells that produce glial cells but do not produce nerve cells.
- Neural precursor cells are aggregates of progenitor cells including neural stem cells, neuronal progenitor cells and glial progenitor cells, and have the ability to proliferate and produce neurons and glia.
- Neural progenitor cells can be identified using markers such as Nestin, GLAST, Sox2, Sox1, Musashi, and Pax6.
- Neural cell marker-positive and proliferation marker (Ki67, pH3, MCM)-positive cells can also be identified as neural progenitor cells.
- Cerebral tissue refers to cells that constitute the fetal or adult cerebrum (e.g., cortical neural precursor cells, dorsal cerebral nervous system precursor cells, ventral cerebral nervous system precursor cells, cerebral layer structure Specific nerve cells (neurons), layer 1 neurons, layer 2 neurons, layer 3 neurons, layer 4 neurons, layer 5 neurons, layer 6 neurons, glial cells (astrocytes and oligodendrocytes), these progenitor cells, etc.), means a tissue in which one or more types are layered and three-dimensionally arranged.
- the fetal cerebrum is also called the forebrain or telencephalon.
- the presence of each cell can be confirmed by a known method, for example, the presence or absence of cell marker expression, the degree of expression, and the like.
- Cerebral cell markers include FoxG1 (also known as Bf1) expressed in cerebral cells, Sox2 and Nestin expressed in cerebral nervous system progenitor cells, Pax6 and Emx2 expressed in dorsal cerebral nervous system progenitor cells, and ventral cerebral nervous system progenitor cells.
- ventricle refers to a cavity formed by central nervous tissue. In living organisms, it is usually an acellular structure filled with interstitial fluid such as cerebrospinal fluid, and the apical side of nerve tissue faces the ventricle.
- the periventricular layer surrounding the brain ventricle is the area where neural stem cells exist and where cell proliferation and neurogenesis occur during development.
- Whether cell populations and tissues produced by the production method of the present invention contain ventricles can be determined, for example, by using central nervous tissue markers (Bf1, Pax6, etc.) and apical surface markers (PKC-zeta, etc.). It can be detected by methods such as chemistry.
- the "diencephalon” refers to the nerve tissue of the central nervous system in contact with the third ventricle.
- the diencephalon includes tissues such as the epithalamus, thalamus, hypothalamus, and pituitary gland.
- the "hypothalamus” refers to a region of the diencephalon in contact with the pituitary gland.
- the hypothalamus is further subdivided into dorsal and ventral hypothalamus.
- the hypothalamus can be identified using markers such as Rx, Vax1 and Six3.
- the dorsal hypothalamus can be identified using markers such as Otp, Brn2, and vasopressin.
- the ventral hypothalamus can be identified using markers such as Nkx2.1 and SF1.
- non-neuroepithelial tissue refers to any tissue having an epithelial structure other than neuroepithelial tissue.
- Epithelial tissue is formed from any of the germ layers of ectoderm, mesoderm, endoderm and trophectoderm.
- Epithelial tissue includes epithelium, mesothelium, and endothelium.
- tissues included in non-neural epithelial tissues include epidermis, corneal epithelium, nasal epithelium, oral epithelium, tracheal epithelium, bronchial epithelium, airway epithelium, renal epithelium, renal cortical epithelium, placental epithelium, and the like.
- Epithelial tissue is usually connected by various intercellular junctions and forms a tissue having a single-layered or multi-layered structure.
- epithelial polarity refers to the biased distribution of components and cell functions spatially formed in epithelial cells.
- corneal epithelial cells are localized in the outermost layer of the eyeball, and on the apical side, apical side-specific proteins such as membrane-bound mucin (MUC-1, 4, 16) for retaining tear fluid are produced.
- the basal side expresses proteins specific to the basal side, such as ⁇ 6 integrin and ⁇ 1 integrin, for adhesion to the basement membrane.
- Phalloidin, apical markers anti-MUC-1 antibody, anti- PKC-zeta antibody, etc.
- immunohistochemistry using basolateral markers anti- ⁇ 6 integrin antibody, anti- ⁇ 1 integrin antibody, etc.
- the term "placode” mainly refers to the primordium of an organ formed by thickening a part of the epidermal ectoderm during the development process of vertebrates.
- Tissues derived from placode include the lens, nose, inner ear, trigeminal nerve, glandular pituitary gland, and the like.
- Six1, Six4, Dlx5, Eya2, Emx2, Bf1 and the like are examples of markers for the placode or its precursor tissue, the preplacode region.
- pituitary placode refers to a thickened structure formed in the epidermal ectoderm region during embryogenesis, which expresses pituitary progenitor cell markers.
- Pituitary progenitor cell markers include Lim3 (Lhx3), Pitx1/2, Islet1/2 and the like.
- the pituitary placode expresses at least one, preferably all pituitary progenitor cell markers selected from the group consisting of Lim3, Pitx1/2 and Islet1/2.
- the pituitary placode invaginates to form Rathke's pouch, which is a developing pouch-like structure, and further develops to form the glandular pituitary gland.
- the term "adenohypophysis” refers to a tissue containing at least one type of anterior or middle lobe pituitary cells.
- Pituitary cells include pituitary hormone-producing cells, which produce hormones that regulate physiological function, and non-hormone-producing cells.
- Pituitary hormone-producing cells include growth hormone (GH)-producing cells, prolactin (PRL)-producing cells, adrenocorticotropic hormone (ACTH)-producing cells, thyroid-stimulating hormone (TSH)-producing cells, and follicle-stimulating hormone (FSH)-producing cells.
- GH growth hormone
- PRL prolactin
- ACTH adrenocorticotropic hormone
- TSH thyroid-stimulating hormone
- Non-hormone producing cells include vascular endothelial cells, pericytes, follicular astrocytes, pituitary stem cells, pituitary progenitor cells.
- the glandular pituitary contains at least one, preferably two, selected from the group consisting of growth hormone (GH)-producing cells, prolactin (PRL)-producing cells, and adrenocorticotropic hormone (ACTH)-producing cells. , more preferably three pituitary hormone-producing cells.
- the glandular pituitary contains growth hormone (GH)-producing cells, prolactin (PRL)-producing cells, adrenocorticotropic hormone (ACTH)-producing cells, thyroid-stimulating hormone (TSH)-producing cells, follicle-stimulating hormone (FSH)-producing cells.
- pituitary hormone-producing cells and at least one, preferably two or more (2, 3, 4, 5 or 6) pituitary hormone-producing cells selected from the group consisting of luteinizing hormone (LH)-producing cells.
- Growth hormone (GH)-producing cell markers anti-Pit1 antibody , anti-GH antibody, etc.
- prolactin (PRL)-producing cell marker anti-Pit1 antibody, anti-PRL antibody, etc.
- ACTH adrenocorticotropic hormone
- thyroid-stimulating hormone (TSH)-producing cell markers anti-GATA2 antibody, anti-ACTH antibody, etc.
- FSH follicle-stimulating hormone
- LH luteinizing hormone
- pituitary stem cells refer to undifferentiated multipotent stem cells and progenitor cells that exist in the pituitary gland and contribute to the regeneration of pituitary tissue and the supply of pituitary hormone-producing cells. Whether the cell population and tissue produced by the production method of the present invention contain pituitary stem cells can be determined, for example, by Sox2, Sox9, E-Cadherin, Nestin, S100 ⁇ , GFR ⁇ 2, Prop1, CD133, ⁇ -Catenin, Klf4.
- CXADR Coxsackievirus-Adenovirus Common Receptor
- PRRX1/2 Coxsackievirus-Adenovirus Common Receptor
- Ephrin-B2 ACE and other pituitary stem cell markers and Ki67
- phosphorylated histone H3 immune system using antibodies against cell proliferation markers such as MCM Chemistry
- proliferating cell labeling assay using nucleic acid analogues such as BrdU, EdU, IdU
- fluorescence-labeled dipeptide ⁇ -alanyl-lysyl-N-7-amino-4-methylcoumarin-3-acetic acid uptake assay
- pituitary gland It can be detected by a technique such as a pitusphere formation assay.
- oral epithelium refers to the epithelial tissue and its cells that form the oral cavity.
- Oral epithelium includes, for example, oral mucosal epithelium, salivary gland epithelium, and odontogenic epithelium.
- Oral mucosal epithelium is usually a mucosal tissue consisting of stratified squamous epithelium, and contains basal cells, Merkel cells, melanin-producing cells, etc. on the basement membrane in contact with connective tissue. is formed.
- Oral mucosal epithelium can be detected, for example, as cytokeratin 7, 8, 13, 14, 19 positive tissue.
- “niche” or “stem cell niche” refers to the microenvironment involved in the proliferation, differentiation, maintenance of properties, etc. of stem cells.
- biological niches include hematopoietic stem cell niche, hair follicle stem cell niche, intestinal epithelial stem cell niche, muscle stem cell niche, and pituitary niche. In these niches, there are stem cells specific to each tissue and supporting cells that provide the niche. maintained.
- the "pituitary niche” refers to the microenvironment involved in the proliferation, differentiation, maintenance of properties, etc. of pituitary stem cells.
- the pituitary niche includes the marginal cell layer (MCL) niche that exists around the residual cavity (Rathke fissure) that remains between the anterior and middle pituitary lobes as a trace of the hollow part of the sac-like Rathke's pouch during development, and Parenchymal niches interspersed in the anterior pituitary gland.
- MCL marginal cell layer
- mesenchymal cells are non-epithelial cells that are mainly derived from mesoderm and neural crest and form connective tissue. Some of these cells are multipotent somatic stem cells called mesenchymal stem cells. Whether or not the cell populations and tissues produced by the production method of the present invention contain mesenchymal cells can be determined using antibodies against mesenchymal cell markers such as Nestin, Vimentin, Cadherin-11, Laminin, and CD44. It can be detected by methods such as chemistry.
- mesenchymal stem cells are included CD9, CD13, CD29, CD44, CD55, CD59, CD73, CD105, CD140b, CD166, VCAM-1, STRO-1, c-Kit, Sca-1, Nucleostemin, CDCP1 , BMPR2, BMPR1A and BPMR1B.
- the present invention provides a cell population containing pituitary tissue and a method for producing the same. Hereinafter, it is also called the manufacturing method of the present invention.
- One aspect of the production method of the present invention is a method for producing a cell population containing pituitary tissue, including the following steps (1') to (2).
- (1′) a first step of culturing pluripotent stem cells in the presence of a JNK signaling pathway inhibitor to form a cell population;
- the Wnt signaling pathway inhibitor is used in combination with the JNK signaling pathway inhibitor.
- a more preferred embodiment of the production method of the present invention is a method for producing a cell population containing pituitary tissue, including the following steps (a) and steps (1') to (2).
- Pluripotent stem cells are cultured in a medium containing 1) a TGF ⁇ family signaling pathway inhibitor and/or Sonic hedgehog signaling pathway agonist, and 2) an undifferentiated maintenance factor in the absence of feeder cells a step to do, (1′) a first step of culturing (preferably suspension culture) the cells obtained in step a in the presence of a JNK signaling pathway inhibitor; (2) cells containing pituitary tissue obtained by culturing (preferably suspension culture) the cell population obtained in the first step in the presence of a BMP signaling pathway agent and a Sonic hedgehog signaling pathway agent; Second step to obtain the population.
- the first step is a step of forming cell aggregates
- the cell population obtained in the first step subjected to the second step may be a cell aggregate.
- the Wnt signaling pathway inhibitor is used in combination with the JNK signaling pathway inhibitor.
- a more preferred embodiment of the production method of the present invention is a method for producing a cell population containing pituitary tissue, including the following steps (a) and steps (1) to (3).
- Pluripotent stem cells are cultured in a medium containing 1) a TGF ⁇ family signaling pathway inhibitor and/or Sonic hedgehog signaling pathway agonist, and 2) an undifferentiated maintenance factor in the absence of feeder cells a step to do, (1) a first step of culturing (preferably suspension culture) the cells obtained in step a in the presence of a JNK signaling pathway inhibitor and a Wnt signaling pathway inhibitor; (2) a second step of culturing (preferably suspension culture) the cell population obtained in the first step in the presence of a BMP signaling pathway agent and a Sonic hedgehog signaling pathway agent; (3) The third step of culturing (preferably suspension culture) the cell population obtained in the second step in the absence of the Sonic hedgehog signaling pathway agent to obtain a cell population containing pituitary tissue.
- the first step is a step
- Step a Pluripotent stem cells are treated with 1) a TGF ⁇ family signaling pathway inhibitor and/or Sonic hedgehog signaling pathway agonist, and 2) undifferentiated maintenance in the absence of feeder cells.
- a step of culturing in a medium containing factors will be described.
- step (a) treating the pluripotent stem cells with a TGF ⁇ family signaling pathway inhibitor and/or Sonic hedgehog signaling pathway agonist, and then culturing (preferably suspension culture) in the first step.
- This changes the state of pluripotent stem cells improves the efficiency of formation of non-neural epithelial tissues, improves the quality of the obtained cell population (aggregate), facilitates differentiation, prevents cell death, and increases pituitary cell growth. Improves manufacturing efficiency.
- Step (a) is performed in the absence of feeder cells.
- the absence of feeder cells (feeder-free) in the present invention means a condition in which substantially no feeder cells are contained (for example, the ratio of feeder cells to the total number of cells is 3% or less).
- the pluripotent stem cells are preferably embryonic stem cells or induced pluripotent stem cells.
- Induced pluripotent stem cells can be obtained from predetermined institutions, and can also be purchased as commercial products.
- human induced pluripotent stem cell lines 201B7, 201B7-Ff cells, 253G1 cells, 253G4 cells, 1201C1 cells, 1205D1 cells, 1210B2 cells, and 1231A3 cells are available from Kyoto University and iPS Academia Japan.
- induced pluripotent stem cell lines for example, Ff-I01 cells, Ff-I14 cells and QHJI01s04 cells established at Kyoto University are available from Kyoto University.
- HC-6 #10 strain, 1231A3 strain and 1383D2 strain are available from RIKEN, a national research and development agency.
- the TGF ⁇ family signaling pathway (that is, the TGF ⁇ superfamily signaling pathway) is a signaling pathway transduced by the Smad family in cells with transforming growth factor ⁇ (TGF ⁇ ), Nodal/Activin, or BMP as a ligand. .
- the TGF ⁇ family signaling pathway inhibitor refers to a substance that inhibits the TGF ⁇ family signaling pathway, that is, the signaling pathway transmitted by the Smad family, specifically TGF ⁇ signaling pathway inhibitor, Nodal/Activin signaling pathway Inhibitors and BMP signaling pathway inhibitors may be mentioned.
- TGF ⁇ family signaling pathway inhibitor a TGF ⁇ signaling pathway inhibitor is preferred.
- the TGF ⁇ signal transduction pathway inhibitor is not particularly limited as long as it inhibits the signal transduction pathway caused by TGF ⁇ , and may be any of nucleic acids, proteins, and low-molecular-weight organic compounds. Examples of such substances include substances that directly act on TGF ⁇ (e.g., proteins, antibodies, aptamers, etc.), substances that suppress the expression of genes encoding TGF ⁇ (e.g., antisense oligonucleotides, siRNA, etc.), and substances that inhibit the binding of TGF ⁇ receptors to TGF ⁇ . Inhibitory substances and substances that inhibit physiological activities caused by signal transduction by TGF ⁇ receptors (eg, TGF ⁇ receptor inhibitors, Smad inhibitors, etc.) can be mentioned. Proteins known as TGF ⁇ signaling pathway inhibitors include Lefty.
- SB431542 (sometimes abbreviated as "SB431") (4-[4-(3,4-methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide)
- SB505124 (2-[4-(1,3-Benzodioxol-5-yl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-6-methylpyridine
- SB525334 (6-[2 -(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline)
- LY2157299 (4-[5,6-Dihydro-2-(6-methyl- 2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide
- SB431542 is a compound known as an inhibitor of TGF ⁇ receptor (ALK5) and Activin receptor (ALK4/7) (ie TGF ⁇ R inhibitor).
- SIS3 is a TGF ⁇ signaling pathway inhibitor that inhibits phosphorylation of SMAD3, an intracellular signaling factor under the control of TGF ⁇ receptors.
- ITD-1 is a TGF- ⁇ type II receptor proteasomal degradation promoter. It is known to those skilled in the art that the above compounds and the like have activity as TGF ⁇ signaling pathway inhibitors (for example, described in Expert Opinion on Investigational Drugs, 2010, 19.1: 77-91.).
- the TGF ⁇ signaling pathway inhibitor preferably includes an Alk5/TGF ⁇ R1 inhibitor.
- the concentration of the TGF ⁇ signaling pathway inhibitor in the medium can be appropriately set according to the substance used within a range that can achieve the above effects.
- the concentration of the TGF ⁇ signaling pathway inhibitor in step (a) can be appropriately set according to the substance used within a range that can achieve the above effects.
- SB431542 as the TGF ⁇ signaling pathway inhibitor in step (a)
- a TGF ⁇ signaling pathway inhibitor other than SB431542 it is preferably used at a concentration that exhibits the same TGF ⁇ signaling pathway inhibitory activity as SB431542 at the above concentrations.
- the TGF ⁇ signaling pathway inhibitory activity of SB431542 and the like can be determined by a method well known to those skilled in the art, for example, by detecting Smad phosphorylation by Western blotting (Mol Cancer Ther. (2004) 3, 737-45. ).
- a Shh signaling pathway agonist is a substance that can enhance signal transduction mediated by Shh.
- Shh signaling pathway agonists include proteins belonging to the Hedgehog family (eg, Shh, Ihh), Shh receptors, Shh receptor agonists, Smo agonists, Purmorphamine (9-cyclohexyl-N-[4-(morpholinyl)phenyl] -2-(1-naphthalenyloxy)-9H-purin-6-amine), GSA-10 (Propyl 4-(1-hexyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxymido) benzoate) , Hh-Ag1.5, 20(S)-Hydroxycholesterol, SAG (Smoothened Agonist: N-Methyl-N'-(3-pyridinylbenzol)-N'-(3-chlorobenzo[b]thiophene-2-carbonyl)-1 , 4-d
- the Shh signaling pathway agent preferably contains at least one selected from the group consisting of SAG, Purmorphamine and GSA-10, more preferably SAG.
- the concentration of the substance acting on the Shh signaling pathway in the medium can be appropriately set according to the substance to be used within a range in which the above effects can be achieved.
- SAG is generally about 1 nM to about 2000 nM, preferably about 10 nM to about 1000 nM, more preferably about 10 nM to about 700 nM, even more preferably about 50 nM to about 700 nM, particularly preferably about 100 nM to about 600 nM in step (a). , most preferably at a concentration of about 100 nM to about 500 nM.
- Shh signaling promoting activity can be determined by a method well known to those skilled in the art, for example, a reporter gene assay focusing on Gli1 gene expression (Oncogene (2007) 26, 5163-5168).
- the medium used in step (a) contains an undifferentiated maintenance factor to enable undifferentiated maintenance culture.
- the undifferentiation maintenance factor is not particularly limited as long as it is a substance that has an effect of suppressing differentiation of pluripotent stem cells.
- Undifferentiated maintenance factors widely used by those skilled in the art include, in the case of primed pluripotent stem cells (e.g., human ES cells, human iPS cells), FGF signaling pathway agonists, TGF ⁇ family signaling pathways An active substance, insulin, etc., can be mentioned.
- FGF signaling pathway agonists include fibroblast growth factors (eg, bFGF, FGF4 and FGF8).
- TGF ⁇ family signaling pathway agonists include TGF ⁇ signaling pathway agonists and Nodal/Activin signaling pathway agonists.
- TGF ⁇ signaling pathway agonists include, for example, TGF ⁇ 1 and TGF ⁇ 2.
- Nodal/Activin signaling pathway agonists include, for example, Nodal, ActivinA, and ActivinB. These substances may be used alone or in combination.
- the medium in step (a) preferably contains bFGF as an undifferentiated maintenance factor.
- Undifferentiated maintenance factors are usually mammalian undifferentiated maintenance factors. Examples of mammals include those described above. Since the undifferentiation maintenance factor may have cross-reactivity between species of mammals, any mammalian undifferentiation maintenance factor can be used as long as the undifferentiated state of the pluripotent stem cells to be cultured can be maintained. good too.
- the undifferentiation maintenance factor is preferably a mammalian undifferentiation maintenance factor of the same species as the cells to be cultured.
- human undifferentiated maintenance factors eg, bFGF, FGF4, FGF8, EGF, Nodal, ActivinA, ActivinB, TGF ⁇ 1, TGF ⁇ 2, etc.
- the undifferentiated maintenance factor is preferably isolated.
- the undifferentiation maintenance factor can be produced by any host or artificially synthesized as long as it has the ability to maintain undifferentiation of the pluripotent stem cells to be cultured.
- the factor for maintaining undifferentiation used in the present invention is preferably modified in the same manner as that produced in vivo, and is produced in cells of the same type as the pluripotent stem cells to be cultured under conditions that do not contain xenogeneic components. is more preferred.
- One aspect of the production method according to the present invention includes a step of providing an isolated undifferentiated maintenance factor.
- One aspect of the production method according to the present invention includes the step of exogenously (or exogenously) adding an isolated factor for maintaining undifferentiation to the medium used in step (a).
- An undifferentiation maintenance factor may be added in advance to the medium used in step (a).
- the concentration of the undifferentiated maintenance factor in the medium used in step (a) is a concentration that can maintain the undifferentiated state of the cultured pluripotent stem cells, and can be appropriately set by those skilled in the art.
- concentration is usually about 4 ng/mL to about 500 ng/mL, preferably about 10 ng/mL to about 200 ng/mL, more preferably about 30 ng/mL. mL to about 150 ng/mL.
- Step (a) is performed in the absence of feeder cells.
- Cultivation of pluripotent stem cells in step (a) may be carried out under either suspension culture or adherent culture, preferably adherent culture.
- an appropriate matrix may be used as a scaffold to provide the pluripotent stem cells with a scaffold that replaces feeder cells.
- Pluripotent stem cells are adherently cultured in a cultureware whose surface is coated with a scaffold matrix.
- Matrices that can be used as scaffolds include laminin (Nat Biotechnol. 28, 611-615 (2010)), laminin fragments (Nat Commun 3, 1236 (2012)), basement membrane preparations (Nat Biotechnol 19, 971-974 (2001)), gelatin, collagen, heparan sulfate proteoglycan, entactin, vitronectin, and the like.
- Laminin 511 is preferably used for the matrix (Nat Biotechnol 28, 611-615 (2010)).
- the laminin fragment is not particularly limited as long as it has adhesiveness to pluripotent stem cells and enables maintenance and culture of pluripotent stem cells under feeder-free conditions, but is preferably an E8 fragment.
- Laminin E8 fragment was identified as a fragment having strong cell adhesive activity among fragments obtained by digesting laminin 511 with elastase (EMBO J., 3: 1463-1468, 1984, J. Am. Cell Biol., 105:589-598, 1987).
- the E8 fragment of laminin 511 is preferably used (Nat Commun 3, 1236 (2012), Scientific Reports 4, 3549 (2014)).
- the laminin E8 fragment need not be an elastase digestion product of laminin and may be recombinant. It may be one produced by a genetically modified animal (such as a silkworm). From the viewpoint of avoiding contamination with unidentified components, a recombinant laminin fragment is preferably used.
- the E8 fragment of laminin 511 is commercially available and can be purchased from Nippi Co., Ltd., for example.
- the laminin or laminin fragment used in the present invention is preferably isolated.
- the surface is preferably coated with isolated laminin 511 or E8 fragment of laminin 511, more preferably with E8 fragment of laminin 511.
- Pluripotent stem cells are adherently cultured in cultureware.
- the medium used in step (a) is not particularly limited as long as it allows undifferentiated maintenance culture of pluripotent stem cells under feeder-free conditions (feeder-free medium).
- the medium used in step (a) may be serum medium or serum-free medium. From the viewpoint of avoiding contamination with chemically undetermined components, the medium used in step (a) is preferably a serum-free medium.
- the medium may contain serum replacement.
- the culture time of the pluripotent stem cells in step (a) is not particularly limited as long as the effect of improving the quality of the cell population (aggregate) that can be formed in the subsequent first step can be achieved, but usually 0.5 to 144 hours, preferably 2 to 96 hours, more preferably 6 to 48 hours, even more preferably 12 to 48 hours, particularly preferably 18 to 28 hours, for example 24 hours. That is, the step (a) is started 0.5 to 144 hours, preferably 18 to 28 hours before the start of the first step, and the first step is continued after the step (a) is completed.
- human pluripotent stem cells are adherently cultured in a serum-free medium containing bFGF in the absence of feeder cells.
- the adherent culture is preferably carried out in a cultureware surface-coated with laminin-511, E8 fragment of laminin-511 or vitronectin.
- the adherent culture is preferably performed using StemFit as a feeder-free medium.
- StemFit medium contains bFGF as an undifferentiated maintenance component (Scientific Reports (2014) 4, 3594).
- human pluripotent stem cells are suspended in a bFGF-containing serum-free medium in the absence of feeder cells.
- human pluripotent stem cells may form aggregates of human pluripotent stem cells.
- culture conditions such as culture temperature and CO 2 concentration can be appropriately set.
- the culture temperature is, for example, about 30°C to about 40°C, preferably about 37°C.
- the CO 2 concentration is, for example, about 1% to about 10%, preferably about 5%, when using a bicarbonate-buffered medium.
- JNK c-Jun N-terminal kinase
- JNK is a kinase belonging to the MAPK family and is involved in intracellular signal transduction stimulated by various environmental stresses, inflammatory cytokines, growth factors, and GPCR agonists.
- the JNK signaling pathway inhibitor is not limited as long as it can suppress signal transduction transmitted by JNK.
- a JNK signaling pathway inhibitor for example, a mechanism of inhibiting the upstream or downstream factors of the JNK signaling mechanism, or the enzymatic activity, multimerization, binding to other factors or nucleic acids of JNK itself, promoting degradation, etc.
- JNK signaling pathway inhibitors include JNK inhibitors, Rac inhibitors, MKK inhibitors, MEK inhibitors, Src inhibitors, receptor tyrosine kinase (RTK) inhibitors, ASK inhibitors, and the like. Not limited.
- JNK inhibitors include, for example, JNK-IN-8 ((E)-3-(4-(dimethylamino)but-2-enamide)-N-(3-methyl-4-( (4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide), SP600125 (Anthra[1-9-cd]pyrazol-6(2H)-one), DB07268 (2-[[2 -[(3-Hydroxyphenyl)amino]-4-pyrimidinyl]amino]benzamide), Tanzisertib (trans-4-[[9-[(3S)-Tetrahydro-3-furanyl]-8-[(2,4,6 -trifluorophenyl)amino]-9H-purin-2-yl]amino]cyclohexaneol), Bentmapimod (1,3-Benzothiazol-2-y
- JNK inhibitors for example, described in J Enzyme Inhib Med Chem. 2020; 35(1): 574-583.
- Rac inhibitors include EHT1864 (5-(5-(7-(Trifluoromethyl)quinolin-4-ylthio)pentyloxy)-2-(morpholinomethyl)-4H-pyran-4-one dihydrochloride), NSC23766 (N6-[ 2-[[4-(Diethylamino)-1-methylbutyl]amino]-6-methyl-4-pyrimidinyl]-2-methyl-4,6-quinolinediamine trihydrochloride), EHop-016 (N4-(9-Ethyl-9H -carbazol-3-yl)-N2-[3-(4-morpholinyl)propyl]-2,4-pyrimidinediamine), 1A-116(N-(3,5-Dimethylphenyl)-N′-[2-(trifluoromethyl )phenyl]guanidine), ZCL278 (2-(4-bromo-2-chlorophenoxy)-N-(4-(N-(4,6
- ARS-853 (1-[3-[4-[2-[[4-Chloro-2-hydroxy- 5-(1-methylcyclopropyl)phenyl]amino]acetyl]-1-piperazinyl]-1-azetidinyl]-2-propen-1-one), Salirasib (2-(((2E,6E)-3,7,11 -Trimethyldodeca-2,6,10-trien-1-yl)thio)benzoic acid), ML141 (4-(5-(4-methoxyphenyl
- the timing of addition of the JNK signaling pathway inhibitor in the present invention is not limited as long as the effect of improving the efficiency of production of pituitary tissue from human pluripotent stem cells is exhibited. It is preferably already added at the time of adding the agent, and within 72 hours from the start of differentiation induction. A more preferable time to add the JNK inhibitor is at the same time as the initiation of differentiation induction.
- step (1) is the first step of culturing pluripotent stem cells in the presence of a JNK signaling pathway inhibitor and a Wnt signaling pathway inhibitor.
- the Wnt signaling pathway is a signaling pathway that uses Wnt family proteins as ligands and mainly Frizzled as receptors. Examples of the signaling pathway include the canonical Wnt pathway (Canonical Wnt pathway), non-canonical Wnt pathway (Non-Canonical Wnt pathway), and the like.
- the canonical Wnt pathway is mediated by ⁇ -catenin.
- Non-classical Wnt pathways include Planar Cell Polarity (PCP) pathway, Wnt/JNK pathway, Wnt/Calcium pathway, Wnt-RAP1 pathway, Wnt-Ror2 pathway, Wnt-PKA pathway, Wnt-GSK3MT pathway, Wnt-aPKC pathway , Wnt-RYK pathway, Wnt-mTOR pathway, and the like.
- PCP Planar Cell Polarity
- Wnt/JNK pathway Wnt/Calcium pathway
- Wnt-RAP1 pathway Wnt-Ror2 pathway
- Wnt-PKA pathway Wnt-GSK3MT pathway
- Wnt-aPKC pathway Wnt-RYK pathway
- Wnt-mTOR pathway and the like.
- the Wnt signaling pathway inhibitor is not limited as long as it can suppress signal transduction triggered by Wnt family proteins.
- Inhibitors may be nucleic acids, proteins, or small organic compounds. Examples of such substances include substances that inhibit Wnt processing and extracellular secretion, substances that act directly on Wnt (e.g., proteins, antibodies, aptamers, etc.), and substances that suppress the expression of genes encoding Wnt (e.g., antisense oligos). nucleotides, siRNA, CRISPRi, etc.), substances that inhibit binding between Wnt receptors and Wnts, and substances that inhibit physiological activities caused by signal transduction by Wnt receptors.
- proteins belonging to the secret Frizzled Related Protein (sFRP) class proteins belonging to the secret Frizzled Related Protein (sFRP1) class (sFRP1-5, Wnt Inhibitory Factor-1 (WIF-1), Cerberus), Dickkopf (Dkk) class proteins (Dkk1-4, Kremen), APCDD1, APCDD1L, proteins belonging to the Draxin family, IGFBP-4, Notum, proteins belonging to the SOST/Sclerostin family, and the like.
- Wnt signaling pathway inhibitors Compounds well known to those skilled in the art can be used as Wnt signaling pathway inhibitors.
- inhibitors of the classical Wnt signaling pathway include Frizzled inhibitors, Disheveled (Dvl) inhibitors, Tankyrase (TANK) inhibitors, casein kinase 1 inhibitors, catenin-responsive transcription inhibitors, p300 inhibitors, CREB-binding protein (CBP) inhibitors, BCL-9 inhibitors, TCF degradation inducers (Am J Cancer Res. 2015; 5(8): 2344-2360) and the like.
- Non-classical Wnt pathway inhibitors include, for example, porcupine (PORCN) inhibitors, calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitors, TGF- ⁇ -activated kinase 1 (TAK1) inhibitors, Nemo-Like Kinase ( NLK) inhibitor, LIM Kinase inhibitor, mammalian target of rapamycin (mTOR) inhibitor, Rac inhibitor, c-Jun NH 2-terminal kinase (JNK) inhibitor, protein kinase C (PKC) inhibitor, methionine aminopeptidase 2 (MetAP2) inhibitors, calcineurin inhibitors, nuclear factor of activated T cells (NFAT) inhibitors, ROCK inhibitors and the like.
- PORCN porcupine
- CaMKII calcium/calmodulin-dependent protein kinase II
- NLK Nemo-Like Kinase
- KY02111 N-(6-Chloro-2-benzothiazolyl)-3,4-dimethoxybenzenepropanamide
- KY03-I (2-(4-( 3,4-dimethoxyphenyl)butanamide)-6-Iodobenzothiazole).
- PORCN inhibitors such as IWP-2 (N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin -2-yl)thio]acetamide), IWP-3 (2-[[3-(4-fluorophenyl)-3,4,6,7-tetrahydro-4-oxothieno[3,2-d]pyrimidin-2- yl]thio]-N-(6-methyl-2-benzothiazolyl)acetamide), IWP-4 (N-(6-methyl-2-benzothiazolyl)-2-[[3,4,6,7-tetrahydro-3 -(2-methylphenyl)-4-oxothieno[3,2-d]pyrimidin-2-yl]thio]acetamide), IWP-L6 (N-(5-phenyl-2-pyridinyl)-2-[(3,
- the Wnt signaling pathway inhibitor preferably contains at least one selected from the group consisting of a PORCN inhibitor, KY02111 and KY03-I, more preferably a PORCN inhibitor.
- Wnt signaling pathway inhibitors also preferably include substances having inhibitory activity on the non-canonical Wnt pathway of Wnt.
- Wnt signaling pathway inhibitors more preferably include substances having inhibitory activity on the Wnt/Planar Cell Polarity (PCP) pathway.
- PORCN inhibitors used in the present invention are preferably the group consisting of IWP-2, IWP-3, IWP-4, IWP-L6, IWP-12, LGK-974, Wnt-C59, ETC-159 and GNF-6231 It contains at least one selected from the above, more preferably contains IWP-2 or Wnt-C59, and still more preferably contains IWP-2.
- the concentration of the Wnt signaling pathway inhibitor in the medium can be appropriately set according to the substance used within a range that can achieve the above effects. From the viewpoint of improving the production efficiency of cells that constitute the pituitary gland, for example, when IWP-2, which is a PORCN inhibitor, is used as the Wnt signaling pathway inhibitor, the concentration is usually about 10 nM to about 50 ⁇ M. , preferably about 10 nM to about 30 ⁇ M, more preferably about 100 nM to about 10 ⁇ M, most preferably about 0.5 ⁇ M.
- Wnt-C59 one of the PORCN inhibitors
- its concentration is usually about 10 pM to about 1 ⁇ M, preferably about 100 pM to about 500 nM, more preferably about 50 nM.
- KY02111 its concentration is generally about 10 nM to about 50 ⁇ M, preferably about 10 nM to about 30 ⁇ M, more preferably about 100 nM to about 10 ⁇ M, and even more preferably about 5 ⁇ M.
- Wnt signaling pathway inhibitors other than those mentioned above it is desirable to use them at concentrations exhibiting Wnt signaling pathway inhibitory activity equivalent to the above concentrations.
- a TGF ⁇ signaling pathway inhibitor is preferably further present in the medium of the first step (step (1) or step (1')).
- the TGF ⁇ signaling pathway inhibitor used in the first step the same substances as exemplified in step (a) can be used.
- the TGF ⁇ signaling pathway inhibitors in step (a) and the first step may be the same or different, but are preferably the same.
- the concentration of the TGF ⁇ signaling pathway inhibitor in the medium can be appropriately set according to the substance used within the range where the above effects can be achieved.
- SB431542 is used as a TGF ⁇ signaling pathway inhibitor, it is usually used at a concentration of about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 100 ⁇ M, more preferably about 100 nM to about 50 ⁇ M, still more preferably about 500 nM to about 10 ⁇ M. be.
- a TGF ⁇ signaling pathway inhibitor other than SB431542 it is preferably used at a concentration that exhibits the same TGF ⁇ signaling pathway inhibitory activity as SB431542 at the above concentrations.
- TAK1 transforming growth factor- ⁇ -activated kinase 1
- MAKKK MAP kinase kinase kinase family that mediates signaling activated by TGF ⁇ , bone morphogenetic proteins (BMPs), interleukin-1 (IL-1), TNF- ⁇ , etc. .
- a TAK1 inhibitor is not limited as long as it can suppress signal transduction mediated by TAK1. Any of nucleic acids, proteins, and low-molecular-weight organic compounds may be used. Examples of the substance include a substance that inhibits binding of TAK1 to a substrate, a substance that inhibits phosphorylation of TAK1, a substance that promotes dephosphorylation of TAK1, a substance that inhibits transcription and translation of TAK1, and a substance that promotes degradation of TAK1. etc.
- TAK1 inhibitor for example, (5Z)-7-Oxozeaenol ((3S,5Z,8S,9S,11E)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3- methyl-1H-2-benzoxacyclotetradecine-1,7(8H)-dione), N-Des(aminocarbonyl)AZ-TAK1 inhibitor (3-Amino-5-[4-(4-morpholinylmethyl)phenyl]-2-thiophenecarboxy) , Takinib (N1-(1-Propyl-1H-benzomidazol-2-yl)-1,3-benzenedicarboxamide), NG25 (N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl ) phenyl]-4-methyl-3-(1H-pyrrolo[2,3-b]pyridin-4-yl
- the TAK1 inhibitor is preferably (5Z)-7-Oxozeaenol.
- (5Z)-7-Oxozeaenol is used as the TAK1 inhibitor in the first step, it is usually about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 50 ⁇ M, more preferably about 100 nM to about 25 ⁇ M, still more preferably about 500 nM to A concentration of about 10 ⁇ M is used.
- a TAK1 inhibitor other than (5Z)-7-Oxozeaenol it is preferably used at a concentration that exhibits TAK1 inhibitory activity equivalent to that of (5Z)-7-Oxozeaenol at the above concentrations.
- TAK1 inhibitory activity is described, for example, in Cell chemical biology 24.8 (2017): 1029-1039. can be determined by a method such as the kinase assay described in . From the viewpoint of controlling the proportion of cells contained in the pituitary tissue, the TAK1 inhibitor can be added at any stage of the first step and subsequent steps and then removed. In a preferred embodiment, the TAK1 inhibitor is added at the start of step (b) described below.
- the medium used in the first step is not particularly limited as long as it is as described in the definition section above.
- the medium used in the first step can be serum medium or serum-free medium. From the viewpoint of avoiding contamination with chemically undetermined components, a serum-free medium is preferably used in the present invention. In order to avoid complicated preparation, it is preferable to use a serum-free medium supplemented with an appropriate amount of a serum substitute such as commercially available KSR.
- the amount of KSR added to the serum-free medium for example, in the case of human ES cells, is generally about 1% to about 30%, preferably about 2% to about 20%.
- the serum-free medium includes, for example, a 1:1 mixture of IMDM and F-12 supplemented with 5% KSR, 450 ⁇ M 1-monothioglycerol and 1x Chemically Defined Lipid Concentrate, or 5% to 20% KSR in GMEM. , NEAA, pyruvate and 2-mercaptoethanol.
- the cells may be in either an adherent state or a floating state.
- pluripotent stem cells are dispersed into single cells and then reaggregated to form cell aggregates in a floating state. For this reason, it is preferable to disperse the pluripotent stem cells, for example the pluripotent stem cells obtained in step (a), into single cells before starting the first step.
- the "dispersed cells” obtained by the dispersing operation are preferably single cells, but may include, for example, cell clusters consisting of a small number of cells, from 2 to 100, and from 2 to 50 cells. It may contain clumps of different cells. "Dispersed cells” may contain, for example, 70% or more single cells and 30% or less cell clusters, preferably 80% or more single cells and 20% or less cell clusters.
- Methods for dispersing pluripotent stem cells include mechanical dispersion treatment, cell dispersion treatment, and cell protective agent addition treatment, and these treatments may be combined.
- a method for dispersing the cells it is preferable to carry out the cell-dispersing solution treatment at the same time as the cell protective agent addition treatment, followed by mechanical dispersion treatment.
- Cell protective agents used in cell protective agent addition treatment include FGF signaling pathway agents, heparin, Rho-associated protein kinase (ROCK) inhibitors, myosin inhibitors, polyamines, integrated stress response: ISR) inhibitors, caspase inhibitors, cell adhesion promoters, serum, or serum substitutes.
- Preferred cytoprotective agents include ROCK inhibitors.
- a ROCK inhibitor from the start of culture in the first step.
- ROCK inhibitors examples include Y-27632 ((R)-(+)-trans-4-(1-Aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide, dihydrochloride), Fasudil (HA1077) (1-(5- isoquinolinylsulfonyl) homopiperazine, hydrochloride), H-1152 (5-[[(2S)-hexahydro-2-methyl-1H-1,4-diazepin-1-yl]sulfonyl]-4-methyl-isoquinoline, dihydrochloride) -1100 (Hydroxyfasudil) (1-(1-Hydroxy-5-isoquinolinesulfonyl) homopiperazine, hydrochloride), Chroman 1 ((3S)-N-[2-[2-(dimethylamino)ethoxy]-4-(1H-pyrazol- 4-yl)phenyl]-6-meth
- cell adhesion promoters include adhesamine and adhesamine-RGDS derivatives (manufactured by Nagase & Co., Ltd.).
- a prepared cell protective agent can also be used as the cell protective agent.
- the prepared cytoprotective agent include RevitaCell Supplement (manufactured by Thermo Fisher Scientific), CloneR, CloneR2 (manufactured by Stemcell Technologies) and the like. These substances may be used alone or in combination.
- the concentration is usually about 10 nM to about 10 mM, preferably about 100 nM to about 1 mM, more preferably about 1 ⁇ M to about 100 ⁇ M.
- the concentration is usually about 10 pM to about 1 mM, preferably about 100 pM to about 100 ⁇ M, more preferably about 1 nM to about 10 ⁇ M. to the culture environment.
- the cell dispersion used for the cell dispersion treatment can include a solution containing at least one enzyme such as trypsin, collagenase, hyaluronidase, elastase, pronase, DNase, papain, or a chelating agent such as ethylenediaminetetraacetic acid.
- a chelating agent such as ethylenediaminetetraacetic acid.
- Commercially available cell dispersions such as TripLE Select (manufactured by Thermo Fisher Scientific), TripLE Express (manufactured by Thermo Fisher Scientific), and Accumax (manufactured by Innovative Cell Technologies) can also be used.
- a preferred cell dispersion for treatment of pluripotent stem cells obtained after step (a) is phosphate buffered saline (PBS) supplemented with 5 mM EDTA, but is not limited thereto.
- PBS phosphate buffered saline
- Mechanical dispersion methods include pipetting or scraping with a scraper.
- the dispersed cells are suspended in the medium.
- a method for dispersing pluripotent stem cells includes, for example, a method in which colonies of pluripotent stem cells are treated with ethylenediaminetetraacetic acid or Accumax in the presence of a ROCK inhibitor, and further dispersed by pipetting.
- a suspension of dispersed pluripotent stem cells is seeded in non-cell-adhesive cultureware.
- the cultureware is non-adhesive, cells are cultured in suspension, and multiple pluripotent stem cells aggregate to form cell aggregates.
- a plurality of cell aggregates may be simultaneously formed in one culture vessel.
- a certain number of cells dispersed in each well of a multiwell plate U bottom, V bottom
- Pluripotent stem cells are preferably seeded.
- the cells rapidly aggregate to form one cell aggregate in each well.
- the cultureware can be made non-cell-adhesive by processing such as coating the surface of the cultureware with a superhydrophilic polymer.
- Non-cell-adhesive multiwell plates include, for example, PrimeSurface 96V bottom plate (MS-9096V, manufactured by Sumitomo Bakelite). Centrifugation may be performed to form cell aggregates more quickly. A uniform population of cell aggregates can be obtained by collecting the cell aggregates formed in each well from a plurality of wells. If the cell aggregates are uniform, the production efficiency for each well and for each repeated experiment can be more stabilized in subsequent steps, and cells that constitute the pituitary gland can be produced with higher reproducibility.
- Another embodiment for forming cell aggregates from dispersed pluripotent stem cells is to use a cultureware in which one well is divided into a plurality of microwells and two or more cell aggregates are formed.
- the suspension culture in any one or more of the first step, second step, b step, and third step is performed in such a manner that at least one well is formed.
- the well is divided into a plurality of microwells, suspension culture is performed so that one cell cluster is formed in each microwell, and each well is A number of cell clusters corresponding to divided microwells may be prepared.
- a mortar in which cells settle in one place on the bottom surface to promote the formation of aggregates a downward square pyramid, a recessed shape, etc., a grid, a cultureware in which a plurality of protrusions, etc. are formed, or an aggregate. It is also possible to use a culture device or the like whose bottom surface is partially processed so that cells can adhere to it so as to facilitate the formation of aggregates.
- the culture area per well of the cultureware having microwells is not particularly limited, but from the viewpoint of efficiently producing cell aggregates, the bottom area is preferably larger than 1 cm 2 (equivalent to a 48-well plate), more preferably 2 cm.
- Examples of such cultureware include AggreWell (manufactured by StemCell Technologies), PAMCELL (manufactured by ANK), spheroid microplate (manufactured by Corning), NanoCulture Plate/Dish (manufactured by Organogenix) Cell- Able (manufactured by Toyo Gosei Co., Ltd.), EZSPHERE (manufactured by AGC Techno Glass), SPHERICALPLATE 5D (manufactured by Mito Kogyo Co., Ltd.), TASCL (manufactured by Sims Bio), microwell bag (eg, Scientific reports, 2022, 12.1: 1 -11.), but not limited to these.
- a three-dimensional cell culture vessel that can replace the medium of the entire plate at once while cell aggregates remain in each well.
- examples of such a three-dimensional cell culture vessel include PrimeSurface 96 slit well plate (manufactured by Sumitomo Bakelite Co., Ltd.). This plate has narrow openings (slits) through which the medium can enter and exit at the top of each of the 96 wells. Since the slit is set to a width that makes it difficult for cell aggregates to pass through, it is possible to exchange the medium for the entire plate at once while preventing cell aggregates from adhering to each other. quality can be improved.
- the concentration of pluripotent stem cells in the first step can be appropriately set so as to form cell aggregates more uniformly and efficiently.
- human pluripotent stem cells for example, human iPS cells obtained from step (a)
- a solution prepared to obtain about 8 ⁇ 10 3 to about 1.2 ⁇ 10 4 cells is added to each well, and the plate is allowed to stand to form cell aggregates.
- EZSPHERE SP dish 35 mm Type 905 which is a culture device having about 260 microwells per dish
- a solution prepared to give about 4 ⁇ 10 4 to about 1.6 ⁇ 10 7 cells, particularly preferably about 8 ⁇ 10 4 to about 1.2 ⁇ 10 7 cells is added to the dish, and the dish is allowed to stand. to form cell aggregates.
- human pluripotent stem cells for example, human iPS cells obtained from step (a)
- AggreWell 800, 6-well plate which is a culture device having about 1800 microwells per well.
- a solution prepared so as to obtain preferably about 4 ⁇ 10 4 to about 1.6 ⁇ 10 7 cells, particularly preferably about 8 ⁇ 10 4 to about 1.2 ⁇ 10 7 cells is added to each well, and the plate is plated. Centrifuge to form cell aggregates. Cell numbers can be determined by counting with a hemocytometer.
- the suspension culture time required to form cell aggregates can be appropriately determined depending on the pluripotent stem cells used, but it is desirable to be as short as possible in order to form uniform cell aggregates.
- the process by which dispersed cells form cell aggregates is divided into a process of cell aggregation and a process of aggregated cells forming aggregates. From the time the dispersed cells are seeded (i.e., at the start of suspension culture) until the cells aggregate, for example, in the case of human pluripotent stem cells (human iPS cells, etc.), preferably within about 24 hours, more preferably Within about 12 hours.
- the time of seeding the dispersed cells i.e., the start of suspension culture
- the formation of cell aggregates for example, in the case of human pluripotent stem cells (human iPS cells, etc.), preferably within about 72 hours, More preferably within about 48 hours.
- the time required to form cell aggregates can be appropriately adjusted by adjusting the tool for aggregating cells, centrifugation conditions, and the like.
- epithelial-like structures can be reproducibly formed in cells differentiated from the formed aggregates.
- Experimental manipulations for forming cell aggregates include, for example, plates with small wells (for example, plates with a well bottom area of about 0.1 to 2.0 cm 2 in terms of a flat bottom) and small spaces using micropores.
- Plates with small wells include, for example, a 24-well plate (an area of about 1.88 cm 2 in terms of flat bottom), a 48-well plate (an area of about 1.0 cm 2 in terms of flat bottom), and a 96-well plate (an area of about 0.0 cm 2 in terms of flat bottom). 35 cm 2 , inner diameter of about 6 to 8 mm), 384-well plate. A 96-well plate is preferred.
- the shape of the plate with small wells the shape of the bottom when the wells are viewed from above includes polygonal, rectangular, elliptical, and perfect circle, preferably perfect circle.
- the shape of the bottom surface when the wells are viewed from the side is preferably a structure in which the outer periphery is high and the interior is low, and examples thereof include a U bottom, a V bottom, and an M bottom.
- U-bottoms or V-bottoms, most preferably V-bottoms are mentioned.
- a cell culture dish eg, 60 mm to 150 mm dish, culture flask
- the bottom of the small plate of wells preferably uses a cell non-adhesive bottom, preferably a cell non-adhesive coated bottom.
- a three-dimensional printer or a 3D printer Dispersed single cells or spheroids composed of multiple cells are suspended in biocompatible ink (bioink) and output by a bio 3D printer (eg BIO X manufactured by Celllink, etc.), or A cell population with a desired form can be prepared by a method of pricking a cell population with a needle and accumulating it (Syfuse Spike, etc.).
- cell aggregates are determined by the size and number of cells of cell aggregates, macroscopic morphology, microscopic morphology by tissue staining analysis and its uniformity, expression of differentiation and undifferentiated markers and their uniformity, differentiation markers can be determined based on the expression control and its synchrony, reproducibility of differentiation efficiency between aggregates, and the like.
- adherent culture is performed.
- the pluripotent stem cells on the cultureware after step (a) may be used as they are in the first step, or the pluripotent stem cells may be dispersed into single cells and then seeded again on the adhesive cultureware. good.
- Appropriate extracellular matrices or synthetic cell adhesion molecules may be used as scaffolds in performing reseeding after dispersal of pluripotent stem cells into single cells.
- the scaffold allows adherent culture of pluripotent stem cells in a surface-coated cultureware.
- the extracellular matrix is preferably matrigel or laminin.
- Synthetic cell adhesion molecules include poly-D-lysine, synthetic peptides containing a cell adhesion domain such as the RGD sequence, and the like.
- the number of seeded cells is not particularly limited as long as differentiation to the pituitary gland occurs, but from the viewpoint of reproducing adhesion and interaction between cells, the cell density is within 72 hours after seeding on the cultureware. It is also preferable that the density is such that it reaches semi-confluence corresponding to 60% or more.
- micropatterned cultureware as the adhesive cultureware.
- the micropattern on the cultureware can be composed of a cell-adhesive region and a cell-non-adhesive region, and cells are preferably adherently cultured in the cell-adhesive region.
- the shapes of the cell adhesive region and the cell non-adhesive region are not limited as long as they can be developed on the cultureware.
- a single cell-adhesive region and a cell-non-adhesive region may be formed on one culture device, or a plurality of regions may be formed.
- the cell adhesive region is preferably artificially treated for the purpose of improving adhesiveness.
- micropatterned cultureware examples include CYTOOchip (manufactured by CYTOO) and ibidi Micropatterning (manufactured by ibidi).
- a culture device can also be prepared using a PDMS mold and matrix.
- a cultureware coated with an extracellular matrix, a substrate that promotes cell adhesion, or the like is processed with a laser or the like using, for example, a cell processing device (Model: CPD-017, manufactured by Kataoka Seisakusho) to obtain a cell adhesive region. and the cell non-adhesive region may be formed in any shape.
- a cell processing device Model: CPD-017, manufactured by Kataoka Seisakusho
- the cell non-adhesive region may be formed in any shape.
- the cultureware preferably has a channel (microchannel) for perfusion of the medium, and cells may be cultured under a perfusion environment in the first step and subsequent steps.
- a culture device is also called a microfluidic chip.
- the culture device e.g., microfluidic chip
- may be connected to another culture device e.g., microfluidic chip for culturing cells or tissues other than the cells cultured in the production method of the present invention via channels. This makes it possible to reproduce the interaction of the pituitary gland with other cells or tissues.
- Other cells or tissues to be co-cultured with the pituitary gland include tissues regulated by hormones secreted from the pituitary gland, tissues promoting the growth, differentiation, maturation, and survival of the pituitary gland, such as brain, blood vessels, bones, and muscles. , fat, thyroid, liver, adrenal gland, testis, ovary, breast cells or tissue, and the like.
- Methods for medium perfusion include, but are not limited to, the use of magnetic stirrers, peristaltic pumps, and the like.
- the cultureware may have a membrane permeable to oxygen or medium.
- the cultureware may be capable of forming concentration gradients of compounds, growth factors, and the like.
- the membrane is for example a porous membrane.
- cells can be cultured by the production method of the present invention on one side separated by the membrane, and other cells or tissues, feeder cells, etc. can be cultured on the other side.
- the cells constituting the pituitary gland, their progenitor cells, and the cell population containing these cells can be cultured without contamination with other cells or tissues.
- a medium replacement operation for example, an operation to add a new medium without discarding the original medium (medium addition operation)
- about half the original medium (30% of the volume of the original medium
- about 90%, for example, about 40-60%) is discarded and about half of the new medium is added (30-90% of the volume of the original medium, for example, about 40-60%) (half medium replacement operation).
- An operation of discarding about the entire amount (90% or more of the volume of the original medium) and adding about the entire amount (90% or more of the volume of the original medium) of new medium can be mentioned.
- Half volume medium exchange operation When adding a specific component at a certain point, for example, after calculating the final concentration, about half of the original medium is discarded, and about half of the new medium containing the specific component at a higher concentration than the final concentration is added ( Half volume medium exchange operation) may be performed.
- the concentration of the components contained in the original medium is diluted at a certain point to lower the concentration, for example, the medium exchange operation is performed multiple times a day, preferably multiple times (for example, 2 to 3 times) within an hour. good.
- the cells or cell aggregates may be transferred to another culture vessel if the components contained in the original medium are diluted to a lower concentration.
- Tools used for the medium exchange operation are not particularly limited, and examples thereof include pipettors, Pipetman (registered trademark), multichannel pipettes, continuous pipettors, and the like.
- pipettors When using a 96-well plate as culture equipment, a multichannel pipette may be used.
- the culture time in the first step is usually about 8 hours to 6 days, preferably about 12 hours to 60 hours.
- a compound that promotes differentiation into placode regions in the first step and subsequent steps.
- examples of compounds having the above effects include BRL-54443, phenanthroline, and parthenolide described in US Pat. No. 20160326491A1.
- BRL-54443 as a compound that promotes differentiation into placode regions, the concentration is usually about 10 nM to about 100 ⁇ M, when using phenanthroline, usually about 10 nM to about 100 ⁇ M, and when using Parthenolide, the concentration is usually about 10 nM to about 100 ⁇ M. used in
- culturing may be performed in the presence of an agent acting on the Sonic hedgehog signaling pathway.
- an agent acting on the Sonic hedgehog signaling pathway As the Shh signal transduction pathway active substance used in the first step, those exemplified in step (a) can be used.
- the Shh signaling pathway agonists in step (a) and the first step may be the same or different, but are preferably the same and are preferably SAG.
- the concentration of the substance acting on the Shh signaling pathway in the medium can be appropriately set according to the substance to be used within a range in which the above effects can be achieved.
- SAG When SAG is used as the Shh signaling pathway agonist in the first step, it is generally about 1 nM to about 3 ⁇ M, preferably about 10 nM to about 2 ⁇ M, more preferably about 30 nM to about 1 ⁇ M, still more preferably about 50 nM to about 500 nM. used at a concentration of
- Step (2) the cell population obtained in the first step is cultured in the presence of the BMP signaling pathway agonist and the Sonic hedgehog signaling pathway agonist.
- the formed cell aggregates may be continuously cultured in suspension in step (2).
- the cells may be adherently cultured in the step (2).
- adhesion culture may be performed in step (2).
- a BMP signaling pathway agonist is a substance that can enhance the signaling pathway mediated by BMP.
- Substances that can enhance signaling pathways mediated by BMPs include, for example, substances that stabilize and enhance the potency of BMP ligands in the culture environment, the type I BMP receptors ALK-1, ALK-2, ALK- 3, a substance that binds to ALK-6 and activates and triggers intracellular signal transduction downstream of the receptor, Smad-1, Smad-5, Smad-8, Smad-9 involved in intracellular BMP signal transduction substances that induce phosphorylation of Smad-1/5/8/9, and substances that induce/enhance functions such as activation and suppression of gene transcription by Smad-1/5/8/9.
- BMP signaling pathway agents examples include BMP proteins such as BMP2, BMP4 or BMP7, GDF proteins such as GDF5, 6 and 7, anti-BMP receptor antibodies and BMP partial peptides. These substances may be used alone or in combination.
- BMP signaling pathway agonist from the viewpoint of biological activity, osteoblasts against cells such as mouse progenitor chondrocyte cell line ATDC5, mouse calvaria-derived cell line MC3T3-E1, mouse striated muscle-derived cell line C2C12, etc.
- examples thereof include substances capable of inducing differentiation into cell-like cells and alkaline phosphatase production.
- substances having the above activity include BMP2, BMP4, BMP5, BMP6, BMP7, BMP9, BMP10, BMP13/GDF6, BMP14/GDF5, GDF7 and the like.
- BMP2 protein and BMP4 protein are available, for example, from R&D Systems, BMP7 protein, for example, from Biolegend, GDF5 protein, for example, from Peprotech, GDF6 protein, for example, from Prime Gene, and GDF7 protein, for example, from FUJIFILM Wako Pure Chemical Industries, Ltd. is.
- the BMP signaling pathway agonist preferably comprises at least one protein selected from the group consisting of BMP2, BMP4, BMP7, BMP13 and GDF7, more preferably BMP4.
- the concentration of the BMP signaling pathway active substance in the medium can be appropriately set according to the substance used within the range where the above effects can be achieved. From the viewpoint of improving the production efficiency of cells that constitute the pituitary gland, when BMP4 is used as a BMP signaling pathway agonist, it is usually about 1 pM to about 100 nM, preferably about 10 pM to about 50 nM, more preferably about 25 pM to about 25 nM. , more preferably from about 25 pM to about 5 nM, particularly preferably from about 100 pM to about 5 nM, most preferably from about 500 pM to about 2 nM.
- BMP signaling pathway active substance other than BMP4 when using a BMP signaling pathway active substance other than BMP4, it is preferably used at a concentration that exhibits the same BMP signaling pathway promoting activity as BMP4 at the concentration described above.
- a person skilled in the art uses, for example, a commercially available recombinant BMP protein as an active substance of the BMP signaling pathway, the activity described in the product package insert, for example, the ED50 value of the ability to induce alkaline phosphatase production in mouse progenitor chondrocyte cell line ATDC5
- the concentration of the BMP signaling pathway agonist to be added can be easily determined.
- BMP signaling pathway agonists include, for example, Smurf1 inhibitors, Chk1 inhibitors, phosphorylated Smad stabilizers, and the like.
- Examples of compounds having the above activity include A-01 ([4-[[4-Chloro-3-(trifluoromethyl)phenyl]sulfonyl]-1-piperazinyl][4-(5-methyl-1H-pyrazol -1-yl)phenyl]methanone), PD 407824 (9-Hydroxy-4-phenyl-pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione), SB4 (2-[[( 4-bromophenyl)methyl]thio]benzoxazole), SJ000291942 (2-(4-Ethylphenoxy)-N-(4-fluoro-3-nitrophenyl)-acetamide) and derivatives thereof.
- the Shh signaling pathway agent used in step (2) the same substances as exemplified in step (a) can be used.
- the Shh signaling pathway agents in steps (a) and (2), optionally the Shh signaling pathway agents in step (1), may be the same or different, but are preferably the same; SAG is also preferred.
- the concentration of the substance acting on the Shh signaling pathway in the medium can be appropriately set according to the substance to be used within a range in which the above effects can be achieved.
- SAG is used as the Shh signaling pathway agonist in step (2), it is generally about 1 nM to about 5 ⁇ M, preferably about 10 nM to about 4.5 ⁇ M, more preferably about 50 nM to about 4 ⁇ M, still more preferably about 100 nM. Concentrations of ⁇ 3 ⁇ M are used.
- the medium used in step (2) is not particularly limited as long as it contains the Shh signaling pathway active substance and the BMP signaling pathway active substance.
- Examples of the medium used in step (2) include the medium mentioned in the first step.
- the start time of step (2) is preferably 0.5 hours to 6 days from the start of culture in the first step, more preferably 0.5 hours to 72 hours. and more preferably within 24 hours to 60 hours.
- step (2) is started during the above period in the presence of a Wnt signaling pathway inhibitor, a non-neuroepithelium-like tissue is formed on the surface of the cell aggregates, and the pituitary gland is formed very efficiently. be.
- the start time of step (2) is preferably the surface layer of the cell aggregates formed in the first step. It is the stage when 10% or more, more preferably 30% or more, and still more preferably 50% or more of the cells form tight junctions with each other.
- a person skilled in the art can easily determine whether or not tight junctions are formed in cell aggregates by techniques such as microscopic observation and immunostaining using an anti-ZO-1 antibody.
- Initiation of culture in the presence of the BMP signaling pathway agent in step (2) is carried out by performing the above-described medium replacement operation (e.g., medium addition operation, half volume medium replacement operation, full volume medium replacement operation, etc.) may be performed, or the cells may be transferred to another culture vessel.
- medium replacement operation e.g., medium addition operation, half volume medium replacement operation, full volume medium replacement operation, etc.
- the period of culture in the medium containing the BMP signaling pathway active substance in step (2) can be set as appropriate.
- the culture time in step (2) is usually 8 hours or longer, preferably 10 hours or longer, more preferably 12 hours or longer, still more preferably 14 hours or longer, and most preferably 16 hours or longer.
- the period of culture in the medium containing the Shh signaling pathway active substance in step (2) can be set as appropriate.
- the suspension culture in step (1) is further performed in the presence of an active substance of Shh signaling pathway, from the viewpoint of improving pituitary hormone (especially ACTH) secretion ability, in step (1) and step (2)
- the culture period in the presence of the Shh signaling pathway agonist is preferably 30 days.
- an FGF signaling pathway agent to the culture environment from the viewpoint of promoting differentiation into pituitary placodes.
- the FGF signal transduction pathway agent is not particularly limited as long as it is a substance capable of enhancing the signal transduction pathway mediated by FGF (fibroblast growth factor).
- FGF signaling pathway agents include FGF proteins such as FGF1, FGF2 (sometimes referred to as bFGF), FGF3, FGF8 and FGF10, anti-FGF receptor antibodies, FGF partial peptides and the like. These substances may be used alone or in combination.
- FGF2 protein and FGF8 protein are available, for example, from FUJIFILM Wako Pure Chemical Industries, Ltd.
- FGF signaling pathway agent preferably contains at least one selected from the group consisting of FGF2, FGF3, FGF8 and FGF10, and variants thereof, more preferably FGF2, more preferably recombinant human FGF2 include.
- the concentration of the FGF signaling pathway active substance in the medium can be appropriately set according to the substance used within the range where the above-mentioned effects can be achieved. From the viewpoint of differentiation into cells constituting the pituitary gland and promotion of cell survival and proliferation, when FGF2 is used as the FGF signaling pathway agonist, it is usually about 1 pg/ml to about 100 ⁇ g/ml, preferably about 10 pg/ml. /ml to about 50 ⁇ g/ml, more preferably about 100 pg/ml to about 10 ⁇ g/ml, more preferably about 500 pg/ml to about 1 ⁇ g/ml, most preferably about 1 ng/ml to about 200 ng/ml. be done.
- an FGF signaling pathway active substance other than FGF2 when using an FGF signaling pathway active substance other than FGF2, it is preferably used at a concentration that exhibits the same FGF signaling pathway promoting activity as FGF2 at the above concentration.
- the FGF signaling pathway promoting activity of the substance to be added can be measured, for example, by a method such as a cell proliferation test using 3T3 cells.
- Heparin is available as the sodium salt from, for example, Fujifilm Wako Pure Chemical Industries.
- the concentration of heparin or heparan sulfate in the medium can be appropriately set within a range in which the above effects can be achieved.
- the concentration of sodium heparin in the medium is usually about 1 ng/ml to about 100 mg/ml, preferably about 10 ng/ml to about 50 mg/ml, more preferably about 100 ng/ml to about 10 mg/ml, still more preferably about 500 ng.
- heparan sulfate When heparan sulfate is used, it is preferably at a concentration that has the same FGF protein-protecting activity as heparin at the concentration described above.
- modified FGF such as Thermostable FGF2 described in US Pat.
- FGF2 sustained-release beads of Thermostable FGF2 is available, for example, from HumanZyme.
- StemBeads FGF2 are available, for example, from StemCulture.
- the timing of addition of the FGF signaling pathway active substance in step (2) and subsequent steps can be set as appropriate.
- the FGF signaling pathway agonist is added 6 hours later, more preferably 12 hours later, more preferably 18 hours later than the addition of the BMP signaling pathway agonist in step (2).
- step (2) additives used in step (a) or the first step, such as JNK signaling pathway inhibitors, Wnt signaling pathway inhibitors, TGF ⁇ signaling pathway inhibitors, TAK1 inhibitors, etc., are continuously added. is also preferred.
- the JNK signaling pathway inhibitor, Wnt signaling pathway inhibitor, or TGF ⁇ signaling pathway inhibitor added in step (2) may be different from the substance used in the previous steps, but is preferably the same. be.
- the concentration and type of additive can be adjusted as appropriate.
- the timing of addition of these substances may be simultaneous with the start of step (2), or may be different.
- Step (b) the cell population obtained in step (2) is cultured under conditions in which a BMP signaling pathway inhibitor is added.
- the formed cell aggregates may be continuously cultured in suspension in step (b).
- the cells may be adherently cultured in step (b).
- BMP signaling pathway inhibitors are not limited as long as they can suppress signal transduction triggered by BMP family proteins. Any of nucleic acids, proteins, and low-molecular-weight organic compounds may be used. Such substances include, for example, substances that inhibit BMP processing and extracellular secretion, substances that directly act on BMPs (e.g., proteins, antibodies, aptamers, etc.), and substances that suppress the expression of genes encoding BMPs (e.g., antisense oligos). nucleotides, siRNA, etc.), substances that inhibit binding between BMP receptors and BMPs, and substances that inhibit physiological activities caused by signal transduction by BMP receptors.
- BMP receptors include type I BMP receptors and type II BMP receptors.
- Type I BMP receptors are BMPR1A, BMPR1B, and ACVR
- type II BMP receptors are TGF-betaR-II and ActR-II. , ActR-IIB, BMPR2, MISR-II.
- BMP signaling pathway inhibitors include, for example, Noggin, Chordin, Follistatin, Gremlin, Inhibin, Twisted Gastrulation, Coco, and secretory proteins belonging to the DAN family. Since the BMP signaling pathway agent is added to the culture medium in the step (2), the BMP signaling pathway in the step (b) from the viewpoint of more effectively inhibiting the subsequent BMP signaling pathway.
- the inhibitory substance is a substance that inhibits the signal transduction pathway after BMP secretion to the outside of the cell, such as a substance that inhibits the binding of BMP receptor and BMP, and inhibits physiological activity caused by signal transduction by BMP receptor. It preferably contains a substance or the like, more preferably an inhibitor of the type I BMP receptor.
- BMP signaling pathway inhibitors include, for example, inhibitors of type I BMP receptors.
- Examples of compounds having the above activity include K02288 (3-[(6-Amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenol), Dorsomorphin (6-[4-[2 -(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidine), LDN-193189 (4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[ 1,5-a]pyrimidin-3-yl]quinoline dihydrochloride), LDN-212854 (5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline ), LDN-214
- the BMP signaling pathway inhibitor is preferably a type I BMP receptor inhibitor, more preferably selected from the group consisting of K02288, Dorsomorphin, LDN-193189, LDN-212854, LDN-214117, ML347, DMH1 and DMH2. At least one, more preferably K02288 to LDN-193189.
- the concentration of the BMP signaling pathway inhibitor in the medium can be appropriately set according to the substance used within the range where the above effects can be achieved. From the viewpoint of pituitary tissue formation efficiency, when K02288 is used as the BMP signaling pathway inhibitor in step (b), the It is used at a concentration of 50 ⁇ M, more preferably from about 500 nM to about 25 ⁇ M. When LDN-193189 is used as a BMP signaling pathway inhibitor, it is usually used at a concentration of about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 10 ⁇ M, more preferably about 25 nM to about 1 ⁇ M, still more preferably about 100 nM to about 500 nM. used.
- LDN-212854 When LDN-212854 is used as a BMP signaling pathway inhibitor, it is usually used at a concentration of about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 10 ⁇ M, more preferably about 25 nM to about 5 ⁇ M, still more preferably about 250 nM to about 3 ⁇ M. used.
- ML347 When ML347 is used as a BMP signaling pathway inhibitor, it is usually used at a concentration of about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 50 ⁇ M, more preferably about 100 nM to about 50 ⁇ M, still more preferably about 1 ⁇ M to about 25 ⁇ M. be.
- DMH2 When used as a BMP signaling pathway inhibitor, it is usually used at a concentration of about 1 nM to about 100 ⁇ M, preferably about 10 nM to about 10 ⁇ M, more preferably about 25 nM to about 5 ⁇ M, still more preferably about 250 nM to about 3 ⁇ M. be.
- a BMP signaling pathway inhibitor other than K02288 it is desirable to use it at a concentration that exhibits the same BMP signaling pathway inhibitory activity as K02288 at the above concentrations.
- the timing of starting step (b) after step (2) is implemented can be set as appropriate.
- the timing of starting step (b) is usually 8 hours or more and 15 days or less, preferably 10 hours or more and 12 days or less, more preferably 12 hours or more and 9 days or less, and furthermore It is preferably 14 hours or more and 8 days or less, most preferably 16 hours or more and 7 days or less.
- the cell population may be treated with adrenocortical hormones by adding the adrenocortical hormones to the medium.
- adrenocortical hormone treatment pituitary hormone-producing cells other than ACTH-producing cells (i.e., GH-producing cells, PRL-producing cells, TSH-producing cells, LH-producing cells, FSH-producing cells, etc.) from the pituitary placode and/or Rathke's pouch ) differentiation is promoted.
- adrenocortical hormones include natural glucocorticoids such as hydrocortisone, cortisone acetate and fludrocortisone acetate; artificially synthesized glucocorticoids such as dexamethasone, betamethasone, prednisolone, methylprednisolone and triamcinolone. It can be, but is not limited to.
- the concentration of adrenocortical hormones in the medium is not particularly limited as long as it can promote differentiation from the pituitary placode and/or Rathke's pouch into pituitary hormone-producing cells (excluding ACTH-producing cells).
- hydrocortisone for example, it is usually 100 ng/ml or more, preferably 1 ⁇ g/ml or more, which can be appropriately set depending on the type of adrenocortical hormones.
- concentration of hydrocortisone is usually 1000 ⁇ g/ml or less, preferably 100 ⁇ g/ml.
- the concentration of hydrocortisone in the medium is usually about 100 ng/ml to about 1000 ⁇ g/ml, preferably about 1 to about 100 ⁇ g/ml.
- concentration in the medium can be about 1/25 that of hydrocortisone.
- the pituitary placode and/or Rathke's pouch differentiate into pituitary hormone-producing cells (excluding ACTH-producing cells).
- ACTH-producing cells excluding ACTH-producing cells.
- adrenocortical hormones are added to the medium. That is, until the appearance of ACTH-producing cells is confirmed in the cell aggregates, the cell aggregates are cultured in a medium to which no adrenocortical hormones are added, and after the appearance of ACTH-producing cells is confirmed, the adrenal cortex is The second step and subsequent steps are continued in a medium containing hormones.
- the appearance of ACTH-producing cells can be confirmed by immunohistological staining using an antibody against ACTH. When human pluripotent stem cells are used, the appearance of ACTH-producing cells can generally be expected after 30 days from the start of the first step. add adrenocortical hormones to
- the period of treatment of cell aggregates with adrenocortical hormones is not particularly limited as long as differentiation from the pituitary placode and/or Rathke's pouch into pituitary hormone-producing cells (excluding ACTH-producing cells) can be promoted.
- the cells are treated until promotion of differentiation into pituitary hormone-producing cells (excluding ACTH-producing cells) is confirmed in the adrenocortical hormone-treated group.
- the clumps are treated with corticosteroids.
- the treatment period is usually 7 days or more, preferably 12 days or more.
- the upper limit of the treatment period is not particularly limited. Once the promotion is confirmed, corticosteroids may be removed from the culture medium.
- Retinoic acid transduction pathway agents include, for example, substances that bind to retinoic acid receptor (RAR) or retinoid X receptor (RXR) and activate downstream transcription.
- Examples of compounds having the above effects include all-trans retinoic acid, isotretinoin, 9-cis retinoic acid, TTNPB (4-[(E)-2-[(5,5,8,8-Tetramethyl-5 ,6,7,8-tetrahydronaphthalene)-2-yl]-1-propenyl]benzoic acid), Ch55 (4-[(E)-3-(3,5-di-tert-butylphenyl)-3-oxo- 1-propenyl]benzoic acid), EC19 (3-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl]benzoic acid), EC23 (4- [2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl]-benzoicacid), Fenretinide (4-hydroxyphenylretinamide), Acitretin ((all
- the retinoic acid transduction pathway active substance in step (2) and subsequent steps preferably includes all-trans retinoic acid to EC23.
- the concentration of the retinoic acid transduction pathway active substance in the medium is not particularly limited as long as it is within a range capable of achieving the above effects. It is about 30 ⁇ M, preferably about 100 pM to about 20 ⁇ M, more preferably about 10 nM to about 10 ⁇ M, even more preferably about 100 nM to about 5 ⁇ M.
- a retinoic acid transduction pathway active substance other than EC23 it is preferably used at a concentration that exhibits retinoic acid transduction pathway activity equivalent to that of EC23 at the concentration described above.
- the Notch signaling pathway is a signal activated by direct interaction between Notch proteins, which are receptors expressed on the cell membrane, and Notch ligands (Delta, Jagged, etc.) expressed on the membranes of adjacent cells. Represents the transfer pathway.
- Notch proteins In cells to which Notch signals have been transduced, Notch proteins undergo stepwise processing, and intracellular domains excised on the membrane are transported into the nucleus to control the expression of downstream genes.
- the Notch signaling pathway inhibitor is not particularly limited as long as it can suppress signal transduction mediated by Notch. Any of nucleic acids, proteins, and low-molecular-weight organic compounds may be used. Such substances include, for example, functionally deficient Notch receptors and ligands, substances that inhibit Notch processing (S1 cleavage), substances that inhibit glycosylation of Notch and Notch ligands, substances that inhibit cell membrane translocation, Notch Substances that inhibit intracellular domain (NICD) processing (S2 cleavage, S3 cleavage) ( ⁇ -secretase inhibitors), substances that degrade NICD, substances that inhibit NICD-dependent transcription, and the like can be mentioned.
- Notch processing S1 cleavage
- substances that inhibit glycosylation of Notch and Notch ligands substances that inhibit cell membrane translocation
- Notch Substances that inhibit intracellular domain (NICD) processing S2 cleavage, S3 cleavage) ( ⁇ -secretase inhibitors)
- Notch signaling pathway inhibitors Compounds well known to those skilled in the art can also be used as Notch signaling pathway inhibitors.
- Examples of compounds having activity as Notch signaling pathway inhibitors include DAPT (N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester), DBZ ((2S)- 2-[[2-(3,5-difluorophenyl)acetyl]amino]-N-[(7S)-5-methyl-6-oxo-7H-benzo[d][1]benzazepin-7-yl]propanamide) , MDL28170 (benzyl N-[(2S)-3-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]butan-2-yl]carbamate), FLI-06 (cyclohexyl 2,7,7-tri
- the concentration of the Notch signaling pathway inhibitor in the medium is not particularly limited as long as the above effects can be achieved. to about 50 ⁇ M, preferably about 1 nM to about 30 ⁇ M, more preferably about 100 nM to about 20 ⁇ M, even more preferably about 1 ⁇ M to about 10 ⁇ M.
- a Notch signaling pathway inhibitor other than DAPT it is preferably used at a concentration that exhibits Notch signaling pathway inhibitory activity equivalent to that of DAPT at the above concentration.
- the cell population obtained in step b is cultured in the absence of the Shh signaling pathway agonist to obtain a cell population containing pituitary tissue, which is referred to as step (3′).
- the formed cell aggregates may be cultured in suspension in the third step.
- the cells may be adherently cultured in the third step. After suspension culture of the cells in step (2) or step (b), adhesion culture may be performed in the third step.
- the medium used in the third step is not particularly limited as long as it does not contain Shh signaling pathway agents.
- the conditions under which the Shh signaling pathway active substance is not added in this step refer to conditions under which the Shh signaling pathway active substance is not intentionally added to the culture environment of the cell population, and the Shh signal is unintentionally caused by autocrine or the like by the cell population.
- the case where the signaling pathway active substance is contained in the culture environment is also included in the non-addition condition of the Shh signaling pathway active substance.
- Examples of the medium used in the third step include the medium mentioned in the first step, gfCDM medium containing 10% to 20% KSR, and the like.
- the third step and subsequent steps may include a step of embedding the cell aggregates in a gel and culturing them.
- gels include gels using agarose, methylcellulose, collagen, Matrigel, etc. Matrigel is preferably used.
- the cell aggregates may be embedded as they are, or the cells after dispersion and isolation may be seeded in the gel. good too.
- a specific cell type such as basal cells may be sorted using a cell sorter or the like and then seeded.
- co-culturing with cells other than the pituitary gland such as fibroblasts, mesenchymal cells, and vascular cells, can also be performed.
- Gel-embedded culture as described above is, for example, Nature 501, 373-379 (2013), Nature, 499, 481-484 (2013), Nat Protoc 14, 518-540 (2019), Genes 2020, 11, 603, etc. can be implemented by referring to
- a culture method in which cells are physically shaken for the purpose of improving nutrition and oxygen supply to cells and improving substance exchange.
- Examples of such culture methods include methods other than stationary culture such as shaking culture, rotary culture, and agitation culture.
- the means for performing shaking culture, rotary culture, stirring culture, etc. is not particularly limited. This can be done by putting down A person skilled in the art can appropriately set parameters such as the speed of shaking culture, rotation culture, and agitation culture within a range that does not cause damage to cells.
- the speed is, for example, 5 to 60 rpm, preferably 5 to 40 rpm, more preferably 5 to 20 rpm.
- Shaking speed range can be set.
- the shaking speed range is set in the range of, for example, 15 to 60 rpm, preferably 15 to 50 rpm, more preferably 15 to 45 rpm. It is possible.
- the shaking speed range is set in the range of, for example, 5 to 50 rpm, preferably 5 to 40 rpm, more preferably 5 to 30 rpm. It is possible.
- a spinner flask e.g., 3152, manufactured by Corning
- the culture is carried out at a rotational speed that does not allow the cell aggregates to visually settle.
- Cultivation can also be carried out using a three-dimensional rotary floating culture apparatus (for example, CellPet CUBE, manufactured by J-Tech; Clinostar, manufactured by Celvivo). From the viewpoint of suppressing physical injury to cells such as friction, it is also preferable to culture the cell aggregates embedded in the gel with shaking, rotation, or agitation.
- a three-dimensional rotary floating culture apparatus for example, CellPet CUBE, manufactured by J-Tech; Clinostar, manufactured by Celvivo.
- the third step and subsequent steps it is also preferable to culture in a high-oxygen atmosphere from the viewpoint of suppressing cell death and promoting cell growth.
- High-oxygen conditions in the culture process can be realized, for example, by connecting an oxygen bomb to an incubator for culturing cells and artificially supplying oxygen.
- the oxygen concentration for such purposes is usually 25% to 80%, more preferably 30% to 60%.
- culture equipment with high gas exchange efficiency can be used from the viewpoint of increasing the amount of oxygen supplied to the medium in which the cell aggregates are cultured.
- examples of such cultureware include a cell culture dish, a Lumox dish with a gas-permeable film on the bottom of the plate (manufactured by Sarstedt Co., Ltd.), and a VECELL 96-well plate (manufactured by Bethel Co., Ltd.). It is also preferable to use in combination with the above-described culture under high oxygen concentration conditions.
- a cell protective agent can be added to the medium from the viewpoint of maintaining the structure of the non-neural epithelial tissue in the cell aggregate.
- Cell protective agents used in the third step and subsequent steps include the FGF signaling pathway agonists, heparin, ROCK inhibitors, basement membrane preparations, myosin inhibitors, polyamines, ISR inhibitors, and caspase inhibitors. , serum, or serum substitutes.
- myosin inhibitors include blebbistatin, which is an inhibitor of non-muscle myosin II ATPase, ML-7, ML-9, W-7, which are inhibitors of myosin light chain kinase (MLCK), MLCK inhibitor peptide 18, and these and derivatives thereof.
- the added cytoprotective agent may be different from that added in the first step, but is preferably the same.
- Preferred cytoprotective agents include ROCK inhibitors.
- a ROCK inhibitor When Y-27632, a ROCK inhibitor, is added as a cytoprotective agent in the third step and subsequent steps, it is usually about 10 nM to about 10 mM, preferably about 100 nM to about 1 mM, more preferably about 1 ⁇ M to about 100 ⁇ M. Add to the culture environment so that the concentration is When the ROCK inhibitor Chroman 1 is added, it is usually added to the culture environment at a concentration of about 10 pM to about 1 mM, preferably about 100 pM to about 100 ⁇ M, more preferably about 1 nM to about 10 ⁇ M.
- the concentration is usually about 10 nM to about 10 mM, preferably about 100 nM to about 1 mM, more preferably about 1 ⁇ M to about 100 ⁇ M. Add to the culture environment as follows.
- substances other than cell protective agents that have the effect of maintaining the structure of non-neural epithelial tissues.
- substances that promote cell adhesion include substances that promote cell adhesion, substances that promote synthesis of basement membrane components, substances that inhibit decomposition of basement membrane components, and the like.
- Substances that promote cell adhesion may be those that promote cell-to-cell adhesion, cell-to-basement membrane adhesion, cell-to-cultureware adhesion, or the like, and production of factors involved in cell adhesion.
- Substances that promote cell adhesion include, for example, adhesamine, adhesamine-RGDS derivatives, pyrintegrin, biotin tripeptide-1, acetyltetrapeptide-3, RGDS peptide and derivatives thereof.
- Substances that promote the synthesis of basement membrane components include, for example, ascorbic acid derivatives. Examples of ascorbic acid derivatives include sodium ascorbyl phosphate, magnesium ascorbyl phosphate, ascorbyl 2-glucoside, 3-O-ethylascorbic acid, ascorbyl tetrahexyldecanoate, ascorbyl palmitate, ascorbyl stearate, and ascorbyl-2.
- ascorbic acid 2-phosphate which is a type of ascorbic acid derivative that promotes the synthesis of basement membrane components
- it is usually 10 ⁇ g/ml or more and 1000 ⁇ g/ml or less, preferably 30 ⁇ g/ml or more and 500 ⁇ g/ml.
- ascorbic acid 2-phosphate which is a type of ascorbic acid derivative that promotes the synthesis of basement membrane components
- it is added to the culture environment at a concentration of 50 ⁇ g/ml or more and 300 ⁇ g/ml or less, more preferably.
- other ascorbic acid, ascorbic acid derivatives, etc. are added, they may be added so that the above concentration and molar equivalent are approximately the same.
- substances having the above activity include antioxidant substances, substances having free radical scavenger action, NADPH oxidase inhibitors, cyclooxygenase inhibitors, lipoxygenase (LOX) inhibitors, superoxide dismutase (SOD)-like substances, and Nrf2 activators. agents and the like.
- substances having the above activity include ascorbic acid, N-acetyl-L-cysteine, ( ⁇ )- ⁇ -tocopherol acetate, apocynin (4′-Hydroxy-3′-methoxyacetophenone), nicotinamide, taurine (2- aminoethanesulfonic acid), IM-93 (1-Isopropyl-3-(1-methyl-1H-Indole-3-yl)-4-(N,N-dimethyl-1,3-propanediamine)-1H-Pyrrole- 2,5H-dione), Caffeic Acid (3,4-Dihydroxycinnamic Acid), Celastrol (3-Hydroxy-24-nor-2-oxo-1(10), 3,5,7-friedelatetraen-29-oic Acid; Tripterin), Ebselen (2-Phenyl-1,2-benzoisoselenazol-3(2H)-one), (-)-Epigallocatechin
- the substance having the action of reducing oxidative stress used in the present invention preferably contains at least one selected from the group consisting of ascorbic acid, N-acetyl-L-cysteine and derivatives thereof.
- Ascorbic acid for example as its derivative, ascorbic acid diphosphate, at a concentration of about 1 nM to about 1 M, preferably about 10 nM to about 100 mM, more preferably about 100 nM to about 10 mM, even more preferably about 1 ⁇ M to about 3 mM.
- N-acetyl-L-cysteine is added to the medium at a concentration of, for example, about 1 nM to about 1 M, preferably about 10 nM to about 100 mM, more preferably about 100 nM to about 10 mM, even more preferably about 1 ⁇ M to about 5 mM. be able to.
- a substance that inhibits the stress response signaling pathway (a substance that inhibits the intracellular signaling mechanism against stress).
- the stress-activated protein kinase pathway (SAPK) is one of the major intracellular signaling mechanisms for stress.
- Inhibitors of the stress responsive MAP kinase pathway include e.g. MAP3K inhibitors, MAP2K inhibitors, ASK inhibitors, MEK inhibitors, Akt inhibitors, Rho family kinase inhibitors, JNK inhibitors, p38 inhibitors, MSK inhibitors, STAT inhibitors, NF- ⁇ B inhibitors, CAMK inhibitors and the like.
- MEK inhibitors include selumetinib (AZD6244, 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide), mirdametinib (PD0325901, N-[ (2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino) benzamide), Trametinib (GSK1120212, N-[3-[3-cyclopropyl-5-(2- fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide), U0126 (1,4-diamino-2,3- dicyano-1,4-bis(2-aminophenylthio)butadiene), PD18435
- Examples of p38 inhibitors include SB203580 (4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine), Doramapimod (BIRB 796, 1-[5-tert -butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea), SB202190 (FHPI, 4-[4-( 4-fluorophenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]phenol), ralimetinib dimesylate (5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5- yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine; methanesulfonic acid), VX-7
- JNK inhibitors include those mentioned in the first step.
- the substance that inhibits the intracellular signal transduction mechanism against stress used in the present invention is preferably one or more selected from the group consisting of MEK inhibitors, p38 inhibitors and JNK inhibitors.
- SB203580 When SB203580 is used as a p38 inhibitor, it is usually added to the medium at a concentration of about 1 nM to about 1 mM, preferably about 10 nM to about 100 ⁇ M, more preferably about 100 nM to about 10 ⁇ M, still more preferably about 500 nM to about 5 ⁇ M. can do.
- PD0325901 When PD0325901 is used as a MEK inhibitor, it is usually added to the medium at a concentration of about 1 nM to about 1 mM, preferably about 10 nM to about 100 ⁇ M, more preferably about 100 nM to about 10 ⁇ M, still more preferably about 500 nM to about 5 ⁇ M. can do.
- JNK-IN-8 When JNK-IN-8 is used as the JNK inhibitor, it can be added to the medium at the same concentration as described in the first step.
- other MEK inhibitors, p38 inhibitors, and JNK inhibitors When other MEK inhibitors, p38 inhibitors, and JNK inhibitors are used, it is preferable to add them at a concentration having an inhibitory activity equivalent to that of the above inhibitors.
- the present invention provides cell populations comprising pituitary tissue, particularly cell populations comprising 1) nervous system cells or neural tissue, 2) pituitary tissue, and 3) mesenchymal cells. Hereinafter, it is also referred to as the cell population of the present invention.
- the cell population of the present invention can be preferably produced by the production method of the present invention described above.
- Nervous system cells or nervous tissues in the cell population of the present invention are preferably central nervous system cells or tissues, or their progenitor tissues. (e.g., hypothalamus) and cells derived from these tissues, more preferably diencephalon (hypothalamus) or precursor tissues thereof, and still more preferably having a ventricle-like structure in the tissue It is the diencephalon or its precursor tissue.
- Nervous system cells or nerve tissues are, for example, N-Cadherin-positive neuroepithelial tissues.
- pituitary tissue in the cell population of the present invention is preferably formed continuously with non-neural epithelial tissue, and the non-neural epithelial tissue and pituitary tissue are 1) nervous system cells or neural tissue and 3) mesenchyme More preferably, at least one of the lineage cells is coated. It is also preferred that the non-neural epithelial tissue is oral epithelium or its progenitor tissue.
- the pituitary tissue preferably contains pituitary hormone-producing cells and pituitary progenitor cells that are precursor cells thereof, preferably contains pituitary stem cells, preferably contains follicular astrocytes, pituitary hormone-producing cells, More preferably, it includes all pituitary progenitor cells, pituitary stem cells, and follicular astrocytes.
- Pituitary hormone-producing cells include, for example, at least one selected from the group consisting of growth hormone (GH)-producing cells, prolactin (PRL)-producing cells, and adrenocorticotropic hormone (ACTH)-producing cells.
- a pituitary niche is formed in the pituitary tissue, and it is also preferred that the pituitary niche is an MCL niche-like structure around the residual space remaining between the anterior and middle pituitary lobes. It is also preferred that the niche is a stromal niche-like structure, more preferably comprising both a MCL niche-like structure and a stromal niche-like structure.
- the mesenchymal cells in the cell population of the present invention are preferably head mesenchymal cells.
- Mesenchymal cells are preferably present between non-neural epithelial tissue covering the surface of the cell population and 1) nervous system cells or neural tissue present inside the cell population.
- ventricle-like vacuoles are formed inside the neuroepithelial tissue, and 1) the surface of the neuroepithelial tissue is in contact with the vacuole, and the surface of the neuroepithelial tissue is Ezrin, PKC-zeta-positive apical surface is.
- the mesenchymal cells contained in the cell population of the present invention express at least one mesenchymal cell marker selected from the group consisting of, for example, Nestin, Vimentin, Cadherin-11, Laminin, CD44, CD90 and CD105. do.
- Non-neuroepithelial tissue that can be included in the present invention expresses at least one non-neuroepithelial tissue marker selected from the group consisting of, for example, cytokeratin, E-Cadherin and EpCAM.
- Pituitary stem cells that can be included in the cell population of the present invention include, for example, Sox2, Sox9, E-Cadherin, Nestin, S100 ⁇ , GFR ⁇ 2, Prop1, CD133, ⁇ -Catenin, Klf4, Oct4, Pax6, Coxsackievirus-Adenovirus Common Receptor (CXADR), PRRX1/2, Ephrin-B2 and at least one pituitary stem cell marker selected from the group consisting of ACE.
- a preferred embodiment of the cell population of the present invention contains pituitary stem cell markers (eg, CXADR)-positive pituitary stem cells.
- the ratio of the number of pituitary stem cells in the cell population may be 1% or more, preferably 3% or more, or 5% or more.
- the present invention provides a method for producing pituitary tissue, wherein the method comprises cells containing pituitary tissue obtained by the above "2.
- Method for producing cell population containing pituitary tissue It is characterized by collecting pituitary tissue from a population.
- One embodiment includes steps (1), (2) and (4) below. (1) a first step of culturing pluripotent stem cells in the presence of a JNK signaling pathway inhibitor and a Wnt signaling pathway inhibitor to obtain a cell population; (2) The cell population obtained in the first step is cultured (preferably suspension culture) in the presence of a BMP signaling pathway agonist and a Sonic hedgehog signaling pathway agonist, resulting in a cell population containing pituitary tissue.
- a second step of obtaining (4) A fourth step of recovering pituitary tissue from the cell population obtained in the second step.
- the first step and the second step can be performed in the same manner as the first step and the second step of "2.
- Method for producing a cell population containing pituitary tissue Moreover, you may implement a process before a 1st process if desired. Moreover, you may implement a 3rd process between a 2nd process and a 4th process if desired.
- the fourth step of recovering the pituitary tissue from the cell population containing the pituitary tissue is, if the formed cell population is a planar tissue obtained by adhesion culture or the like, for example, using a needle or the like under microscopic observation.
- the pituitary tissue can be recovered by a technique such as physical exfoliation. If the formed cell cluster is a three-dimensional tissue such as a cell cluster, use tweezers or the like under microscope observation to peel and collect the pituitary tissue formed outside the cell cluster (Rathke's pouch). performed by Pituitary tissue is described, for example, in Nature communications, 2016, 7. It can be identified as a translucent thin epithelium on the surface of the obtained cell mass, as described in .
- freezing and thawing preferably slow freezing, can also be used as a method for collecting pituitary tissue from the cell population (cell mass) in the fourth step. In this method, the outer pituitary tissue is detached from the cell mass without physical treatment by freezing and thawing a cell mass having pituitary tissue on the outside and mesenchymal nerve or neuroepithelial tissue on the inside. It is.
- the cell population of the present invention, the cell population produced by the production method of the present invention, or the tissue recovered from the cell population may be pituitary tissue. Therefore, it is possible to provide a reagent for evaluating the toxicity and efficacy of a test substance, which comprises the cell population of the present invention, the cell population produced by the production method of the present invention, or the pituitary tissue collected from the cell population. .
- the present invention can provide a toxicity/drug efficacy evaluation method using the above-described cell population or pituitary tissue collected from the cell population.
- a test substance comprising a step of contacting a cell population or pituitary tissue collected from the cell population with a test substance, and assaying the effect of the test substance on the cell population or pituitary tissue toxicity and efficacy evaluation methods.
- a step of contacting a cell population or a pituitary tissue collected from the cell population with a vector used for transducing a nucleic acid or gene of a specific sequence into a cell Toxicity and efficacy evaluation when the vector is used for gene therapy and other uses, including the step of assaying the effect on the pituitary tissue, such as the effect of the transgene, the delivery of the transgene, the degree of cytotoxicity, etc. method.
- the cell population of the present invention, the cell population produced by the production method of the present invention, or the pituitary tissue recovered from the cell population and used as a reagent for evaluating the toxicity and efficacy of a test substance is genetically engineered by genome editing. It is also preferable that the cells are produced using the pluripotent stem cells as raw materials.
- the gene edited in the source pluripotent stem cell is preferably a disease-associated gene, more preferably a disease-associated gene for pituitary disease.
- pituitary disease examples include acromegaly, Cushing's disease, prolactin-producing pituitary adenoma, TSH (thyroid stimulating hormone)-producing pituitary adenoma, craniopharyngioma, Rathke's cyst, hypophysitis, hypopituitarism, pediatric Growth hormone deficiency, male low gonadotropin (LH, FSH) hypogonadism, hypothalamic/pituitary amenorrhea, multiple endocrine neoplasia, etc., and their causative genes and disease-related genes are multipotent. Although it is preferable as a target for genome editing in sex stem cells, it is not limited to this.
- Another aspect of the disease-associated gene is a gene involved in pituitary to hypothalamic cancer and tumorigenesis.
- diseases-related genes include AIP, GPR101, MEN1, MEN4, CDKN1B, PRKAR1A, PRKACB 2q16, SDHA/B/C/D, SDHAF2, NF1, DICER1, GNAS, USP8, PIK3CA, MTND1, 2, 4 , 5, MTTL2, MTTM, MTCYB, MTRNR2, and the like.
- the pituitary tissue described in the present application can also be prepared by collecting cells from normal and diseased areas of the pituitary gland and other tissues of healthy subjects or patients to establish iPS cells.
- compositions comprising the cell population of the present invention, the cell population produced by the production method of the present invention, or the pituitary tissue recovered from the cell population. and a pharmaceutical composition (composition for transplantation, tissue for transplantation or Transplant).
- the pharmaceutical composition preferably contains a pharmaceutically acceptable carrier in addition to the cell population of the present invention, the cell population produced by the production method of the present invention, or the pituitary tissue collected from the cell population.
- a physiological aqueous solvent can be used as a pharmaceutically acceptable carrier.
- the pharmaceutical composition may contain preservatives, stabilizers, reducing agents, tonicity agents, etc., which are commonly used in medicines containing tissues or cells to be transplanted in transplantation medicine.
- treatment of diseases caused by disorders of the pituitary gland comprising the cell population of the present invention, the cell population produced by the production method of the present invention, or the pituitary tissue recovered from the cell population.
- Medication can be provided.
- therapeutic agents for diseases based on pituitary disorders include implants containing a suspension containing the cell population of the present invention or a cell population produced by the production method of the present invention.
- Suspensions include, for example, cell populations suspended in media, artificial tears, or saline.
- the suspension may contain non-neural epithelial cells isolated from the cell population, and may contain factors that promote cell adhesion, such as extracellular matrix and hyaluronic acid.
- Pituitary tissue collected from a cell population may be used instead of the cell mass.
- a disease based on pituitary disorders which comprises the step of transplanting an effective amount of pituitary tissue from the cell population of the present invention or the cell population produced by the production method of the present invention to a subject in need of transplantation.
- a therapeutic method can be provided.
- the pituitary disorder-based disease may be a pituitary disorder-based animal disease or a pituitary disorder-based non-human animal disease.
- diseases based on pituitary disorders include panhypopituitarism, pituitary dwarfism, hypoadrenocorticism, partial hypopituitarism, and isolated anterior pituitary hormone deficiency.
- pituitary function/hormone secretion deficiency after surgery such as pituitary adenoma, craniopharyngioma, etc.
- the cell population of the present invention, the cell population produced by the production method of the present invention, or the pituitary tissue recovered from the cell population and used as a therapeutic agent for diseases based on pituitary disorders is genetically engineered by genome editing. It is also preferred that the cells are produced using the pluripotent stem cells as raw materials.
- Genes targeted for genome editing include genes involved in differentiation of pituitary tissue by the production method of the present invention, genes involved in differentiation into unintended cells other than the pituitary gland produced by the production method of the present invention, and pituitary gland These include, but are not limited to, hormone-associated genes secreted from cells, genes involved in disease infection, and the like.
- Example 1 Examination of the effect of a JNK inhibitor on cell differentiation in the production of a cell population containing pituitary tissues (pituitary organoids) from human iPS cells]
- Human iPS cells (HC-6#10 strain, obtained from RIKEN) were cultured under feeder-free conditions according to the method described in Scientific Reports, 4, 3594 (2014).
- StemFit medium manufactured by Ajinomoto Co.
- Laminin 511-E8 manufactured by Nippi
- subconfluent human iPS cells (HC-6 #10 strain) were washed twice with 0.5 mM EDTA/PBS, and then further incubated with 5 mM EDTA/PBS at 37°C. Treated for 10 minutes. Cells were detached from the culture dish surface by pipetting and dispersed into single cells. Thereafter, the human iPS cells dispersed into single cells were seeded on a plastic culture dish coated with Laminin511-E8, and Y-27632 (ROCK inhibitor, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., 10 ⁇ M) in the presence of StemFit. Feeder-free culture was performed in the medium.
- Laminin511-E8 Laminin511-E8
- Y-27632 Y-27632
- the number of seeded human iPS cells dispersed into single cells was 7 ⁇ 10 3 . .
- the medium was entirely replaced with StemFit medium without Y-27632. Thereafter, once every 1 to 2 days, the entire medium was replaced with StemFit medium containing no Y-27632. Seven days after seeding, the cells were cultured until subconfluent (60% of the culture area was covered with cells).
- SB431542 TGF- ⁇ signaling pathway inhibitor, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., final concentration 5 ⁇ M
- SAG Shh signaling pathway active substance, manufactured by Enzo Life Sciences, final concentration 300 nM
- the prepared subconfluent human iPS cells were treated with 0.5 mM EDTA/PBS in the same manner as in the above subculture.
- a serum-free medium for differentiation induction was added, and the cells were peeled from the culture dish surface by pipetting and dispersed into single cells.
- the human ES cells dispersed into single cells were transferred to a non-cell-adhesive 96-well culture plate (PrimeSurface 96V bottom plate, MS-9096V, manufactured by Sumitomo Bakelite Co., Ltd.) at 9 ⁇ 10 3 cells per well.
- the cells were suspended in 100 ⁇ l of serum-free medium at 37° C. and 5% CO 2 for suspension culture.
- the serum-free medium at that time was a mixture of F-12 + Glutamax medium (manufactured by Thermo Fisher Scientific) and IMDM + Glutamax medium (manufactured by Thermo Fisher Scientific) at a volume ratio of 1: 1, and 5% Knockout Serum Replacement (manufactured by Thermo Fisheric Scientific). ), 450 ⁇ M 1-monothioglycerol (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), 1 ⁇ Chemically defined lipid concentrate (manufactured by Thermo Fisher Scientific), 50 units / ml penicillin-50 ⁇ g / ml streptomycin (manufactured by Nacalai Tesque) Serum medium was used.
- this serum-free medium is also referred to as 5% KSR gfCDM.
- Y-27632 final concentration 10 ⁇ M
- IWP-2 Wnt signaling pathway inhibitor, manufactured by Tocris Bioscience
- 0.5 ⁇ M and SB431542 TGF signaling pathway inhibitor, manufactured by Wako Pure Chemical Industries, Ltd., 1 ⁇ M
- JNK c-Jun N-terminal kinase inhibitor JNK-IN-8 (Merck, 1 ⁇ M ) were compared with those without addition.
- JNK c-Jun N-terminal kinase
- BMP4 was added to the medium to be added at 1 nM to a final concentration in the well of 0.5 nM, and SAG was added to the medium to be added at 1.4 ⁇ M to a final concentration in the well of 700 nM. After that, on days 6, 10, 13, 17, 21 and 24 after the start of suspension culture, half the medium was replaced with a serum-free medium containing IWP-2, SB431542 and SAG but not Y-27632 and BMP4. .
- phase-contrast observation was performed using an inverted microscope (manufactured by Keyence Corporation, BIOREVO BZ-9000) (lower diagram in Fig. 1). Spherical cell aggregates with a diameter of about 1000 ⁇ m were formed by the differentiation induction method. A comparison of the conditions with and without the addition of the JNK inhibitor revealed that the size of the cell clusters was about 100 ⁇ m smaller in diameter under the conditions with the addition of the JNK inhibitor than under the conditions without the addition of the JNK inhibitor, and the surface of the cell clusters was similar to that of the pituitary tissue.
- Example 2 Examination of timing of addition of JNK inhibitor in production of cell population containing pituitary tissue (pituitary organoid) from human iPS cells]
- a cell population containing cells constituting pituitary tissue was produced according to the steps shown in FIG. 2A.
- human iPS cells strain 1231A3, obtained from RIKEN
- StemFit medium was used as a feeder-free medium
- Lamin511-E8 was used as a feeder-free scaffold. Differentiation was induced under the same conditions as in Example 1, except for the addition of the JNK inhibitor.
- JNK-IN-8 manufactured by Merck, 1 ⁇ M
- JNK c-Jun N-terminal kinase
- Example 3 Examination of the effect of a JNK inhibitor on pituitary hormone secretion ability in the production of a cell population containing pituitary tissue (pituitary organoid) from human iPS cells]
- a cell population containing cells constituting pituitary tissue was produced according to the steps shown in FIG. 3A.
- human iPS cells 201B7 strain, obtained from Kyoto University
- StemFit medium was used as a feeder-free medium
- Lamin511-E8 was used as a feeder-free scaffold.
- the subconfluent human iPS cells were treated with a cell dispersion using TrypLE Select, and dispersed into single cells by pipetting. Then, the human ES cells dispersed into single cells were suspended in 100 ⁇ L of serum-free medium at 9000 cells per well of a non-cell-adhesive 96-well culture plate, and placed at 37° C., 5% CO 2 . Suspension culture was carried out under these conditions.
- the serum-free medium (gfCDM+KSR) at that time was a serum-free medium obtained by adding 5% KSR, 450 ⁇ M 1-monothioglycerol, and 1x Chemically defined lipid concentrate to a 1:1 mixture of F-12 medium and IMDM medium. .
- Y-27632 (final concentration 10 ⁇ M), IWP-2 (0.5 ⁇ M), SB431542 (1 ⁇ M), and SAG (100 nM) were added to the serum-free medium at the start of suspension culture (day 0 after initiation of differentiation induction).
- 100 ⁇ L of a serum-free medium containing IWP-2, SB431542, BMP4 (0.5 nM) and SAG (700 nM) without Y-27632 was added per well. After that, on days 6, 9, 12, 15, 19, 22, and 26 after the initiation of differentiation induction, half the medium was replaced with a serum-free medium containing IWP-2, SB431542, and SAG but without Y-27632 and BMP4. gone. After the 19th day, the oxygen partial pressure during culture was set to 40%.
- the cell aggregates on the 29th day after the initiation of differentiation induction were each fixed with 4% paraformaldehyde, and frozen sections were prepared.
- the pituitary progenitor markers Pitx1 anti-Pitx1 antibody, homemade (Nature Communications, 7: 10351, 2016, Cell Reports, 30, 18-24, January 7, 2020)
- Lhx3 anti-Lhx3 Antibodies, homemade (Nature Communications, 7: 10351, 2016, Cell Reports, 30, 18-24, January 7, 2020)
- immunostaining using antibodies against epithelial cell marker E-cadherin did After primary antibody reaction, detection was performed using a secondary antibody (manufactured by Life Technologies) fluorescently labeled with Alexa488, 555, and 647.
- Example 4 Examination of the effect of a JNK inhibitor on pituitary hormone secretion ability in the production of a cell population containing pituitary tissue (pituitary organoid) from human iPS cells]
- a cell population containing cells constituting pituitary tissue was produced according to the steps shown in FIG. 4A. Specifically, the culture supernatant of the human iPS cell line 201B7-derived cell mass prepared by the method described in Example 3 was collected over time, and the secretion amount of ACTH per cell mass was measured.
- the culture supernatant was collected before half the medium was replaced, frozen at -150°C, and used in clinical tests after all specimens were collected.
- the ACTH concentration in the recovered medium was measured by the ELISA method (inspection entrusted to SRL Co., Ltd.). Based on the ACTH concentration (pg/mL) data obtained, the total number of cell clusters and the total amount of culture medium at the time of sampling were corrected to the ACTH concentration under conditions in which 20 cell clusters were cultured in 20 ml of medium. made it A similar experiment was performed twice.
- the ACTH concentration in the medium was about 5 times higher at day 61 of differentiation induction. , 103 days and 152 days after differentiation induction, and about 1.3 times higher at 201 days after differentiation induction.
- the concentration of ACTH in the medium was higher on the 61st and 103rd days of differentiation induction than under the non-addition condition, but on the 152nd and 201st days of differentiation induction, It was lower than the additive-free condition.
- the addition of a JNK inhibitor improves the ACTH secretion ability per cell mass in the induction of pituitary tissue differentiation from pluripotent stem cells, and the concentration of the added JNK inhibitor is preferably 3 ⁇ M or less. (Fig. 4B).
- Example 5 Examination of effect of shaking culture in production of cell population containing pituitary tissue (pituitary organoid) from human iPS cells]
- a cell population containing cells constituting pituitary tissue was produced according to the steps shown in the upper diagram of FIG. Specifically, cell clusters on day 30 of differentiation induction produced from human iPS cell line 1231A3 by the method described in Example 2 were transferred to a cell non-adhesive T75 tissue culture flask (manufactured by Corning), and then was carried out.
- Example 6 Examination of the effect of a substance having an action to reduce oxidative stress in the production of a cell population containing pituitary tissue (pituitary organoid) from human iPS cells]
- a cell population containing cells constituting pituitary tissue was produced according to the steps shown in the upper diagram of FIG. Specifically, a cell mass containing pituitary tissue was prepared from the human iPS cell line 1231A3 by the method described in Example 5. On day 30 of induction of differentiation, the cell mass was transferred to a T75 flask, and the culture conditions were changed.
- N-acetylcysteine was added to the medium at a concentration of 1 mM from day 10 of induction of differentiation, and compared with non-addition conditions.
- NAC N-acetylcysteine
- the cell clusters were about 50 ⁇ m smaller in diameter under the conditions where NAC was added than under the non-addition conditions, and the proliferation of non-target cells was suppressed. Furthermore, by carrying out suspension culture, cell clusters with a high proportion covered with epithelial tissue containing pituitary gland were formed on day 51 of induction of differentiation. The above results indicated that the addition of a substance that reduces oxidative stress is useful for the production of pituitary tissue from pluripotent stem cells.
- the human ES cells were treated with a cell dispersion using TrypLE Select and further dispersed into single cells by pipetting. Thereafter, the human ES cells dispersed into single cells were suspended in 100 ⁇ L of serum-free medium at 1.0 ⁇ 10 4 cells per well of a non-cell-adhesive 96-well culture plate, Suspension culture was carried out under the condition of 5% CO2 .
- the serum-free medium (gfCDM+KSR) at that time was a serum-free medium obtained by adding 5% KSR, 450 ⁇ M 1-monothioglycerol, and 1x Chemically defined lipid concentrate to a 1:1 mixture of F-12 medium and IMDM medium. .
- Y-27632 (final concentration: 20 ⁇ M) and SAG (100 nM) were added to the serum-free medium at the start of suspension culture (0 days after initiation of differentiation induction) (step (1)). Two days after initiation of differentiation induction, 100 ⁇ L of serum-free medium containing BMP4 (5 nM) and SAG (2 ⁇ M) without Y-27632 was added per well. On the 6th, 9th, 12th and 15th days after initiation of differentiation induction, half the medium was replaced with a serum-free medium containing BMP4 and SAG without Y-27632 (start of step (2)).
- the frozen sections were immunostained using antibodies against PITX1 (anti-Pitx1 antibody, homemade) and an epithelial cell marker E-cadherin (manufactured by Takara Bio Inc.).
- PITX1 anti-Pitx1 antibody, homemade
- E-cadherin epithelial cell marker
- RAX::Venus-positive neuroepithelial tissue was present on the inside (Fig. 8B-1 to 3).
- LHX3-positive cells were present in the outer cell layer containing non-neural epithelial tissues positive for PITX1 and E-cadherin (FIGS. 8B-1 to 8B-3).
- the conditions under which PITX1-positive and E-cadherin-positive non-neural epithelial tissues are formed with the highest probability are the addition of IWP2 and SB431542 from day 0 to day 29 of the start of suspension culture, and the addition of BMP4. was carried out from day 2 to day 6 after the start of suspension culture (Fig. 8B-3). From this result, the outer non-neural epithelial tissue is formed with high efficiency under the differentiation induction conditions in which the Wnt signal inhibitor and the TGF ⁇ signal inhibitor are added from human iPS cells, and part of the outer non-neural epithelium is LHX3-positive. It has been shown that cell clumps that are pituitary placodes can be produced.
- the lower right scale bar in FIGS. 8B-1-3 indicates 200 ⁇ m.
- Example 7 Examination of the effect of a JNK inhibitor on the induction of pituitary epithelial tissue and pituitary hormone-secreting cells in the production of a cell population containing pituitary tissue (pituitary organoid) from human iPS cells]
- human iPS cells 201B7 strain
- suspension culture was performed in the same manner as in Example 4, continued until day 103, and the obtained cell aggregates were used.
- Cryosections were prepared in the same manner as in Example 3.
- Example 8 Confirmation of presence of pituitary hormone-secreting cells in production of cell population containing pituitary tissue (pituitary organoid) from human iPS cells.
- human iPS cells strain 1231A3
- suspension culture was performed in the same manner as in Example 6, and frozen sections were prepared in the same manner as in Example 3 using cell aggregates on day 59 of culture.
- the obtained sections were immunostained using anti-ACTH antibody (Lab Vision) and anti-SOX2 antibody (Santa Cruz), and cell nuclei were stained with DAPI.
- a pituitary epithelial tissue was formed on the surface layer of the cell aggregate, and ACTH-positive cells were present throughout the cell aggregate (Fig. 11).
- the lower right scale bar in FIG. 11 indicates 200 ⁇ m.
- Example 9 Examination of SAG addition period in production of cell population containing pituitary tissue (pituitary organoid) from human iPS cells] Using human iPS cells (201B7 strain), cell aggregates were produced according to the steps shown in FIG. 12A. However, regarding the SAG treatment period, SAG was added to the group from immediately after the start of differentiation induction to 30 days after the start of differentiation induction, and after 30 days from immediately after the start of differentiation induction (up to 61st, 103rd and 131st days). Two groups were set to be added, and the ACTH secretion ability was compared. ACTH was measured in the same manner as in Example 4. As a result, it was found that the ACTH secretion ability was improved by stopping the SAG treatment 30 days after the initiation of differentiation induction (Fig. 12B).
- Example 10 Examination of gene expression changes in production of cell population containing pituitary tissue (pituitary organoid) from human ES cells] Using human ES cells (KhES-1 strain), cell aggregates were produced according to the steps shown in FIG. 13A. Expression changes of pituitary markers (PITX1, LHX3, POMC (ACTH progenitor cells)) and hypothalamic markers (RAX, NKX2.1 (TTF1)) in order to confirm the degree of differentiation at each culture day after initiation of differentiation induction was examined by quantitative PCR. Specifically, it was carried out as follows. RNA was extracted from 6 cell aggregates per sample using the RNeasy Micro Kit (Qiagen).
- Quantitative PCR was performed using a Biomark HD (Fluidigm). ⁇ GAPDH(Hs02758991_g1) ⁇ PITX1(Hs00267528-m1) ⁇ LHX3(Hs01033412_m1) ⁇ POMC(Hs01596743_m1) ⁇ RAX(Hs00429459-m1) ⁇ TTF1(Hs00968940-m1)(TaqMan Probes;Thermo Fisher Scientific ) was used. The obtained data were normalized using GAPDH as an endogenous control, and quantitative results were obtained using the comparative Ct method ( ⁇ Ct method).
- Example 11 Confirmation of expression of various hormone-secreting cells in production of cell population containing pituitary tissue (pituitary organoid) from human ES cells.
- Cell aggregates were produced using the same differentiation induction method as in Example 10 using human ES cells (KhES-1 strain). Frozen sections were prepared in the same manner as in Example 3 using cell aggregates 103 days after the start of suspension culture.
- Anti-prolactin (PRL) antibody (manufactured by Dako), anti-POU1F1 antibody (homemade), anti-thyroid stimulating hormone (TSH) antibody (manufactured by Dako), anti-luteinizing hormone (LH) antibody (manufactured by Dako) and anti-follicular stimulation
- TSH thyroid stimulating hormone
- LH leukinizing hormone
- Immunostaining was performed using a hormone (FSH) antibody (manufactured by Dako), and cell nuclei were stained with DAPI.
- FSH hormone
- the cell aggregates 152 days after the start of the suspension culture were immunostained using an anti-growth hormone (GH) antibody (manufactured by Santa Cruz), and the cell nuclei were stained with DAPI.
- GH anti-growth hormone
- Example 12 Examination of the structure of cell aggregates containing pituitary tissue (pituitary organoids) using an electron microscope]
- a cell aggregate containing pituitary tissue was produced using the same differentiation induction method as in Example 10, and the culture was continued from day 51 onwards to day 201 after the start of suspension culture in FIG. 13A.
- Cell aggregates were fixed with 4% paraformaldehyde, 1% glutaraldehyde and 2% sucrose at 4°C for 3 days. After dehydration with an alcohol solution and polymerization and embedding with LR-WHlTE resin (Nissin EM) according to a conventional method, ultra-thin sections were prepared and observed with an electron microscope (Hitachi H-7500).
- FIG. 15A arrow head
- Fig. 15A, B, C “ ⁇ ”
- Endocrine cells containing many secretory granules were scattered, but these cells maintained a certain immature state, and the type of endocrine cells was unclear.
- Endocrine cells appeared to be strongly polarized towards the basement membrane and the outer border, eg desmosomes were localized in the outer layer (Fig. 15C: arrow head).
- the presence of folliculo-stellate cells (FSCs) was also observed within the organoid wall (FIG. 15D: dashed line).
- the lower right scale bar in FIG. 15A indicates 8 ⁇ m
- the lower right scale bar in FIGS. 15B and 15C indicates 2 ⁇ m
- the lower right scale bar in FIG. 15D indicates 500 nm.
- Example 13 Examination of the presence of pituitary stem cells in cell aggregates containing pituitary tissue (pituitary organoids) by immunostaining
- the follicular astrocytes in the pituitary confirmed in Example 12 are reported to be a type of adult pituitary stem cells, and the pituitary-hypothalamic organoids produced by this production method contain not only hormone-producing cells It was suggested to contain pituitary stem cells. Therefore, cell aggregates containing pituitary tissue were produced in the same manner as in Example 10, and CXADR, a pituitary stem cell marker, was applied to the cell aggregates on day 103 after the start of suspension culture (differentiation induction). Immunostaining was performed.
- Example 3 frozen sections were prepared for each. Immunostaining was performed on these frozen sections using an anti-ACTH antibody (mouse, 1:200; Fitzgerald) and an anti-CXADR antibody (rabbit; 1:100; Atlas antibodies), and cell nuclei were stained with DAPI. These stained sections were observed using a confocal laser scanning microscope (manufactured by Olympus) to obtain immunostained images. As a result, in the region where pituitary tissue exists, ACTH-positive cells were present inside the cell aggregates, and CXADR-positive and ACTH-negative cells were present on the opposite side (outside the cell aggregates) (Fig. 16).
- hormone-producing cells and pituitary stem cells exhibit polarity.
- the presence of pituitary stem cells in pituitary-hypothalamic organoids derived from pluripotent stem cells has not been reported so far, and was confirmed for the first time in this example.
- the lower right scale bar in FIG. 16 indicates 50 ⁇ m.
- Example 14 Examination of ACTH secretion ability of cell aggregates containing pituitary tissue (pituitary organoids)]
- a cell aggregate containing pituitary tissue was produced in the same manner as in Example 10, and the ability to secrete ACTH was examined. Twenty cell aggregates with different culture days after the start of suspension culture are transferred to a 10 cm suspension culture dish containing serum-free medium (20 mL) supplemented with 20% KSR, cultured at 37 ° C. for 3 to 4 days, and then cultured. Clear was collected. The ACTH concentration in the recovered culture supernatant was measured by the ELISA method used in clinical testing (contracted to SRL Co., Ltd.).
- Example 15 Identification of unintended cells expressed in pituitary organoids prepared from human ES cells (genetic analysis/immunostaining)]
- human ES cells KhES-1 strain
- RNeasy Micro Kit both manufactured by Qiagen
- the probes include Thermo Fisher Scientific TaqMan probes (GAPDH (Hs02758991_g1), ACTB (Hs01060665-g1), PITX1 (Hs00267528-m1), PITX2 (Hs04234069-mH), LHX3 (Hs01033412_m1), PO5MC (Hs01033412_m1), PO5MC (Hs049) ⁇ E-cadherin(Hs01023895_m1) ⁇ EpCAM(Hs00901885_m1) ⁇ RAX(Hs00429459-m1) ⁇ TTF1(Hs00968940-m1) ⁇ NESTIN(Hs04187831-g1) ⁇ SOX11(Hs00846583_s1) ⁇ LIN28A(Hs00702808-s1) ⁇ NANOG(Hs04260366- g1), POU5F1 (Hs04260367-gH) was used.As a result, as shown
- cryosections were prepared from tissues on day 103 after the start of suspension culture using the same method as in Example 3, and NESTIN (mouse; 1:500; manufactured by R&D Systems) and SOX11 (sheep; 1:1: 100; manufactured by R&D Systems), immunostaining was performed, and cell nuclei were stained with DAPI.
- NESTIN mouse; 1:500; manufactured by R&D Systems
- SOX11 seep; 1:1: 100; manufactured by R&D Systems
- Example 16 Production and induction of differentiation of pituitary organoids from human iPS cells using cultureware with divided microwells
- Pituitary organoids were produced from human pluripotent stem cells using cultureware with divided microwells according to the steps shown in FIG. 19A.
- Human iPS cell 1231A3 strain was used as pluripotent stem cells.
- Cells used for differentiation induction were prepared in the same manner as in Example 1.
- a serum-free medium for differentiation induction was added, and the cells were peeled off the surface of the culture dish by pipetting, dispersed into single cells, and transferred to a pre-prepared 35 mm EZSPHERE Dish at 1.8 ⁇ per dish. 10 6 cells were suspended in 3 ml of serum-free medium and cultured in suspension at 37° C. and 5% CO 2 . 5% KSR gfCDM was used as the serum-free medium at that time (start of step (1)).
- step (1) At the start of the suspension culture (0 days after the start of the suspension culture, step (1) is started), Y-27632 (final concentration 10 ⁇ M), IWP-2 (final concentration 1 ⁇ M), SB431542 (final concentration 1 ⁇ M) were added to the serum-free medium. , JNK-IN-8 (final concentration 1 ⁇ M), SAG (final concentration 100 nM) were added.
- cell aggregates were collected using a wide-bore 1000 ⁇ l pipette tip and transferred to a 10 cm suspension culture dish.
- 12 ml of 5% KSR gfCDM containing IWP-2, SB431542, JNK-IN-8 and SAG (final concentration 700 nM) without Y-27632 and BMP4 was used.
- 6 ml of medium was collected from the dish without sucking cell aggregates, and 6 ml of new medium was added to replace half of the medium.
- Example 17 Examination of BMP addition timing under JNK inhibitor addition conditions in production of cell population containing pituitary tissue (pituitary organoid) from human iPS cells]
- a cell population containing cells constituting pituitary tissue was produced according to the steps shown in FIG. 20A.
- human iPS cells strain 1231A3, obtained from RIKEN
- StemFit medium was used as a feeder-free medium
- Lamin511-E8 was used as a feeder-free scaffold.
- step (2) was performed about 24 hours (day 1) and about 48 hours (day 2) after initiation of differentiation induction.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
特許文献1及び非特許文献1、2には、ヒト多能性幹細胞をBMPシグナル伝達経路阻害因子乃至作用因子、ソニック・ヘッジホッグ(本明細書において、Shhと記載することがある)シグナル伝達経路作用因子、及びTGF-βシグナル伝達経路阻害剤存在下で分化誘導することにより、下垂体細胞を含む頭部プラコード由来細胞を製造したことが報告されている。しかしながら、製造された細胞は二次元的に培養されたものであり、機能の発揮に重要な生体の複雑な下垂体組織の構造を再現するには至っていない。
本発明者らは、特許文献2から4及び非特許文献3、4において多能性幹細胞から立体的な下垂体組織を製造し、その組織が下垂体ホルモン産生能を有することを報告している。
すなわち、本発明は以下に関する。
(1)多能性幹細胞をc-jun N末キナーゼ(JNK)シグナル伝達経路阻害物質およびWntシグナル伝達経路阻害物質の存在下で培養し、細胞集団を得る第一工程、
(2)第一工程で得られた細胞集団を、BMPシグナル伝達経路作用物質及びソニック・ヘッジホッグシグナル伝達経路作用物質の存在下で培養し、下垂体組織を含む細胞集団を得る第二工程。
[2]第一工程の前に、多能性幹細胞を下記工程(a)に付すことを特徴とする、[1]記載の製造方法;
(a)多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はソニック・ヘッジホッグシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程。
[2-1]前記工程(a)にて添加されるTGFβファミリーシグナル伝達経路阻害物質がAlk5/TGFβR1阻害剤であり、Alk5/TGFβR1阻害剤がSB431542、SB505124、SB525334、LY2157299、GW788388、LY364947、SD-208、EW-7197、A83-01、A77-01、RepSox、BIBF-0775、TP0427736、TGFBR1-IN-1、SM-16、TEW-7197、LY3200882、LY2109761、KRCA 0008、GSK 1838705、Crizotinib、Ceritinib、ASP 3026、TAE684、AZD3463及びこれらの誘導体からなる群から選ばれる少なくとも1つを含む、[2]に記載の製造方法。
[3]第一工程における培養がさらにソニック・ヘッジホッグシグナル伝達経路作用物質の存在下であって、第一工程および第二工程におけるソニック・ヘッジホッグシグナル伝達経路作用物質の存在下における培養期間が、30日である、[1]に記載の製造方法。
[4]第二工程で得られた細胞集団を下記工程(3)に付すことを特徴とする、[1]、[2]、[2-1]及び[3]のいずれかに記載の製造方法;
(3)第二工程で得られた細胞集団を、ソニック・ヘッジホッグシグナル伝達経路作用物質の非存在下で培養し、下垂体組織を含む細胞集団を得る第三工程。
[5]第三工程の前に、第二工程で得られた細胞集団を下記工程(b)に付すことを特徴とする、[4]に記載の製造方法;
(b)第二工程で得られた細胞集団を、BMPシグナル伝達経路阻害物質の存在下で培養するb工程。
[5-1]前記工程(b)で添加されるBMPシグナル伝達経路阻害物質が、I型BMP受容体阻害剤を含む、[5]に記載の製造方法。
[5-2]前記I型BMP受容体阻害剤は、K02288、Dorsomorphin、LDN-193189、LDN-212854、LDN-214117、ML347、DMH1、DMH2、Compound 1、VU5350、OD52、E6201、Saracatinib、BYL719及びこれらの誘導体からなる群より選ばれる少なくとも1つを含む、[5-1]に記載の製造方法。
[6]前記JNKシグナル伝達経路阻害物質は、JNK阻害剤を含む、[1]~[5]、[2-1]、[5-1]及び[5-2]のいずれかに記載の製造方法。
[6-1]前記JNK阻害剤は、SP600125、JNK-IN-8、DB07268、IQ-1S、Tanzisertib、Bentamapimod、BI-78D3、BI-87G3、CC-401、TCS JNK 5a、AS601245、CV-65、D-JNK1、ER-358063、ER-409903、ER-417258、CC-359、CC-930、SB203580及びこれらの誘導体からなる群より選ばれる少なくとも1つを含む、[6]に記載の製造方法。
[6-2]前記JNK阻害剤はJNK-IN-8又はSP600125を含み、1nM~50μMのJNK-IN-8、又は1nM~25μMのSP600125を含有する培地中で前記工程(1)を開始する、[6]又は[6-1]に記載の製造方法。
[7]前記JNKシグナル伝達経路阻害物質は、Rac阻害剤を含む、[1]~[5]、[2-1]、[5-1]及び[5-2]のいずれかに記載の製造方法。
[7-1]前記Rac阻害剤は、NSC23766、EHop-016、ZCL278、MBQ-167、KRpep-2d、ARS-853、Salirasib、ML141、EHT1864及びこれらの誘導体からなる群より選ばれる少なくとも1つを含む、[7]に記載の製造方法。
[8]前記Wntシグナル伝達経路阻害物質が、非古典的Wnt経路に対する阻害活性を有する物質を含む、[1]~[7]、[2-1]、[5-1]、[5-2]、[6-1]、[6-2]、及び[7-1]のいずれかに記載の製造方法。
[8-1]前記非古典的Wnt経路に対する阻害活性を有する物質がPORCN阻害剤であり、PORCN阻害剤がIWP-2、IWP-3、IWP-4、IWP-L6、IWP-12、IWP-O1、LGK-974、Wnt-C59、ETC-131、ETC-159、GNF-1331、GNF-6231、Porcn-IN-1、RXC004、CGX1321およびこれらの誘導体からなる群から選ばれる少なくとも1つを含む、[8]に記載の製造方法。
[9]前記第一工程、第二工程、b工程、及び第三工程のいずれか一つ以上の工程で、TGFシグナル伝達経路阻害物質がさらに存在する、[1]~[8]、[2-1]、[5-1]、[5-2]、[6-1]、[6-2]、[7-1]及び[8-1]のいずれかに記載の製造方法。
[9-1]前記a工程、第一工程、第二工程及びb工程のいずれか一つ以上の工程で添加されるソニック・ヘッジホッグシグナル伝達経路作用物質がSAG、Purmorphamine及びGSA-10からなる群から選ばれる少なくとも1つを含む[1]~[9]、[2-1]、[5-1]、[5-2]、[6-1]、[6-2]、[7-1]、及び[8-1]のいずれかに記載の製造方法。
[10]前記第一工程、第二工程、b工程、及び第三工程のいずれか一つ以上の工程で、TAK1阻害物質がさらに存在する、[1]~[9]、[2-1]、[5-1]、[5-2]、[6-1]、[6-2]、[7-1]、[8-1]、及び[9-1]のいずれかに記載の製造方法。
[10-1]前記TAK1阻害物質が、(5Z)-7-Oxozeaenol、N-Des(aminocarbonyl)AZ-TAK1 inhibitor、Takinib、NG25、Sarsasapogenin及びこれらの誘導体からなる群より選ばれる少なくとも1つを含む、[10]に記載の製造方法。
[11]前記第二工程、b工程、及び第三工程のいずれか一つ以上の工程でFGFシグナル伝達経路作用物質がさらに存在する、[1]~[10]、[2-1]、[5-1]、[5-2]、[6-1]、[6-2]、[7-1]、[8-1]、[9-1]、[10-1]のいずれかに記載の製造方法。
[11-1]前記FGFシグナル伝達経路作用物質はFGF2、FGF3、FGF8、FGF10及びこれらの改変体からなる群より選ばれる少なくとも1つを含む、[11]に記載の製造方法。
[12]前記第二工程、b工程、及び第三工程のいずれか一つ以上の工程で酸化ストレスを軽減する作用を有する物質がさらに存在する、[1]~[11]、[2-1]、[5-1]、[5-2]、[6-1]、[6-2]、[7-1]、[8-1]、[9-1]、[10-1]、[11-1]のいずれかに記載の製造方法。
[12-1]前記酸化ストレスを軽減する作用を有する物質が、アスコルビン酸、N-アセチル-L-システイン、ニコチンアミド及びこれらの誘導体からなる群より選ばれる少なくとも1つを含む、[12]に記載の製造方法。
[13]前記第二工程、b工程、及び第三工程のいずれか一つ以上の工程で、ストレス応答シグナル伝達経路に対する阻害物質がさらに存在する、[1]~[12]、[2-1]、[5-1]、[5-2]、[6-1]、[6-2]、[7-1]、[8-1]、[9-1]、[10-1]、[11-1]、及び[12-1]のいずれかに記載の製造方法。
[14]前記第二工程、b工程、及び第三工程のいずれか一つ以上の工程で、揺動しながら細胞を培養する、[1]~[13]、[2-1]、[5-1]、[5-2]、[6-1]、[6-2]、[7-1]、[8-1]、[9-1]、[10-1]、[11-1]、及び[12-1]のいずれかに記載の製造方法。
[15]前記第一工程で得られる細胞集団が細胞凝集体である、[1]~[14]、[2-1]、[5-1]、[5-2]、[6-1]、[6-2]、[7-1]、[8-1]、[9-1]、[10-1]、[11-1]、及び[12-1]のいずれかに記載の製造方法。
[16]前記第一工程、第二工程、b工程、及び第三工程のいずれか一つ以上の工程を、少なくとも1つのウェルが形成されている培養器材中で実施し、前記ウェルは、複数のマイクロウェルに分割されていて、前記マイクロウェルの1つにつき、1つの細胞塊が形成されるように浮遊培養を実施する、[1]~[15]、[2-1]、[5-1]、[5-2]、[6-1]、[6-2]、[7-1]、[8-1]、[9-1]、[10-1]、[11-1]、及び[12-1]のいずれかに記載の製造方法。
[17][1]~[16]、[2-1]、[5-1]、[5-2]、[6-1]、[6-2]、[7-1]、[8-1]、[9-1]、[10-1]、[11-1]、及び[12-1]のいずれかに記載の製造方法により得られた下垂体組織を含む細胞集団から下垂体組織を回収することを特徴とする、下垂体組織の製造方法。
本明細書において、用語の定義は下記のとおりである。「幹細胞」とは、分化能及び増殖能(特に自己複製能)を有する未分化な細胞を意味する。幹細胞には、分化能力に応じて、多能性幹細胞(pluripotent stem cell)、複能性幹細胞(multipotent stem cell)、単能性幹細胞(unipotent stem cell)等が含まれる。「多能性幹細胞」とは、インビトロにおいて培養することが可能で、かつ、生体を構成する全ての細胞に分化し得る能力(分化多能性:pluripotency)を有する幹細胞をいう。全ての細胞とは、外胚葉、中胚葉及び内胚葉の三胚葉由来の細胞である。「複能性幹細胞」とは、全ての種類ではないが、複数種の組織や細胞へ分化し得る能力を有する幹細胞を意味する。「単能性幹細胞」とは、特定の組織や細胞へ分化し得る能力を有する幹細胞を意味する。
上皮組織は通常種々の細胞間結合によりつながれており、単層または重層化した層構造を有する組織を形成する。これら上皮組織の有無の確認、存在量の定量は光学顕微鏡による観察か、上皮細胞マーカーに対する抗体(抗E-Cadherin抗体、抗N-Cadherin抗体、抗EpCAM抗体等)を用いた免疫組織化学等の手法により可能である。
生体由来の組織中並びに本発明の製造方法等で作製された細胞集団中の上皮細胞並びに上皮組織に上皮細胞極性が存在しているかどうかは、Phalloidin、頂端側マーカー(抗MUC-1抗体、抗PKC-zeta抗体等)並びに基底側マーカー(抗α6インテグリン抗体、抗β1インテグリン抗体等)を用いた免疫組織化学等の手法により検出することができる。
本発明は、下垂体組織を含む細胞集団及びその製造方法を提供する。以下、本発明の製造方法とも称する。
本発明の製造方法の一態様は、下記工程(1’)~(2)を含む、下垂体組織を含む細胞集団の製造方法である。
(1’)多能性幹細胞をJNKシグナル伝達経路阻害物質の存在下で培養し、細胞集団を形成させる第一工程、
(2)第一工程で得られた細胞集団を、BMPシグナル伝達経路作用物質及びソニック・ヘッジホッグシグナル伝達経路作用物質の存在下に培養し、下垂体組織を含む細胞集団を得る第二工程。
工程(1’)において、好ましくは、JNKシグナル伝達経路阻害物質にWntシグナル伝達経路阻害物質を併用する。
(a)多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はソニック・ヘッジホッグシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程、
(1’)a工程で得られた細胞をJNKシグナル伝達経路阻害物質の存在下で培養(好ましくは浮遊培養)する第一工程、
(2)第一工程で得られた細胞集団を、BMPシグナル伝達経路作用物質とソニック・ヘッジホッグシグナル伝達経路作用物質の存在下で培養(好ましくは浮遊培養)し、下垂体組織を含有する細胞集団を得る第二工程。
好ましくは、第一工程は細胞の凝集体を形成させる工程であり、第二工程に付す第一工程で得られた細胞集団は細胞の凝集体であり得る。
工程(1’)において、好ましくは、JNKシグナル伝達経路阻害物質にWntシグナル伝達経路阻害物質を併用する。
(a)多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はソニック・ヘッジホッグシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程、
(1)a工程で得られた細胞をJNKシグナル伝達経路阻害物質およびWntシグナル伝達経路阻害物質の存在下で培養(好ましくは浮遊培養)する第一工程、
(2)第一工程で得られた細胞集団を、BMPシグナル伝達経路作用物質とソニック・ヘッジホッグシグナル伝達経路作用物質の存在下で培養(好ましくは浮遊培養)する第二工程、
(3)第二工程で得られた細胞集団を、ソニック・ヘッジホッグシグナル伝達経路作用物質の非存在下で培養(好ましくは浮遊培養)し、下垂体組織を含む細胞集団を得る第三工程。
好ましくは、第一工程は細胞の凝集体を形成させる工程であり、第二工程に付す第一工程で得られた細胞集団、及び第三工程に付す第二工程で得られた細胞集団は、それぞれ細胞の凝集体であり得る。
多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はソニック・ヘッジホッグシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程について説明する。
工程(a)において、多能性幹細胞をTGFβファミリーシグナル伝達経路阻害物質及び/又はソニック・ヘッジホッグシグナル伝達経路作用物質で処理してから、第一工程において培養(好ましくは浮遊培養)に付すことにより、多能性幹細胞の状態が変わり、非神経上皮組織の形成効率が改善し、得られる細胞集団(凝集体)の質が向上し、分化しやすく、細胞死が生じにくく、下垂体細胞の製造効率が向上する。
本発明におけるフィーダー細胞非存在下(フィーダーフリー)とは、フィーダー細胞を実質的に含まない(例えば、全細胞数に対するフィーダー細胞数の割合が3%以下)条件を意味する。
工程(a)において用いられる培地は、血清培地であっても無血清培地であってもよい。化学的に未決定な成分の混入を回避する観点から、工程(a)において用いられる培地は、好ましくは無血清培地である。培地は、血清代替物を含んでいてもよい。
工程(1’)では、c-Jun N末キナーゼ(JNK)シグナル伝達経路阻害物質の存在下で多能性幹細胞を培養し、細胞集団を得る。
Wntシグナル伝達経路とは、Wntファミリー・タンパク質をリガンドとし、主としてFrizzledを受容体とするシグナル伝達経路である。当該シグナル伝達経路としては、古典的Wnt経路(Canonical Wnt pathway)、非古典的Wnt経路(Non-Canonical Wnt pathway)等が挙げられる。古典的Wnt経路は、β-Cateninによって伝達される。非古典的Wnt経路としては、Planar Cell Polarity(PCP)経路、Wnt/JNK経路、Wnt/Calcium経路、Wnt-RAP1経路、Wnt-Ror2経路、Wnt-PKA経路、Wnt-GSK3MT経路、Wnt-aPKC経路、Wnt-RYK経路、Wnt-mTOR経路等が挙げられる。非古典的Wnt経路では、Wnt以外の他のシグナル伝達経路でも活性化される共通のシグナル伝達因子が存在するが、本発明では前記したJNK経路以外のそれらの因子もWntシグナル伝達経路の構成因子とし、それらの因子に対する阻害物質もWntシグナル伝達経路阻害物質に含まれる。
培地中のShhシグナル伝達経路作用物質の濃度は、上述の効果を達成可能な範囲で用いる物質に応じて適宜設定することが可能である。第一工程においてShhシグナル伝達経路作用物質としてSAGを用いる場合は、通常、約1nM~約3μM、好ましくは約10nM~約2μM、より好ましくは約30nM~約1μM、更に好ましくは約50nM~約500nMの濃度で使用される。
工程(2)は、BMPシグナル伝達経路作用物質及びソニック・ヘッジホッグシグナル伝達経路作用物質の存在下で、第一工程で得られた細胞集団を培養する。第一工程で細胞を浮遊培養している場合は、工程(2)でも引き続き形成された細胞凝集体を浮遊培養すればよい。第一工程で細胞を接着培養している場合は、工程(2)でも引き続き細胞を接着培養すればよい。第一工程で細胞を浮遊培養した後、工程(2)で接着培養してもよい。
培地中のShhシグナル伝達経路作用物質の濃度は、上述の効果を達成可能な範囲で用いる物質に応じて適宜設定することが可能である。工程(2)においてShhシグナル伝達経路作用物質としてSAGを用いる場合は、通常、約1nM~約5μM、好ましくは約10nM~約4.5μM、より好ましくは約50nM~約4μM、更に好ましくは約100nM~約3μMの濃度で使用される。
工程(b)は、BMPシグナル伝達経路阻害物質の添加条件下で、工程(2)で得られた細胞集団を培養する。工程(2)で細胞を浮遊培養している場合は、工程(b)でも引き続き形成された細胞凝集体を浮遊培養すればよい。工程(2)で細胞を接着培養している場合は、工程(b)でも引き続き細胞を接着培養すればよい。
第三工程は、ソニック・ヘッジホッグシグナル(Shh)伝達経路作用物質の非添加条件下で、工程(2)又は工程(b)で培養した細胞集団を培養する。第二工程で得られた細胞集団をShhシグナル伝達経路作用物質の非存在下で培養し、下垂体組織を含む細胞集団を得る第三工程を工程(3)、b工程で得られた細胞集団をShhシグナル伝達経路作用物質の非存在下で培養し、下垂体組織を含む細胞集団を得る第三工程を工程(3’)とする。工程(2)又は工程(b)で細胞を浮遊培養している場合は、第三工程でも引き続き形成された細胞凝集体を浮遊培養すればよい。工程(2)又は工程(b)で細胞を接着培養している場合は、第三工程でも引き続き細胞を接着培養すればよい。工程(2)又は工程(b)で細胞を浮遊培養した後、第三工程で接着培養してもよい。
本発明は、下垂体組織を含む細胞集団、特に1)神経系細胞又は神経組織、2)下垂体組織、及び3)間葉系細胞を含む細胞集団を提供する。以下、本発明の細胞集団とも称する。本発明の細胞集団は、好ましくは上記した本発明の製造方法により製造することができる。
前記非神経上皮組織が口腔上皮またはその前駆組織であることもまた好ましい。下垂体組織は下垂体ホルモン産生細胞やその前駆細胞である下垂体前駆細胞を含むことが好ましく、下垂体幹細胞を含むことが好ましく、濾胞星状細胞を含むことが好ましく、下垂体ホルモン産生細胞、下垂体前駆細胞、下垂体幹細胞、濾胞星状細胞すべてを含むことがさらに好ましい。下垂体ホルモン産生細胞としては、例えば成長ホルモン(GH)産生細胞、プロラクチン(PRL)産生細胞及び副腎皮質刺激ホルモン(ACTH)産生細胞からなる群から選ばれる少なくとも1種が挙げられる。
下垂体組織中に下垂体ニッチが形成されていることもまた好ましく、下垂体ニッチが下垂体前葉と中葉の間に残る遺残腔周辺のMCLニッチ様の構造であることもまた好ましく、下垂体ニッチが実質層ニッチ様の構造であることもまた好ましく、MCLニッチ様の構造と実質層ニッチ様の構造をともに含むことがさらに好ましい。
3)間葉系細胞は、細胞集団の表面を被覆している非神経上皮組織と、細胞集団の内側に存在する1)神経系細胞又は神経組織との間に存在することが好ましい。
本発明に含まれうる非神経上皮組織は、例えば、サイトケラチン、E-Cadherin及びEpCAMからなる群から選ばれる少なくとも1種の非神経上皮組織マーカーを発現する。
本発明の細胞集団に含まれうる下垂体幹細胞は、例えばSox2、Sox9、E-Cadherin、Nestin、S100β、GFRα2、Prop1、CD133、β-Catenin、Klf4、Oct4、Pax6、コクサッキーウイルス・アデノウイルス共通受容体(CXADR)、PRRX1/2、Ephrin-B2及びACEからなる群から選ばれる少なくとも1種の下垂体幹細胞マーカーを発現する。本発明の細胞集団の好ましい態様は、下垂体幹細胞マーカー(例、CXADR)陽性の下垂体幹細胞を含む。該細胞集団における下垂体幹細胞数の割合(下垂体幹細胞数の存在割合)が1%以上、好ましくは3%以上又は5%以上であってもよい
本発明は、下垂体組織の製造方法を提供し、該方法は、上記、「2.下垂体組織を含む細胞集団の製造方法」により得られた下垂体組織を含む細胞集団から下垂体組織を回収することを特徴とする。一実施態様は、下記工程(1)、(2)及び(4)を含む。
(1)多能性幹細胞を、JNKシグナル伝達経路阻害物質とWntシグナル伝達経路阻害物質の存在下で培養し、細胞集団を得る第一工程、
(2)第一工程で得られた細胞集団を、BMPシグナル伝達経路作用物質及びソニック・ヘッジホッグシグナル伝達経路作用物質の存在下で培養(好ましくは浮遊培養)し、下垂体組織を含む細胞集団を得る第二工程、
(4)第二工程で得られた細胞集団から下垂体組織を回収する第四工程。
第一工程及び第二工程は、上記、「2.下垂体組織を含む細胞集団の製造方法」の第一工程及び第二工程と同様にして実施することができる。また、所望により第一工程の前にa工程を実施してもよい。また、所望により第二工程と第四工程の間に、第三工程を実施してもよい。
下垂体組織を含む細胞集団から下垂体組織を回収する第四工程は、形成された細胞集団が接着培養等で得られた平面的な組織である場合は、例えば顕微鏡観察下でニードル等を用い、下垂体組織を物理的に剥離する等の手法で回収することができる。形成された細胞集団が細胞塊等の立体的な組織である場合は、顕微鏡観察下でピンセット等を用い、細胞塊の外側(ラトケ嚢部分)に形成される下垂体組織を剥離・回収することによっておこなわれる。下垂体組織は、例えばNature communications,2016,7.に記載されているように、得られた細胞塊の表層にある半透明な薄い上皮として判別することができる。第四工程における細胞集団(細胞塊)からの下垂体組織の回収方法として、凍結融解、好ましくは緩慢凍結法を用いることもできる。当該方法は、外側に下垂体組織及び内側に間葉系神経や神経上皮組織を有する細胞塊を凍結融解することで物理的処理を施すことなく外側の下垂体組織が細胞塊から剥離されるというものである。
本発明の細胞集団、本発明の製造方法により製造される細胞集団、又は該細胞集団から回収される組織は、下垂体組織であり得る。従って、本発明の細胞集団、本発明の製造方法により製造される細胞集団又は該細胞集団から回収される下垂体組織を含有してなる、被験物質の毒性・薬効性評価用試薬が提供され得る。
また、本発明は、上述の細胞集団又は該細胞集団から回収される下垂体組織を用いて、毒性・薬効評価方法を提供することができる。
例えば、細胞集団又は該細胞集団から回収される下垂体組織と、被験物質とを接触させる工程と、該被験物質が該細胞集団又は下垂体組織に及ぼす影響を検定する工程とを含む、被験物質の毒性・薬効評価方法が挙げられる。
あるいは、細胞集団又は該細胞集団から回収される下垂体組織と、細胞への特定配列の核酸・遺伝子導入に用いるベクターとを接触させる工程と、該ベクター乃至導入遺伝子・核酸の該細胞集団又は下垂体組織に及ぼす影響、例えば導入遺伝子の効果、導入遺伝子の送達性、細胞障害の程度等を検定する工程とを含む、該ベクターの遺伝子治療法及びその他の用法に用いた際の毒性・薬効評価方法が挙げられる。
本発明の一態様として、本発明の細胞集団、本発明の製造方法により製造される細胞集団又は該細胞集団から回収される下垂体組織を含有してなる医薬組成物(移植用組成物、移植用組織またはTransplant)が挙げられる。医薬組成物は好ましくは、本発明の細胞集団、本発明の製造方法により製造される細胞集団又は該細胞集団から回収される下垂体組織の他に、さらに医薬として許容される担体を含む。
下垂体の障害に基づく疾患の治療薬としては、例えば本発明の細胞集団もしくは本発明の製造方法により製造される細胞集団を含む懸濁液を含む移植片が挙げられる。
懸濁液としては、例えば細胞集団を培地、人工涙液または生理食塩水に懸濁した液が挙げられる。懸濁液は、細胞集団から単離された非神経上皮細胞を含んでいてもよく、細胞の接着を促進する因子、例えば細胞外基質やヒアルロン酸等を含んでいてもよい。
細胞塊に代えて細胞集団から回収した下垂体組織を用いてもよい。
前記下垂体の障害に基づく疾患は、下垂体の障害に基づく動物の疾患であってよく、下垂体の障害に基づく非ヒト動物の疾患であってよい。下垂体の障害に基づく疾患としては、具体的には、汎下垂体機能低下症、下垂体性小人症、副腎皮質機能低下症、部分的下垂体機能低下症、下垂体前葉ホルモン単独欠損症、下垂体腺腫等の手術後の下垂体機能・ホルモン分泌不全、頭蓋咽頭腫などが挙げられる。
ヒトiPS細胞(HC-6#10株、理化学研究所より入手)を、Scientific Reports, 4, 3594 (2014)に記載の方法に準じてフィーダーフリー条件で培養した。フィーダーフリー培地としてはStemFit培地(味の素社製)、フィーダーフリー足場にはLaminin511-E8(ニッピ社製)を用いた。
具体的な維持培養操作としては、まずサブコンフレントになったヒトiPS細胞(HC-6#10株)を、0.5mM EDTA/PBSにて2回洗浄後、さらに5mM EDTA/PBSで37℃10分間処理した。ピペッティングを行い、培養ディッシュ表面から細胞を剥がし、単一細胞へ分散した。その後、単一細胞へ分散されたヒトiPS細胞を、Laminin511-E8にてコートしたプラスチック培養ディッシュに播種し、Y-27632(ROCK阻害物質、富士フイルム和光純薬社製、10μM)存在下、StemFit培地にてフィーダーフリー培養した。プラスチック培養ディッシュとして、6ウェルプレート(Corning社製、細胞培養用、培養面積9.5cm2)を用いた場合、単一細胞へ分散されたヒトiPS細胞の播種細胞数は7×103とした。播種した1日後に、Y-27632を含まないStemFit培地に全量培地交換した。以降、1日~2日に1回、Y-27632を含まないStemFit培地にて全量培地交換した。播種後7日間、サブコンフレント(培養面積の6割が細胞に覆われる程度)になるまで培養した。
その後、単一細胞に分散されたヒトES細胞を非細胞接着性の96ウェル培養プレート(PrimeSurface 96V底プレート、MS-9096V、住友ベークライト社製)に、1ウェルあたり9×103細胞になるように100μlの無血清培地に懸濁し、37℃、5%CO2の条件下で浮遊培養した。その際の無血清培地には、F-12+Glutamax培地(Thermo Fisher Scientific社製)とIMDM+Glutamax培地(Thermo Fisher Scientific社製)の体積比1:1混合液に5% Knockout Serum Replacement(Thermo Fisher Scientific社製)、450μM 1-モノチオグリセロール(富士フイルム和光純薬社製)、1x Chemically defined lipid concentrate(Thermo Fisher Scientific社製)、50unit/mlペニシリン-50μg/mlストレプトマイシン(ナカライテスク社製)を添加した無血清培地を用いた。以降、この無血清培地を5% KSR gfCDMともいう。浮遊培養開始時(浮遊培養開始後0日目、工程(1)開始)に、前記無血清培地にY-27632(終濃度10μM)、IWP-2(Wntシグナル伝達経路阻害物質、Tocris Bioscience社製、0.5μM)、SB431542(TGFシグナル伝達経路阻害物質、和光純薬社製、1μM)を添加した。さらに、多能性幹細胞からの下垂体分化誘導におけるJNKシグナル伝達経路阻害の効果を検証するために、c-Jun N末キナーゼ(JNK)阻害剤であるJNK-IN-8(メルク社製、1μM)を添加した条件と無添加条件を比較した。
浮遊培養開始後2日目にY-27632を含まず、IWP-2、SB431542、BMP4(BMPシグナル伝達経路作用物質)、SAGを含む無血清培地を1ウェルあたり100μl加えた。BMP4は添加する培地に1nM添加し、ウェル中の終濃度を0.5nMとし、SAGは添加する培地に1.4μM添加し、ウェル中の終濃度を700nMとなるようにした。その後、浮遊培養開始後6、10、13、17、21及び24日目にY-27632とBMP4を含まず、IWP-2、SB431542とSAGを含む無血清培地を用いて半量培地交換を行った。
実施例2では、図2Aに示す工程に従って、下垂体組織を構成する細胞を含む細胞集団を製造した。具体的には、ヒトiPS細胞(1231A3株、理化学研究所より入手)を、Scientific Reports, 4, 3594 (2014)に記載の方法に準じてフィーダーフリー条件で培養した。フィーダーフリー培地としてはStemFit培地、フィーダーフリー足場にはLaminin511-E8を用いた。
分化誘導の条件としては、実施例1の条件に対し、JNK阻害剤の添加条件以外は実施例1と同様の条件にて分化誘導を実施した。JNK阻害剤の添加条件として、分化誘導開始0、2、6、10、13日目にc-Jun N末キナーゼ(JNK)阻害剤であるJNK-IN-8(メルク社製、1μM)を添加した条件と無添加条件を比較した。分化誘導開始2、6、10、13日目にJNK阻害剤を添加する際は、培地添加ないし交換する際の培地に2μM添加し、ウェル中の終濃度を1μMとなるようにした。
実施例3では、図3Aに示す工程に従って、下垂体組織を構成する細胞を含む細胞集団を製造した。具体的にはヒトiPS細胞(201B7株、京都大学より入手)を、Scientific Reports, 4, 3594 (2014)に記載の方法に準じてフィーダーフリー条件で培養した。フィーダーフリー培地としてはStemFit培地、フィーダーフリー足場にはLaminin511-E8を用いた。
前記サブコンフルエントのヒトiPS細胞を、TrypLE Selectを用いて細胞分散液処理し、さらにピペッティング操作により単一細胞に分散した。その後、前記単一細胞に分散されたヒトES細胞を非細胞接着性の96ウェル培養プレートの1ウェルあたり9000細胞になるように100μLの無血清培地に浮遊させ、37℃、5%CO2の条件下で浮遊培養した。その際の無血清培地(gfCDM+KSR)には、F-12培地とIMDM培地の1:1混合液に5%KSR、450μM 1-モノチオグリセロール、1xChemically defined lipid concentrateを添加した無血清培地を用いた。浮遊培養開始時(分化誘導開始後0日目)に、前記無血清培地にY-27632(終濃度10μM)、IWP-2(0.5μM)、SB431542(1μM)、SAG(100nM)を添加した。
分化誘導開始後2日目にY-27632を含まず、IWP-2、SB431542、BMP4(0.5nM)、SAG(700nM)を含む無血清培地を1ウェルあたり100μL加えた。その後、分化誘導開始後6、9、12、15、19、22、26日目にY-27632とBMP4を含まず、IWP-2、SB431542とSAGを含む無血清培地を用いて半量培地交換を行った。19日目以降は、培養時の酸素分圧を40%とした。
実施例4では、図4Aに示す工程に従って、下垂体組織を構成する細胞を含む細胞集団を製造した。具体的には、実施例3に記載の方法で調製したヒトiPS細胞株201B7由来の細胞塊の培養上清を経時的に回収し、細胞塊あたりのACTHの分泌量を測定した。具体的な測定法としては、分化誘導0日目から30日目まで、JNK阻害剤JNK-IN-8を1μM、3μM又は10μM添加した条件および無添加コントロールの4条件で下垂体組織を含む細胞塊を調製した。このうち、JNK-IN-8を10μM添加した条件では細胞塊の崩壊が確認された。その後、無添加コントロール及びJNK-IN-8を1μM又は3μMを添加し調製した細胞塊を、10cmディッシュ、培地20mlの条件で各条件の細胞塊を浮遊培養し、3乃至4日毎に半量培地交換した。分化誘導61日目、103日目、152日目、201日の半量培地交換前に培養上清を回収し、-150℃で凍結し、すべての検体が揃ったのちに臨床検査で使われているELISA法によって回収した培地中のACTH濃度を測定した(株式会社SRLへ検査委託)。取得したACTHの濃度(pg/mL)のデータをもとに、サンプリング時の細胞塊の総数及び培養培地の総量から細胞塊20個を20mlの培地で培養した条件のACTH濃度に補正し、グラフにした。同様の実験を2回実施した。
実施例5では、図5上図に示す工程に従って、下垂体組織を構成する細胞を含む細胞集団を製造した。具体的には、実施例2に記載の方法でヒトiPS細胞株1231A3から製造した分化誘導30日目の細胞塊を、細胞非接着性のT75組織培養用フラスコ(コーニング社製)に移し、以降の浮遊培養を実施した。浮遊培養の条件としては、F-12培地とIMDM培地の1:1混合液に10%KSR、450μM 1-モノチオグリセロール、1xChemically defined lipid concentrateを添加した無血清培地を用い、1μM SB431542、700nM SAGを添加した。48個の細胞塊を25mlの培地中で浮遊培養し、3日乃至4日毎に半量培地交換を実施した。上記細胞塊を入れたフラスコを往復式のシェーカー(NS-LR、アズワン社製)を用いて30rpmの条件で振盪培養を実施し、同じフラスコで静置培養を実施した条件と比較した。分化誘導43日目に倒立顕微鏡(キーエンス社製、BIOREVO BZ-X800)を用いて、偏射照明による明視野観察を行った(図5下図)。
実施例6では、図6上図に示す工程に従って、下垂体組織を構成する細胞を含む細胞集団を製造した。具体的には、実施例5に記載の方法でヒトiPS細胞株1231A3から下垂体組織を含む細胞塊を調製した。分化誘導30日目にT75フラスコへ細胞塊を移し、培養条件を変更した。酸化ストレスを軽減する作用を有する物質として、Nアセチルシステイン(NAC)を分化誘導の10日目より1mMの濃度で培地中に添加し、無添加条件と比較した。分化誘導30日目及び51日目に倒立顕微鏡(キーエンス社製、BIOREVO BZ-X800)を用いて、偏射照明による明視野観察を行った(図6下図)。
ヒトES細胞(RAX::VenusをノックインしたKhES-1株、理化学研究所)を用いて、図7Aに示す工程に従って、a工程を実施する群と実施しない群を設け、下垂体組織を構成する細胞を含む細胞集団を製造した。
具体的には、サブコンフルエントのヒトES細胞を、実施例1と同様に、Laminin511-E8にてコートしたプラスチック培養ディッシュに播種し、300nM SAGおよび5μM SB431542を含むStemFit培地にてフィーダーフリー培養した(工程(a))。播種した1日後、前記ヒトES細胞を、TrypLE Selectを用いて細胞分散液処理し、さらにピペッティング操作により単一細胞に分散した。その後、前記単一細胞に分散されたヒトES細胞を非細胞接着性の96ウェル培養プレートの1ウェルあたり1.0×104細胞になるように100μLの無血清培地に浮遊させ、37℃、5%CO2の条件下で浮遊培養した。その際の無血清培地(gfCDM+KSR)には、F-12培地とIMDM培地の1:1混合液に5%KSR、450μM 1-モノチオグリセロール、1xChemically defined lipid concentrateを添加した無血清培地を用いた。浮遊培養開始時(分化誘導開始後0日目)に、前記無血清培地にY-27632(終濃度20μM)、SAG(100nM)を添加した(工程(1))。
分化誘導開始後2日目にY-27632を含まず、BMP4(5nM)、SAG(2μM)を含む無血清培地を1ウェルあたり100μL加えた。分化誘導開始後6、9、12、15日目にY-27632を含まず、BMP4とSAGを含む無血清培地を用いて半量培地交換を行った(工程(2)の開始)。その後、分化誘導開始後19、22、26日目にY-27632およびBMP4を含まず、SAGを含む無血清培地を用いて半量培地交換を行った。19日目以降は、培養時の酸素分圧を40%とした。浮遊培養開始後32日目の細胞凝集体を、実施例3と同様に、凍結切片を作製した。凍結切片に関し、下垂体の前駆マーカーであるPITX1(抗Pitx1抗体、自家製)および上皮細胞マーカーであるE-cadherin(タカラバイオ社製)に対する抗体を用いて免疫染色を行い、DAPIで細胞核を染色した。その結果、a工程を実施しない群では、凝集体がうまく形成されず崩壊してしまった(data not shown)。一方で、a工程を実施した群では、PITX1陽性かつE-cadherin陽性細胞を有する組織およびRAX::Venus陽性細胞を有する組織の2種類の層を含む細胞凝集体が形成されていることが確認された。(図7B)しかし、下垂体前駆細胞マーカーであるLHX3(rabbit;1:3,000、タカラバイオ社製)に対する抗体を用いて染色した結果、LHX3陽性細胞はそれほど多く検出されなかった。この結果から、a工程を実施することによって、2層の組織を有する細胞凝集体が得られることが示唆された。図7Bの右下のスケールバーは200μmを示す。
ヒトES細胞(RAX::VenusをノックインしたKhES-1株、理化学研究所)を用いて、図8Aに示す工程に従って、a工程を実施した後、BMP4(5nM)およびSAG(100nM(工程(1))または2μM(工程(2)))に加え、Wntシグナル阻害剤であるIWP2(2μM)およびTGFβシグナル阻害剤であるSB431542(1μM)を添加した培地で浮遊培養を行った。IWP2およびSB431542の添加は、浮遊培養開始0日目から6日目までの期間(図8B-1)、浮遊培養開始0日目から12日目までの期間(図8B-2)または浮遊培養開始0日目から29日目までの期間(図8B-3)行われ、BMP4の添加は、浮遊培養開始2日目から6日目までの期間(図8B-1~3のそれぞれ上段)または浮遊培養開始2日目から18日目までの期間(図8B-1~3のそれぞれ下段)行われた。浮遊培養開始29日目の細胞凝集体を用い、実施例3と同様に、凍結切片を作製した。凍結切片に関し、PITX1(抗Pitx1抗体、自家製)および上皮細胞マーカーであるE-cadherin(タカラバイオ社製)に対する抗体を用いて免疫染色を行った。その結果、凝集体の外側はPITX1陽性かつE-cadherin陽性である非神経上皮組織が存在し、内側はRAX::Venus陽性である神経上皮組織であることが確認された(図8B-1~3)。
またPITX1陽性かつE-cadherin陽性である非神経上皮組織を含む外側の細胞層に、LHX3陽性細胞が存在することがわかった(図8B-1~3)。PITX1陽性かつE-cadherin陽性である非神経上皮組織が最も高確率で形成される条件は、IWP2およびSB431542の添加が浮遊培養開始0日目から29日目までの期間行われ、さらにBMP4の添加が浮遊培養開始2日目から6日目の期間行われた場合であった(図8B-3)。この結果から、ヒトiPS細胞からWntシグナル阻害剤とTGFβシグナル阻害剤を添加した分化誘導条件により、外側の非神経上皮組織が高効率で形成され、外側の非神経上皮の一部がLHX3陽性の下垂体プラコードである細胞塊が製造可能であることが示された。図8B-1~3の右下のスケールバーは200μmを示す。
次に、各工程で添加するIWP2、BMP4およびSAGの至適濃度を検討する目的で、高濃度群(IWP2;2μM、BMP4;5nM、SAG;2μM)および低濃度群(IWP2;0.5μM、BMP4;0.5nM、SAG;700nM)の2群を設け、分化誘導61日目、103日目、152日目、201日目、250日目における培養液中のACTH濃度を指標に比較検討を行った。細胞にはヒトES細胞(KhES-1株)を用い、図9Aに示す工程に従って、下垂体組織を構成する細胞を含む細胞集団を製造した。実施例4に記載されている方法を用いて、培地中のACTH濃度の測定を行った。検討の結果、低濃度群の方が高い培養液中ACTH濃度を示した(図9B)。この結果から、ACTH分泌能の優れた組織を分化誘導するためには、低濃度群(IWP2;0.5μM、BMP4;0.5nM、SAG;700nM)の濃度が適していることが示唆された。
図10Aに示した工程に従って、ヒトiPS細胞(201B7株)を用いて、実施例4と同様の方法で浮遊培養を行い、103日目まで継続し、得られた細胞凝集体を用いて、実施例3と同様に、それぞれ凍結切片を作製した。得られた切片に対して、抗ACTH抗体(Fitzgerald Industries社製)および抗E-cadherin抗体(タカラバイオ社製)を用いて免疫染色を行い、DAPIで細胞核を染色した。その結果、無添加のコントロールと比較し、JNK―IN-8を添加した条件では、細胞凝集体表面を覆う層におけるE-cadherin陽性細胞の割合が高く、細胞凝集体全体におけるACTH陽性細胞の割合も多くなっていることがわかった(JNKi(+);42.2±4.4%,JNKi(-);28.8±4.0% of total cells,mean±SEM,n=8-12)(図10B)。図10Bの右下のスケールバーは200μmを示す。
ヒトiPS細胞(1231A3株)を用いて、実施例6と同様の方法で浮遊培養を行い、培養59日目の細胞凝集体を用いて、実施例3と同様に、凍結切片を作製した。得られた切片に対し、抗ACTH抗体(Lab Vision社製)及び抗SOX2抗体(Santa Cruz社製)を用いた免疫染色を行い、DAPIで細胞核を染色した。その結果、細胞凝集体表面の層に下垂体上皮組織が形成され、細胞凝集体全体にACTH陽性細胞が存在していることが確認された(図11)。図11の右下のスケールバーは200μmを示す。
ヒトiPS細胞(201B7株)を用いて、図12Aに示した工程に従って、細胞凝集体を製造した。ただし、SAGの処理期間について、分化誘導開始直後から30日目までSAGを添加する群と、分化誘導開始直後から30日目以降(61日目、103日目及び131日目まで)もSAGを添加する群の2群を設定し、ACTH分泌能を比較した。ACTHの測定は実施例4と同様の方法で行った。
その結果、分化誘導開始30日後にSAG処理を止めることにより、ACTH分泌能が向上することが分かった(図12B)。
ヒトES細胞(KhES-1株)を用いて、図13Aに示した工程に従って、細胞凝集体を製造した。分化誘導開始後の各培養日数における分化の程度を確認するために、下垂体マーカー(PITX1,LHX3,POMC(ACTH前駆細胞))及び視床下部マーカー(RAX,NKX2.1(TTF1))の発現変化を、定量PCRにより検討した。具体的には、以下の通り実施した。
RNeasy Micro Kit(Qiagen社)を用いて、1サンプル当たり6つの細胞凝集体からRNAを抽出した。定量PCRは、Biomark HD(Fluidigm)を用いて実施した。なお、各遺伝子のプローブは、GAPDH(Hs02758991_g1)、PITX1(Hs00267528-m1)、LHX3(Hs01033412_m1)、POMC(Hs01596743_m1)、RAX(Hs00429459-m1)、TTF1(Hs00968940-m1)(TaqMan Probes;Thermo Fisher Scientific)を用いた。得られたデータは内在性のコントロールとしてGAPDHを用いて規格化(normalize)した上で、比較Ct法(ΔΔCt法)を用いて定量結果を得た。
その結果、LHX3の発現は分化誘導開始6日目から60日目にかけて増加し、LHX3の発現は分化誘導開始19日目から30日目にかけて増加し、POMCの発現は分化誘導開始30日目以降に増加した(図13B)。これらの結果から、段階的に下垂体への分化が誘導されていることが示された。
一方、RAXの発現は分化誘導開始3日目から6日目頃にはプラトーに達し、その後減少した(図13C)。また、TTF1の発現は分化誘導開始6日目から19日目にかけて増加し、その後減少した(図13C)。これらの結果から、分化の初期段階において、下垂体前駆組織への分化と共に、視床下部(腹側視床下部)への分化が進行していることが示唆された。
ヒトES細胞(KhES-1株)を用いて、実施例10と同様の分化誘導法を用いて、細胞凝集体を製造した。浮遊培養開始103日後の細胞凝集体を用いて、実施例3と同様に、凍結切片を作製した。抗プロラクチン(PRL)抗体(Dako社製)、抗POU1F1抗体(自家製)、抗甲状腺刺激ホルモン(TSH)抗体(Dako社製)、抗黄体形成ホルモン(LH)抗体(Dako社製)および抗卵胞刺激ホルモン(FSH)抗体(Dako社製)を用いて免疫染色を行い、DAPIで細胞核を染色した。また、浮遊培養開始152日後における細胞凝集体に対して、抗成長ホルモン(GH)抗体(Santa Cruz社製)を用いて免疫染色を行い、DAPIで細胞核を染色した。その結果、用いた全ての抗体に反応する細胞の存在が確認された。この結果から、下垂体前駆細胞を含む細胞凝集体が、複数種類のホルモンを分泌する能力を有することが示された(図14)。図14の右下のスケールバーは50μmを示す。
実施例10と同様の分化誘導法を用いて、下垂体組織を含む細胞凝集体を製造し、図13Aにおける浮遊培養開始後51日目以降の培養を201日目まで継続した。細胞凝集体を4%パラホルムアルデヒド、1%グルタルアルデヒド及び2%スクロースを用い、4℃で3日間固定した。常法に従い、アルコール溶液による脱水及びLR-WHlTE樹脂(Nissin EM)により重合及び包埋の後、超薄切片を作成し、電子顕微鏡(Hitachi H-7500)により観察した。
その結果、下垂体組織中の多くの細胞が、ホルモン分泌顆粒(hormone-secreting granules)を含んでいた(図15B、C、D)。細胞凝集体の内層(視床下部組織)、特により深い層では、細胞死や繊維化が認められた(図15A:「*」が示す部分)。オルガノイド壁内には、下垂体前葉に相当する、細胞内に分泌顆粒を有する内分泌細胞が存在していた(図15A、B、C)。多くの領域において、下垂体細胞層(pituitary cell layer)は、薄い嚢胞壁(cystic wall)を形成し、偽多列円柱上皮(a false multi-row columnar epithelium)の内分泌細胞から構成されていた。下垂体細胞層の最下層は基底膜様構造を形成し(図15A:arrow head)、最外層には繊毛細胞(ciliated cells)が薄く被覆していた(図15A、B、C:「→」が示す部分)。分泌顆粒を多く含む内分泌細胞が散在していたが、これらの細胞は一定の未熟な状態を維持しており、内分泌細胞の種類ははっきりしなかった。内分泌細胞は基底膜及び外側との境界の方向に強い極性を示している様であり、例えば、デスモソームが外側の層に偏在していた(図15C:arrow head)。加えて、オルガノイド壁内には、濾胞星状細胞(folliculo-stellate cells:FSCs)の存在も認められた(図15D:破線)。図15Aの右下のスケールバーは8μm、図15B、Cの右下のスケールバーは2μm、図15Dの右下のスケールバーは500nmを示す。
実施例12において確認された下垂体中の濾胞星状細胞は、成体下垂体幹細胞の一種であると報告されており、本製法により製造した下垂体-視床下部オルガノイドは、ホルモン産生細胞のみならず下垂体幹細胞を含むことが示唆された。そこで、実施例10と同様の方法にて下垂体組織を含む細胞凝集体を製造し、浮遊培養(分化誘導)開始後103日目の細胞凝集体に対し、下垂体幹細胞のマーカーであるCXADRの免疫染色を行った。具体的には、実施例3と同様に、それぞれ凍結切片を作製した。これらの凍結切片に対し、抗ACTH抗体(mouse,1:200;Fitzgerald)及び抗CXADR抗体(rabbit;1:100;Atlas antibodies)を用いて免疫染色を行い、DAPIで細胞核を染色した。これらの染色された切片を、共焦点レーザー走査型顕微鏡(オリンパス社製)を用いて観察し、免疫染色像を取得した。
その結果、下垂体組織が存在する領域において、ACTH陽性細胞が細胞凝集体の内側に、CXADR陽性及びACTH陰性細胞がその反対側(細胞凝集体の外側)に存在していた(図16)。従って、ホルモン産生細胞及び下垂体幹細胞が、極性を示していることが示唆された。多能性幹細胞から誘導した下垂体-視床下部オルガノイドにおいて、これまで下垂体幹細胞の存在は報告されておらず、本実施例にて初めて確認した。図16の右下のスケールバーは50μmを示す。
実施例10と同様の方法にて下垂体組織を含む細胞凝集体を製造し、ACTH分泌能を検討した。浮遊培養開始後の培養日数の異なる細胞凝集体20個を、20%KSRを添加した無血清培地(20mL)を含む10cm浮遊培養用ディッシュに移し、37℃において3~4日間培養後、培養上清を回収した。回収した培養上清中のACTH濃度は、臨床検査で使われているELISA法によって測定した(株式会社SRLへ検査委託)。その結果、浮遊培養開始後29日目からACTHの分泌が認められ(23pg/mL)、その後培養日数が長くなるにつれてACTH分泌量は顕著に増加した(図17A)。
次に、CRHによるACTH分泌増加及びグルココルチコイドによるACTH分泌抑制が認められるかどうか検討した。具体的には、浮遊培養開始後103日目の細胞凝集体20個を、20%KSRを添加した無血清培地(10mL)が入った10cm浮遊培養用ディッシュに移し、37℃、40%O2条件下で24時間培養後、培養上清を回収した。細胞凝集体を、20%KSRを添加した無血清培地で洗浄後、20%KSRを添加した新しい無血清培地 10mLが入った10cm浮遊培養用ディッシュに移し、CRH(ニプロESファーマ社製)5μg/mL又はDexamethasone(DX、アスペンジャパン社製)500ng/mLを添加した。それぞれ、無添加群をコントロールとして設定した。37℃、40%O2条件下で24時間培養後、培養上清を回収した。回収した培養上清中のACTH濃度は、上記の通り測定した。その結果、CRH刺激により、ACTH分泌量は約三倍に増加した(図17B)。
一方、DX処理により、ACTH分泌量は約40%減少した(図17C)。これらの結果より、本製法により製造した下垂体-視床下部オルガノイドにおいて、ホルモンによるホメオスタシスが維持されていることが示された。
目的外細胞を特定する目的で、遺伝子発現解析の手法を用いて、浮遊培養細胞凝集体に発現している遺伝子の特定を行った。解析のために、分化誘導していないヒトES細胞(KhES-1株)と、図13Aに示した工程に従って作製した浮遊培養開始30日後、60日後および100日後の細胞凝集体をそれぞれ5または6個ずつ用意し、細胞凝集体ごとにRLTバッファーおよびRNeasy Micro Kit(ともにキアゲン社製)を用いて遺伝子解析用サンプルを作製した(全17サンプル)。作製したRNAサンプルをBiomark HD(Fluidigm)を用いて、解析した。プローブには、サーモフィッシャーサイエンティフィック社製のTaqManプローブ(GAPDH (Hs02758991_g1)、ACTB(Hs01060665-g1)、PITX1(Hs00267528-m1)、PITX2 (Hs04234069-mH)、LHX3(Hs01033412_m1)、POMC(Hs01596743_m1)、E-cadherin(Hs01023895_m1)、EpCAM(Hs00901885_m1)、RAX(Hs00429459-m1)、TTF1(Hs00968940-m1)、NESTIN(Hs04187831-g1)、SOX11(Hs00846583_s1)、LIN28A(Hs00702808-s1)、NANOG(Hs04260366-g1)、POU5F1(Hs04260367-gH)を使用した。その結果、図18AのHeat mapに示すように、浮遊培養開始30日後、60日後および100日後の組織において、神経前駆細胞マーカーであるNESTINおよびSOX11が発現していることがわかった。
次に、浮遊培養開始後103日目における組織から、実施例3と同様の手法を用いて凍結切片を作製し、NESTIN(マウス;1:500;R&Dシステムズ社製)およびSOX11(ヒツジ;1:100;R&Dシステムズ社製)に対する抗体を用いて免疫染色を行い、DAPIで細胞核を染色した。その結果、複数の細胞凝集体において、凝集体内部の細胞層にNESTIN陽性かつSOX11陽性の細胞が存在することがわかった(図18B)。上記の結果から、多能性幹細胞からの分化誘導された細胞塊には、下垂体組織、視床下部組織および神経系前駆細胞が存在することが示された(図18B)。図18Bのaの右下のスケールバーは200μm、図18Bのb~dの右下のスケールバーは50μmを示す。
図19Aに示す工程に従って、分割されたマイクロウェルを有する培養器材を用いてヒト多能性幹細胞から下垂体オルガノイドを製造した。多能性幹細胞として、ヒトiPS細胞1231A3株を用いた。分化誘導に用いる細胞は、実施例1と同様に調製した。
その後、調製したサブコンフルエントのヒトiPS細胞1231A3株を、実施例1に記載の方法と同様に5mM EDTA/PBSにて処理した。細胞回収時に分化誘導用の無血清培地を添加し、ピペッティングを行って培養ディッシュ表面から細胞を剥がし、単一細胞へ分散し、事前に調製した35mm EZSPHERE Dishに、1ディッシュあたり1.8×106細胞になるように3mlの無血清培地に懸濁し、37℃、5%CO2の条件下で浮遊培養した。その際の無血清培地には、5% KSR gfCDMを用いた(工程(1)開始)。
実施例17では、図20Aに示す工程に従って、下垂体組織を構成する細胞を含む細胞集団を製造した。具体的には、ヒトiPS細胞(1231A3株、理化学研究所より入手)を、Scientific Reports, 4, 3594 (2014)に記載の方法に準じてフィーダーフリー条件で培養した。フィーダーフリー培地としてはStemFit培地、フィーダーフリー足場にはLaminin511-E8を用いた。
分化誘導の条件としては、BMP4の添加条件およびIWP-2の終濃度を1μMに変更した点以外は実施例1と同様の条件にて分化誘導を実施した。BMP4の添加条件として、分化誘導の開始後約24時間後(1日目)および約48時間後(2日目)に工程(2)を実施した。
Claims (17)
- 下記工程(1)及び(2)を含む、下垂体組織を含む細胞集団の製造方法;
(1)多能性幹細胞をc-jun N末キナーゼ(JNK)シグナル伝達経路阻害物質およびWntシグナル伝達経路阻害物質の存在下で培養し、細胞集団を得る第一工程、
(2)第一工程で得られた細胞集団を、BMPシグナル伝達経路作用物質及びソニック・ヘッジホッグシグナル伝達経路作用物質の存在下で培養し、下垂体組織を含む細胞集団を得る第二工程。 - 第一工程の前に、多能性幹細胞を下記工程(a)に付すことを特徴とする、請求項1記載の製造方法;
(a)多能性幹細胞を、フィーダー細胞非存在下で、1)TGFβファミリーシグナル伝達経路阻害物質及び/又はソニック・ヘッジホッグシグナル伝達経路作用物質、並びに2)未分化維持因子を含む培地で培養するa工程。 - 第一工程における培養がさらにソニック・ヘッジホッグシグナル伝達経路作用物質の存在下であって、第一工程および第二工程におけるソニック・ヘッジホッグシグナル伝達経路作用物質の存在下における培養期間が、30日である、請求項1に記載の製造方法。
- 第二工程で得られた細胞集団を下記工程(3)に付すことを特徴とする、請求項1に記載の製造方法;
(3)第二工程で得られた細胞集団を、ソニック・ヘッジホッグシグナル伝達経路作用物質の非存在下で培養し、下垂体組織を含む細胞集団を得る第三工程。 - 第三工程の前に、第二工程で得られた細胞集団を下記工程(b)に付すことを特徴とする、請求項4に記載の製造方法;
(b)第二工程で得られた細胞集団を、BMPシグナル伝達経路阻害物質の存在下で培養するb工程。 - 前記JNKシグナル伝達経路阻害物質は、JNK阻害剤を含む、請求項1に記載の製造方法。
- 前記JNKシグナル伝達経路阻害物質は、Rac阻害剤を含む、請求項1に記載の製造方法。
- 前記Wntシグナル伝達経路阻害物質が、非古典的Wnt経路に対する阻害活性を有する物質を含む、請求項1に記載の製造方法。
- 前記第一工程、第二工程、b工程、及び第三工程のいずれか一つ以上の工程で、TGFシグナル伝達経路阻害物質がさらに存在する、請求項1~8のいずれか1項に記載の製造方法。
- 前記第一工程、第二工程、b工程、及び第三工程のいずれか一つ以上の工程で、TAK1阻害物質がさらに存在する、請求項1~8のいずれか1項に記載の製造方法。
- 前記第二工程、b工程、及び第三工程のいずれか一つ以上の工程でFGFシグナル伝達経路作用物質がさらに存在する、請求項1~8のいずれか1項に記載の製造方法。
- 前記第二工程、b工程、及び第三工程のいずれか一つ以上の工程で酸化ストレスを軽減する作用を有する物質がさらに存在する、請求項1~8のいずれか1項に記載の製造方法。
- 前記第二工程、b工程、及び第三工程のいずれか一つ以上の工程で、ストレス応答シグナル伝達経路に対する阻害物質がさらに存在する、請求項1~8のいずれか1項に記載の製造方法。
- 前記第二工程、b工程、及び第三工程のいずれか一つ以上の工程で、揺動しながら細胞を培養する、請求項1~8のいずれか1項に記載の製造方法。
- 前記第一工程で得られる細胞集団が細胞凝集体である、請求項1~8のいずれか1項に記載の製造方法。
- 前記第一工程、第二工程、b工程、及び第三工程のいずれか一つ以上の工程を、少なくとも1つのウェルが形成されている培養器材中で実施し、前記ウェルは、複数のマイクロウェルに分割されていて、前記マイクロウェルの1つにつき、1つの細胞塊が形成されるように浮遊培養を実施する、請求項1~8のいずれか1項に記載の製造方法。
- 請求項1~8のいずれか1項に記載の製造方法により得られた下垂体組織を含む細胞集団から下垂体組織を回収することを特徴とする、下垂体組織の製造方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280066380.1A CN118043447A (zh) | 2021-09-30 | 2022-09-27 | 包含垂体组织的细胞群的制备方法及该细胞群 |
CA3234671A CA3234671A1 (en) | 2021-09-30 | 2022-09-27 | Method for producing cell mass including pituitary tissue and cell mass |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021162255 | 2021-09-30 | ||
JP2021-162255 | 2021-09-30 | ||
JP2022-116716 | 2022-07-21 | ||
JP2022116716 | 2022-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023054396A1 true WO2023054396A1 (ja) | 2023-04-06 |
Family
ID=85782780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/036019 WO2023054396A1 (ja) | 2021-09-30 | 2022-09-27 | 下垂体組織を含む細胞集団の製造方法及びその細胞集団 |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA3234671A1 (ja) |
WO (1) | WO2023054396A1 (ja) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996022362A1 (en) | 1995-01-20 | 1996-07-25 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
WO1998030679A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
US6280718B1 (en) | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
WO2002101057A1 (fr) | 2001-06-08 | 2002-12-19 | Dnavec Research Inc. | Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur |
WO2013065763A1 (ja) * | 2011-10-31 | 2013-05-10 | 独立行政法人理化学研究所 | 幹細胞の培養方法 |
US8772460B2 (en) | 2011-12-16 | 2014-07-08 | Wisconsin Alumni Research Foundation | Thermostable FGF-2 mutant having enhanced stability |
WO2016013669A1 (ja) * | 2014-07-25 | 2016-01-28 | 国立研究開発法人理化学研究所 | 腺性下垂体又はその前駆組織の製造方法 |
US20160326491A1 (en) | 2013-11-21 | 2016-11-10 | Memorial Sloan-Kettering Cancer Center | Specification of functional cranial placode derivatives from human pluripotent stem cells |
WO2017126551A1 (ja) * | 2016-01-22 | 2017-07-27 | 国立大学法人名古屋大学 | ヒト多能性幹細胞から視床下部ニューロンへの分化誘導 |
JP2018501804A (ja) * | 2015-01-16 | 2018-01-25 | ゼネラル・エレクトリック・カンパニイ | 揺動プラットフォームバイオリアクターを用いた多能性幹細胞の増殖及び継代 |
WO2019103129A1 (ja) * | 2017-11-24 | 2019-05-31 | 住友化学株式会社 | 下垂体組織を含む細胞塊の製造方法及びその細胞塊 |
JP2021078154A (ja) | 2014-12-24 | 2021-05-20 | キヤノン株式会社 | ズーム制御装置、撮像装置、ズーム制御装置の制御方法、ズーム制御装置の制御プログラム |
JP2021162255A (ja) | 2020-03-31 | 2021-10-11 | 大和ハウス工業株式会社 | 熱融通システム |
JP2022116716A (ja) | 2021-01-29 | 2022-08-10 | 株式会社サンセイアールアンドディ | 遊技機 |
-
2022
- 2022-09-27 WO PCT/JP2022/036019 patent/WO2023054396A1/ja active Application Filing
- 2022-09-27 CA CA3234671A patent/CA3234671A1/en active Pending
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996022362A1 (en) | 1995-01-20 | 1996-07-25 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US6200806B1 (en) | 1995-01-20 | 2001-03-13 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
WO1998030679A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
JP2001508302A (ja) | 1997-01-10 | 2001-06-26 | ライフ テクノロジーズ,インコーポレイテッド | 胚性幹細胞血清置換 |
US6280718B1 (en) | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
WO2002101057A1 (fr) | 2001-06-08 | 2002-12-19 | Dnavec Research Inc. | Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur |
WO2013065763A1 (ja) * | 2011-10-31 | 2013-05-10 | 独立行政法人理化学研究所 | 幹細胞の培養方法 |
US8772460B2 (en) | 2011-12-16 | 2014-07-08 | Wisconsin Alumni Research Foundation | Thermostable FGF-2 mutant having enhanced stability |
US20160326491A1 (en) | 2013-11-21 | 2016-11-10 | Memorial Sloan-Kettering Cancer Center | Specification of functional cranial placode derivatives from human pluripotent stem cells |
WO2016013669A1 (ja) * | 2014-07-25 | 2016-01-28 | 国立研究開発法人理化学研究所 | 腺性下垂体又はその前駆組織の製造方法 |
JP2021078154A (ja) | 2014-12-24 | 2021-05-20 | キヤノン株式会社 | ズーム制御装置、撮像装置、ズーム制御装置の制御方法、ズーム制御装置の制御プログラム |
JP2018501804A (ja) * | 2015-01-16 | 2018-01-25 | ゼネラル・エレクトリック・カンパニイ | 揺動プラットフォームバイオリアクターを用いた多能性幹細胞の増殖及び継代 |
WO2017126551A1 (ja) * | 2016-01-22 | 2017-07-27 | 国立大学法人名古屋大学 | ヒト多能性幹細胞から視床下部ニューロンへの分化誘導 |
WO2019103129A1 (ja) * | 2017-11-24 | 2019-05-31 | 住友化学株式会社 | 下垂体組織を含む細胞塊の製造方法及びその細胞塊 |
JP2021162255A (ja) | 2020-03-31 | 2021-10-11 | 大和ハウス工業株式会社 | 熱融通システム |
JP2022116716A (ja) | 2021-01-29 | 2022-08-10 | 株式会社サンセイアールアンドディ | 遊技機 |
Non-Patent Citations (39)
Title |
---|
"Biomanual Series", vol. 8, 1995, YODOSHA CO., LTD., article "Gene Targeting, Making of Mutant Mouse using ES cell" |
"Gene Targeting, A Practical Approach", 1993, IRL PRESS AT OXFORD UNIVERSITY PRESS |
"Manipulating the Mouse Embryo, A Laboratory Manual", 1994, COLD SPRING HARBOR LABORATORY PRESS |
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
AM J CANCER RES., vol. 5, no. 8, 2015, pages 2344 - 2360 |
CANCER RESEARCH, vol. 78, no. 12, 2018, pages 3101 - 3111 |
CELL CHEMICAL BIOLOGY, vol. 8, 2017, pages 1029 - 1039 |
CELL REPORTS, vol. 30, 7 January 2020 (2020-01-07), pages 18 - 24 |
CELL, vol. 131, no. 5, 2007, pages 861 - 872 |
CELL, vol. 70, 1992, pages 841 - 847 |
CHIKAFUMI OZONE, ET AL.: "Functional anterior pituitary generated in self-organizing culture of human embryonic stem cells", NATURE COMMUNICATIONS, vol. 7, no. 1, 1 January 2016 (2016-01-01), pages 1 - 10, XP055535023, DOI: 10.1038/ncomms10351 * |
DINCER ET AL., CELL REPORTS, vol. 5, 2013, pages 1387 - 1402 |
EMBO J., vol. 3, 1984, pages 1463 - 1468 |
GENES, vol. 11, 2020, pages 603 |
J ENZYME INHIB MED CHEM., vol. 35, no. 1, 2020, pages 574 - 583 |
J. CELL BIOL., vol. 105, 1987, pages 589 - 598 |
M. KATOH: "WNT Signaling Pathway and Stem Cell Signaling Network", CLINICAL CANCER RESEARCH, vol. 13, no. 14, 15 July 2007 (2007-07-15), pages 4042 - 4045, XP055080256, ISSN: 10780432, DOI: 10.1158/1078-0432.CCR-06-2316 * |
MOL CANCER THER., vol. 3, 2004, pages 737 - 45 |
MOLECULAR BIOSYSTEMS, vol. 6, no. 1, 2010, pages 44 - 54 |
NAT BIOTECHNOL, vol. 19, 2001, pages 971 - 974 |
NAT BIOTECHNOL, vol. 28, 2010, pages 611 - 615 |
NAT COMMUN, vol. 3, 2012, pages 1236 |
NAT PROTOC, vol. 14, 2019, pages 518 - 540 |
NAT. BIOTECHNOL., vol. 26, no. 1, 2008, pages 101 - 106 |
NATURE COMMUNICATIONS, vol. 7, 2016, pages 10351 |
NATURE METHODS, vol. 8, 2011, pages 424 - 429 |
NATURE PROTOCOLS, vol. 11, no. 11, pages 2223 - 2232 |
NATURE, vol. 499, no. 7467, 2013, pages 481 - 484 |
ONCO TARGETS THER., vol. 6, 2013, pages 943 - 955 |
ONCOGENE, vol. 26, 2007, pages 5163 - 5168 |
OZONE ET AL., NATURE COMMUNICATIONS, vol. 7, no. 10351, 2016, pages 1 - 10 |
SCIENCE, vol. 318, no. 5858, 2007, pages 1917 - 1920 |
SCIENCE, vol. 341, 2013, pages 651 - 654 |
SCIENTIFIC REPORTS, vol. 12, no. 1, 2022, pages 1 - 11 |
SCIENTIFIC REPORTS, vol. 4, 2014, pages 3594 |
SUGA ET AL., NATURE, vol. 480, no. 7375, 9 November 2011 (2011-11-09), pages 57 - 62 |
SUGA HIDETAKA; KADOSHIMA TAISUKE; MINAGUCHI MAKI; OHGUSHI MASATOSHI; SOEN MIKA; NAKANO TOKUSHIGE; TAKATA NOZOMU; WATAYA TAKAFUMI; : "Self-formation of functional adenohypophysis in three-dimensional culture", NATURE, vol. 480, no. 7375, 9 November 2011 (2011-11-09), London, pages 57 - 62, XP037227898, ISSN: 0028-0836, DOI: 10.1038/nature10637 * |
YAMANAKA ET AL.: "mouse cell", CELL, vol. 126, no. 4, 2006, pages 663 - 676 |
ZIMMER ET AL., STEM CELL REPORTS, vol. 6, 2016, pages 858 - 872 |
Also Published As
Publication number | Publication date |
---|---|
CA3234671A1 (en) | 2023-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10220117B2 (en) | Methods of mammalian retinal stem cell production and applications | |
JP7029144B2 (ja) | 腺性下垂体又はその前駆組織の製造方法 | |
JP7352553B2 (ja) | 嗅神経細胞又はその前駆細胞を含む細胞塊、及びその製造方法 | |
JP6680681B2 (ja) | 小脳前駆組織の製造方法 | |
EP3683306A1 (en) | Method for producing retinal tissues | |
JP2019506901A (ja) | ヒト人工多能性幹細胞からの皮質ニューロンの分化 | |
US20230233617A1 (en) | Methods for differentiating stem cells into dopaminergic progenitor cells | |
WO2023277135A1 (ja) | 鼻腔上皮を構成する細胞の製造方法、及び鼻腔上皮を構成する細胞又はその前駆細胞を含む細胞集団 | |
JPWO2019054515A1 (ja) | 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法 | |
WO2019103129A1 (ja) | 下垂体組織を含む細胞塊の製造方法及びその細胞塊 | |
JP2023169391A (ja) | 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法 | |
WO2023054396A1 (ja) | 下垂体組織を含む細胞集団の製造方法及びその細胞集団 | |
JP2023055915A (ja) | 幹細胞からの成長ホルモン産生細胞の誘導およびその使用 | |
WO2023054395A1 (ja) | 下垂体ホルモン産生細胞を含む細胞凝集体及びその製造方法 | |
CN118043447A (zh) | 包含垂体组织的细胞群的制备方法及该细胞群 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22876262 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023551555 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 3234671 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3234671 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022876262 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022876262 Country of ref document: EP Effective date: 20240430 |